

1 APPEARANCES
2

3 ERIC KENNEDY, ESQ.
4 WEISMAN, KENNEDY & BERRIS CO., L.P.A.
5 101 W. Prospect Avenue
6 Midland Building, Suite 1600
7 Cleveland, OH 44115
8 (216) 781-1111
9 Counsel for the Plaintiffs

10
11 EMILY JOHNSON HENN, ESQ.
12 EMILY KVESELIS, ESQ.
13 COVINGTON & BURLING LLP
14 3000 El Camino Real
15 5 Palo Alto Square
16 Palo Alto, California 94306-2112
17 (650) 632-4715
18 ehenn@cov.com
19 ekveselis@cov.com
20 Counsel for Defendant McKesson and the
21 Witness

22 ABIGAIL G. URQUHART, ESQ.
23 JONES DAY
24 555 South Flower Street, 50th Floor
25 Los Angeles, CA 90071
26 (213) 243-2884
27 urquhart@jonesday.com
28 Counsel for Defendant Walmart

29
30 JOSEPH BUSHAR, ESQ. (Telephone/streaming)
31 WILLIAMS & CONNOLLY, LLP
32 725 Twelfth Street, N.W.
33 Washington, DC 20005
34 (650) 632-4715
35 jbushar@wc.com
36 Counsel for Defendant Cardinal Health

37
38 (Appearances continued on next page)

1 APPEARANCES (Continued)
2 SAMANTHA L. ROCCHINO, ESQ.
3 REED SMITH LLP (Telephone/Streaming)
4 Three Logan Square
5 1717 Arch Street, Suite 3100
6 Philadelphia, Pennsylvania 19103
7 (215) 851 8100
8 srocchino@reedsmit.com
9 Counsel for Defendant AmerisourceBergen
10
11 SCOTT LIVINGSTON, ESQ.
12 MARCUS & SHAPIRA LLP
13 One Oxford Centre, 35th Floor
14 Pittsburgh, Pennsylvania 15219
15 (412) 338-4690
16 livingston@marcus-shapira.com
17 Counsel for Defendant HBC Company
18
19 ERIC SHAPLAND, ESQ. (Telephone)
20 ARNOLD & PORTER KAYE SCHOLER, LLP
21 44th Floor, 777 South Figueroa Street
22 Los Angeles, California 90017-5844
23 (213) 243-4120
24 eric.Shapland@arnoldporter.com
25 Counsel for Defendants Endo Pharmaceuticals,
Inc. and Endo Health Solutions, Inc.
26
27 CIERA LOGAN, ESQ. (Telephone)
28 FOX ROTHSCHILD LLP
29 1301 Atlantic Avenue
30 Midtown Building, Suite 400
31 Atlantic City, New Jersey 08401-7212
32 (609) 572-2236
33 clogan@foxrothschild.com
34 Counsel for Defendant Validus
35 Pharmaceuticals
36
37
38 (Appearances continued on next page)

1

APPEARANCES (Continued)

2

LINDA K. RURANGIRWA, ESQ. (Telephone/stream)
COLLINSON, DAEHNKE, INLOW & GRECO
2110 E. Flamingo Road, Suite 305
Las Vegas, Nevada 89119
(702) 979-2132
Linda.rurangirwa@cdiglaw.com
Counsel for Defendant C&R Pharmacy

6

7 JUSTIN C. TAYLOR, ESQ. (Video/realtme
stream)
8 BAILEY & WYANT, PLLC
500 Virginia Street East | Suite 600
9 Charleston, West Virginia 25301
(304) 720-0714
10 Jtaylor@baileywyant.com

11

12 JUSTIN MANN, ESQ. (Video/realtme stream)
ROPES & GRAY, LLP
1211 Avenue of the Americas
13 New York, New York 10036-8704
(212) 596-9175
14 Justin.mann@ropesgray.com
Counsel for Defendant Mallinckrodt

15

16

17 LUCY ONYEFORO, ESQ. (Video/realtme stream)
ALLEGART BERGER & VOGEL LLP
18 111 Broadway, 20th Floor
New York, New York 10006
19 (212) 616-7060
onyeforo@abv.com
20 Counsel for Defendant Rochester Drug
Cooperative

21

22

(Appearances continued on next page)

23

24

25

1 APPEARANCES:

2 CONOR B. O'CROININ, ESQ.

3 ZUCKERMAN SPAEDER, LLP

4 100 East Pratt Street, Suite 2440

5 Baltimore, Maryland 21202-1031

6 (212) 616-7060

7 cocroinin@zuckerman.com

8 Counsel for Defendant CVS Indiana, L.L.C.,

9 CVS Rx

10

11 Also Present:

12 BRIAN ASQUITH, Law Clerk

13 EVAN WOLFE, Technical Support

14 RYAN WONG, Videographer

15

16 Appearing Via Video/Realtime Stream:

17 AMY KENNEDY

18

19 --00--

20

21

22

23

24

25

1

E X H I B I T S

2

MCK-WALKER

Description

Page

5

6

7

--OO--

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 BE IT REMEMBERED that on Thursday, the 10th
2 day of January, 2019, commencing at the hour of
3 8:57 a.m. in the law offices of Covington & Burling,
4 One Front Street, 35th Floor, San Francisco,
5 California, before me, Sandra Bunch VanderPol, a
6 Certified Shorthand Reporter in and for the State of
7 California, personally appeared.

8 DONALD WALKER,
9 called as a witness (McKesson), who, having been duly
10 sworn, was thereupon examined and interrogated as
11 hereinafter set forth.

12 --oo--

13 THE VIDEOGRAPHER: We are now on the record.

14 My name is Ryan Wong. I'm a videographer
15 for Golkow Litigation Services. Today's date is
16 January 10th, 2019, and the time is 8:57 a.m.

17 This video deposition is being held in
18 San Francisco, California, in the matter of National
19 Prescription Opiate Litigation, for the United States
20 District Court, Northern District of Ohio.

21 The deponent is Donald Walker.

22 Would counsel please identify themselves for
23 the record.

24 MR. KENNEDY: Eric Kennedy, on behalf of
25 plaintiffs.

1 MR. ASQUITH: Brian Asquith, plaintiffs.

2 MR. WOLFE: Evan Wolfe, tech support.

3 MS. URQUHART: Abigail Urquhart, on behalf
4 of Walmart.

5 MR. LIVINGSTON: Scott Livingston, on behalf
6 of HBC.

7 MR. O'CROININ: Conor O'Croinin, on behalf
8 of CVS.

9 MS. KVESELIS: Emily Kveselis, for McKesson
10 and the witness.

11 MS. HENN: Emily Henn, from Covington &
12 Burling, on behalf of McKesson and Mr. Walker.

13 THE VIDEOGRAPHER: On the phone?

14 MR. SHAPLAND: Eric Shapland, on behalf of
15 Endo and Par, at Arnold & Porter.

16 MR. BUSHAR: Joseph Bushar, of Williams &
17 Connolly, on behalf of Cardinal Health.

18 MS. RURANGIRWA: Linda Rurangirwa.

19 Collinson, Daehnke, on behalf of C&R Pharmacy.

20 MS. ROCCHINO: Samantha Rocchino, of Reed
21 Smith, LLP, on behalf of AmerisourceBergen Drug
22 Corporation.

23 THE VIDEOGRAPHER: The court reporter is
24 Sandy VanderPol, and she will now swear in the
25 witness.

1 THE REPORTER: Raise your right hand,
2 please.

3 Do you solemnly swear or affirm that the
4 testimony you are about to give in this proceeding
5 will be the truth, the whole truth, and nothing but
6 the truth, so help you God?

7 THE WITNESS: I do.

8 EXAMINATION

9 BY MR. KENNEDY:

10 Q. Sir, my name is Eric Kennedy. You
11 understand that I represent the plaintiffs in this
12 case?

13 A. I do.

14 Q. And could you please state your full
15 name for the record.

16 A. Donald Walker.

17 Q. And are you currently employed?

18 A. I am not.

19 Q. And your prior employer was McKesson;
20 would that be true?

21 A. That's correct.

22 Q. And so the jury understands where we
23 are today, we are in San Francisco; are we not?

24 A. Yes, we're in San Francisco.

25 Q. And San Francisco would be the

1 worldwide corporate headquarters of McKesson
2 Corporation; would that be true?

3 MS. HENN: Objection to form.

4 THE WITNESS: McKesson's corporate
5 headquarters is currently in San Francisco,
6 California.

7 BY MR. KENNEDY:

8 Q. And we are at the offices of your
9 attorney at this present time; yes?

10 A. Yes, we are.

11 Q. When did you begin your career with
12 McKesson?

13 A. I joined McKesson in 1987.

14 Q. And when you joined them, what was
15 your position?

16 A. My first position with McKesson was
17 as a Transportation Manager with one of the
18 subsidiary companies that McKesson had.

19 Q. Were your responsibilities in any way
20 involved with the regulatory affairs at that time?

21 A. No.

22 Q. And what was the next position that
23 you held with McKesson?

24 A. I held the position with the -- what
25 was then the McKesson Drug Company and

1 Transportation, and had responsibility for
2 transportation planning.

3 Q. And when did you take that position?

4 A. About 1991.

5 Q. Did that position have anything to do
6 with regulatory affairs of the distribution of
7 opioids?

8 A. No, it did not.

9 Q. What did that position basically
10 involve?

11 A. The transportation position that I
12 held was really a position of optimizing delivery
13 efficiencies for our distribution centers.

14 Q. What was your next position at
15 McKesson?

16 A. I was the Distribution Center Manager
17 of our Sacramento Distribution Center.

18 Q. When did you take that position?

19 A. My best recollection is about 1992.

20 Q. And what were your duties and
21 responsibilities then, as the manager of a
22 distribution center?

23 A. I had responsibility for oversight of
24 our daily distribution of pharmaceuticals to
25 pharmacies served by that distribution center.

1 Q. And that position would have involved
2 the distribution of opioids; would it not?

3 A. As part of our distribution, we did
4 distribute controlled substances to pharmacies.

5 Q. Did you have any responsibility at
6 that point in time with respect to the creation,
7 management or implementation of anti-diversion
8 regulations and policies at McKesson?

9 MS. HENN: Object to form.

10 THE WITNESS: No. At that time I was
11 executing against existing policies the company had
12 in place.

13 BY MR. KENNEDY:

14 Q. What were in place from 1992 to the
15 late '90s? What was the policy in place?

16 A. There were -- the policies we had
17 were contained in our Operations Manuals that
18 specified our responsibilities to comply to
19 regulations for handling and distribution of
20 controlled substances.

21 Q. We know about the existence of
22 Standard Operating Procedure 55. Are you familiar
23 with that?

24 A. Yes.

25 Q. Was that the policy and procedure

1 that was in place in the 1990s?

2 A. The Section 55 of our Operations

3 Manual covered the responsibilities with the handling
4 and distribution of controlled substances.

5 Q. Sir, that wasn't my question. I was
6 asking, was Standard Operating Procedure Section 55,
7 was that the policy in place in the 1990s?

8 A. My recollection is that Section 55
9 was the applicable policy in place during a period in
10 the 1990s.

11 Q. How long did you hold the position as
12 a Distribution Center Manager?

13 A. I recall it was approximately 18
14 months.

15 Q. So sometime in 1993/'94, you took on
16 a new position?

17 A. Yes. In 19 -- in that time frame, I
18 don't recall exactly when, I was promoted to a new
19 position of Vice President of Distribution Operations
20 for their Western Region.

21 Q. Western Region would be the western
22 part of the United States?

23 A. Yes.

24 Q. And what were your responsibilities
25 as VP of Distribution of the Western Region?

1 A. I had responsibility for the
2 operations staff in the distribution centers that
3 comprised the Western Region. So the distribution
4 center managers that operated those facilities
5 reported to me.

6 Q. And at that point in time -- how
7 long -- how long did you hold that position?

8 A. I held that position until about
9 1996.

10 Q. And in that position, did you have
11 responsibility -- other than the following of SOP 55,
12 did you have any duties, responsibilities, with the
13 creation and the management of anti-diversion
14 policies and procedures at McKesson?

15 MS. HENN: Objection to form.

16 THE WITNESS: In that role I had
17 responsibility for the distribution centers and their
18 execution of their responsibilities under Section 55
19 to the handling and distribution of controlled
20 substances.

21 BY MR. KENNEDY:

22 Q. You held that position till what
23 year, the VP of the Western Region?

24 A. Approximately 1996.

25 Q. And what position did you take in

1 1996?

2 A. In 1996 I was promoted to the Senior
3 Vice President of Distribution for McKesson
4 Pharmaceutical.

5 Q. Was that a new position also?

6 MS. HENN: Objection to form.

7 THE WITNESS: No. That position, I
8 succeeded an individual who retired from the company.

9 BY MR. KENNEDY:

10 Q. Is that the position you held until
11 the time of your retirement?

12 A. Yes, with the exception of a period
13 of time from approximately 2000 to 2005 where I was
14 responsible for our Six Sigma organization.

15 Q. And what is that?

16 A. Six Sigma is a process improvement
17 methodology that we introduced to the company at that
18 time, and I was the senior leader of our Six Sigma.

19 Q. Did the Six Sigma project in any way
20 relate to the distribution of opioids?

21 A. Not that I recall.

22 Q. From '96 to 2000, in this four-year
23 period, what are your responsibilities as a Senior VP
24 of Distribution as it related to the distribution of
25 opioids?

1 A. As the Senior Vice President of
2 Distribution, included in my responsibility was our
3 Regulatory Affairs Group. It was our overall
4 responsibility to ensure that we were complying with
5 regulations associated with the handling and
6 distribution of controlled substances.

7 Q. And would that be on a national
8 basis?

9 A. Yes.

10 Q. Then from 2000 to 2005, when you no
11 longer had your responsibilities as Senior VP of
12 Distribution, who took over your responsibilities
13 during this five-year period?

14 A. I recall there were two different
15 individuals that had responsibility during that time
16 frame, a Ron Bone and a Brian Magerkurth.

17 Q. And so they had taken over your
18 responsibilities as it related to McKesson's
19 responsibilities as a distributor relating to the
20 distribution of opioids?

21 A. During -- during that time they would
22 have had the responsibility for our Regulatory
23 Affairs, yes.

24 Q. And would their responsibility and
25 your responsibility, when you were acting as the

1 Senior VP, would that have related to the policies
2 and procedures of McKesson in relation to suspicious
3 order monitoring?

4 MS. HENN: Objection to form.

5 THE WITNESS: As part of our overall
6 policies, it did include reporting of suspicious
7 orders.

8 (Exhibit No. 690 was marked.)

9 BY MR. KENNEDY:

10 Q. I am going to show you what we have
11 marked as Plaintiffs' Exhibit 690, if you would,
12 please.

13 MS. HENN: Do you have a second copy for the
14 counsel over here? ^

15 UNIDENTIFIED SPEAKER ON TELEPHONE: And if
16 it does have a Bates number, if that could be read
17 into the record, it would be appreciated.

18 MR. KENNEDY: The Bates number,
19 McKessonMDL00409116 -- that's the starting Bates --
20 to -73. To -173.

21 BY MR. KENNEDY:

22 Q. Mr. Walker, what is the date on this
23 document, if you look at the cover page?

24 A. The date is March 12th, 2014.

25 Q. Large capitals, "McKesson

1 Corporation"?

2 A. Yes.

3 Q. And the title would be the,

4 "Presentation to the U.S. Attorney's Office, Northern
5 District of West Virginia, and DEA." Do you see
6 that?

7 A. Yes.

8 Q. If you will -- if you will go to page
9 -122, the last three -- the last three numbers in the
10 bottom right-hand corner.

11 Is the title of this McKesson's Regulatory
12 Affairs team, Pre-Settlement"?

13 MS. HENN: Objection to form.

14 THE WITNESS: Yes.

15 BY MR. KENNEDY:

16 Q. Presettlement would be prior to 2008;
17 would that be true? There was a settlement between
18 McKesson and the DEA in 2008; do you recall that?

19 A. I recall the settlement in 2008, yes.

20 Q. And this is referencing a
21 pre-settlement; do you see that?

22 A. I see that.

23 Q. My question being, from 2000 to -- up
24 to 2008, the time of the settlement, would this have
25 been the regulatory team at McKesson?

1 MS. HENN: Objection to form.

2 THE WITNESS: Can you repeat.

3 BY MR. KENNEDY:

4 Q. In this time frame, prior to the
5 settlement, prior to 2008, would this presentation to
6 the government -- would this presentation to the
7 government accurately reflect the regulatory team at
8 McKesson?

9 A. The regulatory -- counsel, if your
10 question is if this was the regulatory team prior to
11 2008, yes.

12 Q. And --

13 A. I'm not familiar with this document.
14 So that's why I'm answering the question that way.

15 Q. I just thought I might help you with
16 recollecting back to this period of time.

17 And so my question is, Bruce Russell is one
18 of three of the regulatory team. Do you remember
19 when he was brought on at McKesson, prior to 2008 to
20 make up the regulatory team?

21 A. I don't recall specifically when he
22 was brought on. When I joined the company, Bruce was
23 already an employee of McKesson.

24 Q. All right. And do you know when he
25 took this position as part of the regulatory team?

1 A. I don't recall specifically. He held
2 several -- several different positions. I know that
3 it did include regulatory, but I don't know the
4 dates.

5 Q. And do you know when Mr. Hilliard was
6 brought on and made part of the regulatory team at
7 McKesson?

8 A. Again, I don't recall the specific
9 date. But Mr. Hilliard joined our regulatory team as
10 a result of our acquisition of Foxmeyer Corporation.

11 Q. And when we talk about a regulatory
12 team, can we be in agreement we are talking about the
13 team that managed -- managed and implemented the
14 policies in relation to the distribution of opioids;
15 would that be correct?

16 MS. HENN: Objection to form.

17 THE WITNESS: The regulatory team had
18 responsibility for ensuring the policies were current
19 and in compliance with the regulation, and provided
20 oversight and guidance to our distribution center
21 teams to ensure that all of our distribution centers
22 were in compliance.

23 BY MR. KENNEDY:

24 Q. And when we're talking about
25 compliance, we're talking about -- that would include

1 compliance as it relates to the distribution of
2 opioids; true?

3 A. It would include the distribution of
4 controlled substances, yes.

5 Q. Opioids; correct? They were a
6 controlled substance?

7 A. The -- we had responsibility for all
8 controlled substances.

9 Q. Okay. I want you -- it's just a
10 simple "yes" or "no" question.

11 Opioids are a controlled substance; are they
12 not? "Yes" or "no."

13 A. I understand narcotics are a
14 controlled substance, as defined by the DEA, but I
15 don't have the expertise to understand. We
16 understood them to be controlled substances.

17 Q. Well, let me ask you this. You were
18 in charge of regulatory; you worked at the
19 distribution center; you had a long career working
20 directly with the DEA; correct? Correct?

21 MS. HENN: Objection to form.

22 THE WITNESS: I had a long career with
23 McKesson that included interaction with DEA.

24 BY MR. KENNEDY:

25 Q. And are you saying that you have

1 never understood that opioids were a controlled
2 substance?

3 A. In the regulations, I understand
4 narcotics to be a controlled substance. And what I
5 can't answer for you is whether opioids specifically
6 are called out in the regulation.

7 We were responsible for the oversight and
8 control of controlled substances, including
9 narcotics.

10 Q. Okay. My question is very simple.
11 In your long career at McKesson -- and at the end of
12 the day you were the boss with respect to
13 regulation -- and are you saying that, as you sit
14 here today, you never understood that opioids were a
15 controlled substance that the federal government was
16 addressing when they put the Controlled Substance Act
17 into law in 1970? You never understood that; is that
18 your testimony, sir?

19 MS. HENN: Objection to form.

20 BY MR. KENNEDY:

21 Q. I'm asking you about opioids.

22 A. Again, I very specifically understood
23 narcotics, and I --

24 Q. And you didn't know about opioids?

25 A. And I don't recall opioids being in

1 the regulation.

2 Q. Let me ask you, did you recall, in
3 your long, long career, did you know whether or not
4 oxycodones were within the topic of controlled
5 substances that the DEA and Congress of the
6 United States were intending to be within the purview
7 of what they wanted regulated? Did you understand
8 oxycodones were a part of that?

9 MS. HENN: Objection to form.

10 THE WITNESS: I understood oxycodone to be a
11 Class 2 narcotic, yes.

12 BY MR. KENNEDY:

13 Q. A controlled substance that you had
14 the responsibility at McKesson to regulate; correct?
15 You understood that?

16 A. Yes.

17 Q. Did you understand that hydrocodones
18 were within the purview of controlled substances that
19 the government and the DEA and Congress intended to
20 be subject to their regulation and distribution?

21 A. Yes.

22 Q. The three folks that we see here
23 making up the regulatory team -- and, again, when I
24 say "regulatory team" or "Regulatory Affairs," we
25 could understand that what we are talking about are

1 the responsibilities of McKesson as it related to the
2 prevention of diversion of controlled substances; you
3 understand that?

4 MS. HENN: Objection to form.

5 THE WITNESS: I would describe our
6 regulatory team as having responsibility to ensure
7 that our distribution centers were complying with all
8 regulations, to which McKesson was obligated.

9 BY MR. KENNEDY:

10 Q. Well, tell me what regulations
11 McKesson was obligated to with respect to the
12 distribution of controlled substances, then, so maybe
13 we can communicate better. Tell me.

14 In this period prior to 2008, tell me the
15 regulations that you just referred to that McKesson
16 was responsible to follow.

17 A. At a high level, the responsibility
18 of our distribution centers was to ensure the safe
19 handling, security, recordkeeping associated with the
20 distribution and handling of controlled substances
21 and to -- specifically under the regulation, to guard
22 against diversion and report suspicious orders.

23 Q. And that was under this -- this
24 umbrella of Regulatory Affairs; correct?

25 A. Yes, under our Regulatory Affairs

1 Group, including our distribution centers, that was
2 our compliance responsibility.

3 Q. And prior to 2008, as you've
4 represented to the DEA in this slide presentation,
5 prior to 2008, these three folks, Mr. Walker,
6 Mr. Russell, Mr. Hilliard, they made up the
7 regulatory team; true?

8 MS. HENN: Objection to the form.

9 THE WITNESS: Prior to 2008, this was the
10 regulatory team.

11 BY MR. KENNEDY:

12 Q. So during this period prior to 2008,
13 I want to focus on 2005 to start with; all right?

14 A. Okay.

15 Q. 2005 there was an opioid crisis in
16 the United States; was there not?

17 MS. HENN: Objection to form.

18 THE WITNESS: I -- I don't have the specific
19 knowledge or recollection that there was an opioid
20 crisis in the United States at the time.

21 BY MR. KENNEDY:

22 Q. In 2005?

23 A. Correct.

24 Q. Let me ask you this. Is it just that
25 you don't remember back to 2005, or is it that you

1 believe that back in 2005 you weren't conscious of an
2 opioid crisis in this country?

3 A. I don't recall when the term --
4 basically, the public information associated with
5 what eventually was termed "the opioid crisis" first
6 was identified.

7 Q. Well, let me ask. In 2005 you
8 understood McKesson was selling more opioid narcotics
9 than any company in the United States? You knew
10 that, didn't you?

11 MS. HENN: Objection to form.

12 THE WITNESS: No, I don't have any specific
13 information or recollection that our quantities were
14 the largest in the United States.

15 BY MR. KENNEDY:

16 Q. As you sit here today, do you know
17 and do you understand that over the years McKesson
18 has been the largest distributor of opioids in this
19 country?

20 MS. HENN: Objection to form.

21 THE WITNESS: No, I don't have that
22 knowledge.

23 BY MR. KENNEDY:

24 Q. In 2005 McKesson was selling
25 oxycodones, were they not?

1 A. In 2005 I believe that McKesson
2 was -- oxycodone was one of the controlled substances
3 we sold.

4 Q. McKesson was selling hydrocodones;
5 were they not?

6 A. In 2005?

7 Q. Yes.

8 A. Yes.

9 Q. And if I were to tell you that with
10 respect to narcotics and controlled substances, by
11 2005 McKesson was probably selling over a billion
12 dollars worth of those narcotics, would that be
13 contrary to your memory and your belief of the level
14 of sales of McKesson in 2005?

15 MS. HENN: Objection to form.

16 THE WITNESS: I don't have any specific
17 knowledge in what our sales quantities of those
18 substances were at that time.

19 BY MR. KENNEDY:

20 Q. Let me ask you -- see if we can

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 Q. That's not what I'm asking you. And
11 you -- you're the right guy, and you understand --
12 you heard my question; did you not?

13 MS. HENN: Counsel, could you just ask a
14 question, please.

15 BY MR. KENNEDY:

16 Q. Did you hear my question, sir?

17 A. I heard your question.

18 Q. Did you understand my question?

19 A. I understood your question.

20 Q. I'm going to ask it again, maybe in a
21 little different way.

10 Q. And I'm going to move to strike. And
11 I'm going to ask you again.

12 I want to know about your responsibility to
13 know. I don't want you to parrot something that you
14 want to say or have been prepared to say. I want you
15 to answer my question; all right?

www.nature.com/scientificreports/

© 2013 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).

1

Digitized by srujanika@gmail.com

Digitized by srujanika@gmail.com

For more information about the study, please contact Dr. John D. Cawley at (609) 258-4626 or jdcawley@princeton.edu.

For more information about the study, please contact Dr. Michael J. Hwang at (319) 356-4530 or via email at mhwang@uiowa.edu.

Digitized by srujanika@gmail.com

[View Details](#) | [Edit](#) | [Delete](#)

12 O. So are you going to refuse to answer

13 that question? I want to know, and I will move on.

14 If you are not going to answer that question, I will

15 move on.

16 Are you refusing to answer my question?

17 MS. HENN: Counsel, please just pose

18 questions. He will answer them.

19 BY MR. KENNEDY:

Q. Are you refusing to answer my

21 question, sir?

22 MS. HENN: Objection to form.

For more information about the study, please contact Dr. Michael J. Hwang at (310) 794-3000 or via email at mhwang@ucla.edu.

Golkow Litigation Services





The figure consists of 15 horizontal bars, each composed of two segments: a longer gray segment on the left and a shorter gray segment on the right. The length of the long segment varies significantly between bars, ranging from approximately one-third to three-quarters of the total bar length. The short segment is consistently positioned at the far right end of each bar.

18 Q. And I've written that accurately;
19 correct? Simple question. If I haven't, I will
20 rewrite it; I will write more.

21 Have I written that correctly with respect
22 to Mr. Walker's view as head of regulatory, your view
23 of McKesson's responsibility?

24 MS. HENN: Objection to form.

25 //

1 BY MR. KENNEDY:

2 Q. Have I written that accurately, sir?

3 A. That appears to be what I said.

4 Q. Very good. All right.

5 So let's take a look at whether or not

6 McKesson fulfilled its responsibility --

7 all right? -- according to Mr. Walker's view of their
8 responsibility. All right?

9 A. Okay.

10 (Exhibit No. 801 was marked.)

11 MR. KENNEDY: If you can give me

12 Exhibit 688, please.

13 (Exhibit No. 688 was marked.)

14 BY MR. KENNEDY:

15 Q. So let's look at McKesson's
16 fulfilling of its responsibility, then, as you have
17 described it. This is Exhibit 688, Bates -00496859
18 to -875.

19 This is a memorandum. Do you see that up at
20 the top, it says, "Memorandum"?

21 A. Yes. Give me just a minute.

22 Yes.

23 BY MR. KENNEDY:

24 Q. And this is a Memorandum. This is a
25 DEA document; is it not? Do you see the DEA logo,

1 U.S. Department of Justice, Drug Enforcement
2 Administration? This is a memo from the DEA, from
3 their documents; true?

4 A. That's what's on the document, yes.

5 Q. Well, Mr. Walker, you have seen this
6 document before; have you not? This came from your
7 files.

8 A. Yes, I have seen this document.

9 MS. HENN: Objection to form.

10 BY MR. KENNEDY:

11 Q. When was the last time you saw this
12 document?

13 A. I believe the most recent was in
14 preparation for this deposition.

15 Q. All right. So this is a memorandum.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

25 Q. And this is an internal memoranda

1 that Mr. Mapes, from the DEA, created for Joseph
2 Rannazzisi of the DEA; true? Is that true?

3 A. That would appear to be correct.

4 Q. And you know who Mr. Rannazzisi of
5 the DEA is, do you not?

6 A. Yes, I do.

7 Q. He held an important position with
8 the DEA; did he not?

9 A. Mr. Rannazzisi was the head of
10 diversion control.

11 Q. And that's an important position; is
12 it not?

13 A. I believe so.

14 Q. All right. Let's read the first

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

21 of reading).

22 He's from McKesson; right?

23 MS. HENN: Objection to form.

24 BY MR. KENNEDY:

25 Q. He's legal counsel at McKesson?

1 A. Mr. Gilbert is outside counsel for
2 McKesson.

3 Q. All right. A lawyer; right?

4 A. Yes, he's a lawyer.

5 Q. Ronald Bone, Senior Vice President,
6 Distribution Support. He's from McKesson; correct?

7 A. Yes.

8 Q. Gary Hilliard, Director of Regulatory
9 Affairs was present; right?

10 A. Yes.

11 Q. And as far as that -- the hierarchy,
12 the chain of command in Regulatory, he was right
13 underneath you or he was two down from you; correct?
14 We just looked at that.

15 A. At -- that's not accurate. At this
16 time I was not in the role of Senior Vice President
17 of Distribution. But ultimately he was.

18 Q. Okay. And Michael Mapes, from the
19 DEA, was at the meeting; true? Is that what it
20 indicates?

21 A. That's what the document indicates.

22 Q. Charles E. Trant, Office of Chief
23 Counsel, Diversion and Regulatory Litigation
24 Division, that was a lawyer from the DEA present at
25 the meeting; true?

1 MS. HENN: Objection to form.

2 THE WITNESS: Again, that's what the
3 document represents.

4 BY MR. KENNEDY:

5 Q. Jim Crawford, from the DEA, he was
6 also there; correct?

7 A. According to the document.

8 Q. Kyle Wright, from the DEA, was also
9 at the meeting, according to the document?

10 A. Yes, that's what's written.

11 Q. That last sentence in the first
12 paragraph states:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

21 Q. And you understand that they said
22 they wanted to talk to you about source of supply.
23 That's McKesson, because McKesson is a source of
24 supply to pharmacies; true?

25 MS. HENN: Objection to form.

1 BY MR. KENNEDY:

2 Q. That's what they are talking about?

3 A. McKesson's role in the pharmaceutical
4 supply chain is to supply pharmacies.

5 Q. They are a source of supply? That's
6 what they are talking about in this memo; true?

7 MS. HENN: Objection to form.

8 THE WITNESS: I'm not sure what their intent
9 in writing the "source of supply." But McKesson does
10 supply pharmacies.

11 BY MR. KENNEDY:

12 Q. Are you telling me, you don't know
13 what they mean by "source of supply"? You don't know
14 what that means?

15 MS. HENN: Objection to form. Asked and
16 answered.

17 BY MR. KENNEDY:

18 Q. Is that your testimony?

19 MS. HENN: Same objection.

20 THE WITNESS: Again, I'm not sure
21 specifically what Mr. Mapes is intending or meaning
22 there. What I can assure you is that McKesson
23 supplies pharmacies.

24 BY MR. KENNEDY:


25 Q. All right. From your background,

11 Q. Let me ask you, meetings like this
12 didn't happen every week with the DEA where lawyers
13 are involved, the DEA is bringing all these folks,
14 and McKesson is bringing all these folks? These type
15 meetings with the DEA did not happen every week;
16 would that be true?

17 A. Meetings at DEA headquarters were
18 not, you know, frequent.

19 Q. This didn't even happen every month,
20 where this many people from McKesson were brought in
21 to meet this many people at DEA headquarters? It
22 didn't even happen once a month; did it?

23 A. Not that I recall.





A horizontal bar chart illustrating the distribution of 1500 samples across 15 different categories. The y-axis consists of 15 categorical labels, each preceded by a small gray square. The x-axis represents the count of samples, ranging from approximately 100 to 1000. Each category has a corresponding horizontal bar, with the length of the bar indicating the sample count for that category. The categories are ordered from highest to lowest sample count.

Category	Sample Count
1	~100
2	~100
3	~100
4	~100
5	~100
6	~100
7	~100
8	~100
9	~100
10	~100
11	~100
12	~100
13	~100
14	~100
15	~100
16	~100
17	~100
18	~100
19	~100
20	~100
21	~100
22	~100
23	~100
24	~100
25	~100
26	~100
27	~100
28	~100
29	~100
30	~100
31	~100
32	~100
33	~100
34	~100
35	~100
36	~100
37	~100
38	~100
39	~100
40	~100
41	~100
42	~100
43	~100
44	~100
45	~100
46	~100
47	~100
48	~100
49	~100
50	~100
51	~100
52	~100
53	~100
54	~100
55	~100
56	~100
57	~100
58	~100
59	~100
60	~100
61	~100
62	~100
63	~100
64	~100
65	~100
66	~100
67	~100
68	~100
69	~100
70	~100
71	~100
72	~100
73	~100
74	~100
75	~100
76	~100
77	~100
78	~100
79	~100
80	~100
81	~100
82	~100
83	~100
84	~100
85	~100
86	~100
87	~100
88	~100
89	~100
90	~100
91	~100
92	~100
93	~100
94	~100
95	~100
96	~100
97	~100
98	~100
99	~100
100	~100
101	~100
102	~100
103	~100
104	~100
105	~100
106	~100
107	~100
108	~100
109	~100
110	~100
111	~100
112	~100
113	~100
114	~100
115	~100
116	~100
117	~100
118	~100
119	~100
120	~100
121	~100
122	~100
123	~100
124	~100
125	~100
126	~100
127	~100
128	~100
129	~100
130	~100
131	~100
132	~100
133	~100
134	~100
135	~100
136	~100
137	~100
138	~100
139	~100
140	~100
141	~100
142	~100
143	~100
144	~100
145	~100
146	~100
147	~100
148	~100
149	~100
150	~100
151	~100
152	~100
153	~100
154	~100
155	~100
156	~100
157	~100
158	~100
159	~100
160	~100
161	~100
162	~100
163	~100
164	~100
165	~100
166	~100
167	~100
168	~100
169	~100
170	~100
171	~100
172	~100
173	~100
174	~100
175	~100
176	~100
177	~100
178	~100
179	~100
180	~100
181	~100
182	~100
183	~100
184	~100
185	~100
186	~100
187	~100
188	~100
189	~100
190	~100
191	~100
192	~100
193	~100
194	~100
195	~100
196	~100
197	~100
198	~100
199	~100
200	~100
201	~100
202	~100
203	~100
204	~100
205	~100
206	~100
207	~100
208	~100
209	~100
210	~100
211	~100
212	~100
213	~100
214	~100
215	~100
216	~100
217	~100
218	~100
219	~100
220	~100
221	~100
222	~100
223	~100
224	~100
225	~100
226	~100
227	~100
228	~100
229	~100
230	~100
231	~100
232	~100
233	~100
234	~100
235	~100
236	~100
237	~100
238	~100
239	~100
240	~100
241	~100
242	~100
243	~100
244	~100
245	~100
246	~100
247	~100
248	~100
249	~100
250	~100
251	~100
252	~100
253	~100
254	~100
255	~100
256	~100
257	~100
258	~100
259	~100
260	~100
261	~100
262	~100
263	~100
264	~100
265	~100
266	~100
267	~100
268	~100
269	~100
270	~100
271	~100
272	~100
273	~100
274	~100
275	~100
276	~100
277	~100
278	~100
279	~100
280	~100
281	~100
282	~100
283	~100
284	~100
285	~100
286	~100
287	~100
288	~100
289	~100
290	~100
291	~100
292	~100
293	~100
294	~100
295	~100
296	~100
297	~100
298	~100
299	~100
300	~100
301	~100
302	~100
303	~100
304	~100
305	~100
306	~100
307	~100
308	~100
309	~100
310	~100
311	~100
312	~100
313	~100
314	~100
315	~100
316	~100
317	~100
318	~100
319	~100
320	~100
321	~100
322	~100
323	~100
324	~100
325	~100
326	~100
327	~100
328	~100
329	~100
330	~100
331	~100
332	~100
333	~100
334	~100
335	~100
336	~100
337	~100
338	~100
339	~100
340	~100
341	~100
342	~100
343	~100
344	~100
345	~100
346	~100
347	~100
348	~100
349	~100
350	~100
351	~100
352	~100
353	~100
354	~100
355	~100
356	~100
357	~100
358	~100
359	~100
360	~100
361	~100
362	~100
363	~100
364	~100
365	~100
366	~100
367	~100
368	~100
369	~100
370	~100
371	~100
372	~100
373	~100
374	~100
375	~100
376	~100
377	~100
378	~100
379	~100
380	~100
381	~100
382	~100
383	~100
384	~100
385	~100
386	~100
387	~100
388	~100
389	~100
390	~100
391	~100
392	~100
393	~100
394	~100
395	~100
396	~100
397	~100
398	~100
399	~100
400	~100
401	~100
402	~100
403	~100
404	~100
405	~100
406	~100
407	~100
408	~100
409	~100
410	~100
411	~100
412	~100
413	~100
414	~100
415	~100
416	~100
417	~100
418	~100
419	~100
420	~100
421	~100
422	~100
423	~100
424	~100
425	~100
426	~100
427	~100
428	~100
429	~100
430	~100
431	~100
432	~100
433	~100
434	~100
435	~100
436	~100
437	~100
438	~100
439	~100
440	~100
441	~100
442	~100
443	~100
444	~100
445	~100
446	~100
447	~100
448	~100
449	~100
450	~100
451	~100
452	~100
453	~100
454	~100
455	~100
456	~100
457	~100
458	~100
459	~100
460	~100
461	~100
462	~100
463	~100
464	~100
465	~100
466	~100
467	~100
468	~100
469	~100
470	~100
471	~100
472	~100
473	~100
474	~100
475	~100
476	~100
477	~100
478	~100
479	~100
480	~100
481	~100
482	~100
483	~100
484	~100
485	~100
486	~100
487	~100
488	~100
489	~100
490	~100
491	~100
492	~100
493	~100
494	~100
495	~100
496	~100
497	~100
498	~100
499	~100
500	~100
501	~100
502	~100
503	~100
504	~100
505	~100
506	~100
507	~100
508	~100
509	~100
510	~100
511	~100
512	~100
513	~100
514	~100
515	~100
516	~100
517	~100
518	~100
519	~100
520	~100
521	~100
522	~100
523	~100
524	~100
525	~100
526	~100
527	~100
528	~100
529	~100
530	~100
531	~100
532	~100
533	~100
534	~100
535	~100
536	~100
537	~100
538	~100
539	~100
540	~100
541	~100
542	~100
543	~100
544	~100
545	~100
546	~100
547	~100
548	~100
549	~100
550	~100
551	~100
552	~100
553	~100
554	~100
555	~100
556	~100
557	~100
558	~100
559	~100
560	~100
561	~100
562	~100
563	~100
564	~100
565	~100
566	~100
567	~100
568	~100
569	~100
570	~100
571	~100
572	~100
573	~100
574	~100
575	~100
576	~100
577	~100
578	~100
579	~100
580	~100
581	~100
582	~100
583	~100
584	~100
585	~100
586	~100
587	

18 Q. McKesson, when they provided us with
19 this document, put a black box. Do you know why that
20 black box is there?

21 MS. HENN: Objection to form.

22 THE WITNESS: No. I do not.

23 BY MR KENNEDY:



The page contains approximately 25 horizontal lines, each consisting of a small gray square followed by a long, solid gray bar. These represent redacted text or sensitive information.

12 Q. Now, you have reviewed this document
13 within the last few weeks; true?

14 A. Yes, I believe so.

15 Q. And you clearly would have seen this
16 document back in 2005, 2006? We got it out of your
17 files; correct? You saw it back then; right?

18 MS. HENN: Objection to form.

19 THE WITNESS: I don't recall seeing this
20 document, this internal DEA document, prior to the
21 review with counsel.

22 BY MR. KENNEDY:

A horizontal bar chart illustrating the distribution of 1000 samples across 10 categories. The x-axis represents the number of samples (0 to 1000), and the y-axis represents the category index (0 to 9). The bars are colored grey.

Category	Approximate Sample Range
0	0-100
1	0-100
2	0-100
3	0-100
4	0-100
5	0-100
6	0-100
7	0-100
8	0-100
9	0-100



1 months later. All right. Four months later. If we
2 could look at Exhibit 689, please.

3 (Exhibit No. 689 was marked.)

4 MR. KENNEDY: That's a Bates -00496876 to
5 - 878 .

6 Q. You have got a September 1 meeting,
7 2005. I want to talk about four months later. You
8 have seen this document; have you not?

9 A. Yes, I have.

10 Q. This is from your files.

11 A. Yes, I have seen this document.

12 MS. HENN: Objection to form.

13

15 DEA memo; is it not?

16 A. It would appear to be a DEA memo,
17 yes.



1 Q. Now, this is a DEA memo, again,
2 written to Mr. Rannazzisi; correct?

3 A. That's correct.

Q. Let's look to the first paragraph.

Term	Percentage (%)
Climate change	100
Global warming	98
Green energy	95
Sustainable development	92
Carbon footprint	95
Environmental protection	98

13 The second paragraph states:

14 (Reading) Representing McKesson

16 That's you; right?

17 A. Yes, it is.

18 Q. You're at the second meeting; right?

19 A. Yes, I was at this meeting.

20 Q. And that point you were Senior Vice

21 President of Distribution Operations; correct?

22 A. That is correct.

Q. So you're sitting on top of

24 Regulatory Affairs at that point; true?

25 A. Yes.

1 Q. Bill Mahoney, Distribution Center
2 Manager, Lakeland Distribution Center, Florida, was
3 there; right? McKesson employee; true?

4 A. Yes.

5 Q. Gary Hilliard, Director of Regulatory
6 Affairs, was there; right?

7 A. Yes.

8 Q. McKesson. He's from McKesson; right?

9 A. Yes, he was.

10 Q. And John Gilbert, one of McKesson's
11 lawyers was present; true?

12 A. That is correct.

13 Q. And it says -- next paragraph down it
14 outlines now who is there from the DEA. It says:

15 (Reading) Representing Drug
16 Enforcement Administration (DEA)
17 Office of Diversion Control (OD) were
18 Joseph Rannazzisi, Deputy Assistant
19 Administrator, Michael R. Mapes,
20 Chief, E-Commerce Section (end of
21 reading).

22 Another DEA person; true?

23 A. Yes.

24 Q. Kyle Wright, Chief E-Commerce
25 Operations from the DEA was present; right?

1 A. Yes.

2 Q. And then Charles E. Trant, a DEA
3 Chief Counsel, a lawyer, was also present; right?

4 A. That's what's represented on the
5 document, yes.

6 Q. The next paragraph down. Could you
7 read that to us. Read the next paragraph down.

[REDACTED]













[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

6 BY MR. KENNEDY:

7 Q. The next bullet point down, "The
8 E-Commerce Section" -- that's the DEA -- "retrieved
9 ARCOS data" -- and that's a database where the DEA
10 can look at what McKesson is actually distributing
11 and selling; true? That's what the ARCOS data is?

12 A. The ARCOS data is data that we
13 provided -- that is required by the regulation. So
14 it is data of sales of controlled substances that are
15 required to be reported.

16 Q. So it states:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

22 Q. You know that at this point in time,
23 the DEA, their statistics in ARCOS, were showing that
24 the average monthly, average monthly distribution by
25 a distributorship of McKesson was 5,000 units of

1 hydrocodone? Do you remember that? Remember that
2 communication, all during this period?

3 MS. HENN: Objection to form.

4 THE WITNESS: I recall DEA indicating that
5 5,000 doses of controlled substances was average.

6 BY MR. KENNEDY:

7 Q. That's an average monthly dose;
8 right?

9 A. That's what I recall.



14 Q. -- you don't have any knowledge
15 whether these are correct? You were directly
16 involved with this memo from the beginning, and this
17 led to negotiations and a settlement, and McKesson
18 losing its license to distribute opioids and a
19 \$13 million fine; did it not? You were directly
20 involved with that; were you not?

21 MS. HENN: Objection to form.

22 THE WITNESS: I was directly involved in the
23 settlement with DEA and the penalties that were
24 associated with that.

25 //

1 BY MR. KENNEDY:

The image consists of a series of horizontal grey bars of varying lengths, arranged vertically. The bars are composed of several segments, some of which are separated by small gaps. The lengths of the bars vary significantly, with some being very short and others extending almost to the top of the frame. The overall effect is a sense of repetition and rhythm.

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

19 MR. KENNEDY: Could I have the Elmo, please.

20 MS. HENN: Counsel, we have been going over
21 an hour. Would this be a decent time for a five-,
22 ten-minute break?

23 MR. KENNEDY: Sure.

24 THE VIDEOGRAPHER: We are going off the
25 record. The time is 10:07 a.m.

1 (Recess taken.)

2 THE VIDEOGRAPHER: We are back on the
3 record. The time is 10:22 a.m.

4 BY MR. KENNEDY:

The image consists of a series of horizontal grey bars of varying lengths, arranged vertically. The bars are set against a white background. Some bars have small gaps between them, while others are continuous. The lengths of the bars vary significantly, with some being very short and others extending almost to the top of the frame.

Q. Hydrocodone is a controlled substance; right?

23 A. Yes, it is.

A horizontal bar composed of three distinct grey rectangles. The first rectangle is the narrowest on the far left. To its right is a wider rectangle, and further to the right is the widest rectangle, which is also the longest. These three rectangles are separated by small gaps.



The image consists of a sequence of horizontal grey bars arranged vertically. Each bar is preceded by a small, separate vertical grey bar of the same shade. The length of the horizontal bars varies significantly from one row to the next, creating a dynamic visual pattern. The bars are set against a plain white background.

20 BY MR. KENNEDY:

21 Q. Sir, you sat through the meetings,
22 the negotiations, the pleadings, and all of the legal
23 proceedings with respect to this event; did you not?

24 A. No, that's not accurate. I did not
25 sit through all the meetings and negotiations that

1 took place between counsels.

2 Q. Did you sign the agreement with the
3 DEA in relation to these violations, these sales of
4 hydrocodones? Did you sign the very settlement
5 agreement; sir?

6 A. I signed the 2008 memorandum
7 agreement, yes.

8 Q. Let me back up, because I just -- I
9 just want to be clear about it.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1 able to sell narcotics to pharmacies: Right? If you
2 have got to give your registration back, that's what
3 that means?

4 A. If a registration is suspended or
5 revoked, then you're unable to sell controlled
6 substances.

17 BY MR. KENNEDY:

18 Q. And you ended up surrendering your
19 registration; didn't you?

20 MS. HENN: Objection to form.

21 THE WITNESS: Counsel, that's not correct.

22 We had a limited suspension of certain controlled
23 substances from certain distribution centers, is the
24 result of the agreement with DEA.

25 //

1 BY MR. KENNEDY:

2 Q. We will look at that specifically.

3 Let's go down to -- after some bullet points, I want

4 to go down to the paragraph that starts with

5 "Through."

6 Do you see this paragraph that starts with

7 "Through"?

[REDACTED]





[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 Q. And tell the jury what generic
7 hydrocodones are.

8 A. In all pharmaceuticals or medicines,
9 as a brand drug comes to market, it stays brand for a
10 period of time, at which time a generic drug can be
11 manufactured that has the same pharmacological
12 characteristics as the brand medication. So it's
13 very common in pharmaceutical industry for generics.
14 Amoxicillin is probably the best example that
15 everybody would know.

16 Q. And, sir, the majority of
17 hydrocodones that McKesson was selling were generic;
18 were they not?

19 A. I do not know what quantities were
20 brand versus generic at that point in time.

21 Q. In a general sense, that has always
22 been true at McKesson? You sell more generics than
23 you do brand name controlled substances; hasn't that
24 always be true?

25 MS. HENN: Objection to form.

1 THE WITNESS: Again, I don't have any
2 specific knowledge one way or the other.

3 BY MR. KENNEDY:

The image consists of a grid of horizontal grey bars. The bars are arranged in a descending staircase pattern from the top-left to the bottom-right. Each bar's length corresponds to its position in the sequence. The first bar is the shortest, and each subsequent bar is longer than the previous one. The bars are set against a white background.



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

7 BY MR. KENNEDY:

8 Q. Sir, McKesson had the duty since 1970
9 to identify and report suspicious orders of
10 controlled substances; did they not?

11 A. I don't know specifically when the
12 CFR was generated. It was in the early '70s. But in
13 the time that I was there, we had the responsibility.

14 Q. And that included generic
15 hydrocodones, did it not, that duty, that
16 responsibility?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: We were responsible to report
20 the sales of all pharmaceutical or controlled
21 substances that were reportable to the DEA.

22 MR. KENNEDY: Okay. I'm going to ask to
23 strike your answer. Could you read back my question,
24 sir. I want you to listen real careful, and I want
25 you to answer this question. Not what you want to

1 answer. I want you to answer what I'm asking this
2 point forward, if you could.

3 MS. HENN: Objection to form.

4 MR. KENNEDY: Could you read it back,
5 please.

6 (Record read as follows: QUESTION:

7 And that included generic
8 hydrocodones, did it not, that duty,
9 that responsibility?)

10 MS. HENN: Same objection. Lacks
11 foundation.

12 THE WITNESS: Hydrocodone -- all hydrocodone
13 was a reportable controlled substance.

14 BY MR. KENNEDY:

15 Q. Including generic hydrocodone; true?

16 A. Including generic hydrocodone, yes.

17 Q. Because generic hydrocodone, sir, is
18 just as addictive as brand-name hydrocodone; is it
19 not?

20 MS. HENN: Objection to form.

21 THE WITNESS: I have no expertise on
22 addiction rates or addiction. So I can't comment
23 whether -- one versus the other.

24 BY MR. KENNEDY:

25 Q. They weren't any different

1 chemically; were they?

2 MS. HENN: Objection to form.

3 BY MR. KENNEDY:

4 Q. Branded versus generic aren't
5 different chemically?

6 A. Generally, my understanding is that
7 they were very close, if not identical, in terms of
8 chemical makeup. But, again, I don't have the level
9 of expertise to testify absolutely that they were the
10 same.

11 Q. Generic hydrocodone, sir, your
12 understanding generic hydrocodone was just as likely
13 to cause an overdose and death as a named brand
14 hydrocodone; true?

15 MS. HENN: Objection to form.

16 THE WITNESS: My understanding is that
17 generic hydrocodone, as it's designed for medical
18 purposes, it was the same as brand hydrocodone.

19 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

The image consists of a sequence of horizontal grey bars arranged vertically. Each bar is preceded by a small, separate vertical grey bar of the same shade. The length of the horizontal bars varies significantly from one row to the next. Some rows contain a single long horizontal bar, while others contain multiple shorter horizontal bars. The overall pattern creates a rhythmic and abstract visual effect.

19 BY MR. KENNEDY:

20 Q. By 2005, though, you understood, did
21 you not, that hydrocodones were one of the major
22 causes of addictions in the United States? You knew
23 that by 2005; didn't you?

24 MS. HENN: Objection to form.

25 THE WITNESS: I don't recall, you know,

1 specifically having any awareness of hydrocodone
2 being a national issue in 2005.

3 BY MR. KENNEDY:

4 Q. By 2005, sir, didn't you understand
5 that hydrocodones were one of the most highly
6 diverted drugs in this country?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 BY MR. KENNEDY:

10 Q. Do you understand that by 2005?

11 MS. HENN: Same objection.

12 THE WITNESS: I don't -- I don't have any --
13 any recollection or knowledge of that.

14 BY MR. KENNEDY:

15 Q. So at this point in time, in 2005 to
16 early 2006, when you have this period where you sell
17 two million hydrocodones, are you saying that you did
18 not understand that hydrocodones were one of the most
19 highly diverted drugs in this country? You didn't
20 know that?

21 MS. HENN: Objection. Asked and answered.
22 Lacks foundation.

23 THE WITNESS: I had no knowledge or
24 understanding of addiction rates of hydrocodone.

25 ///

1 BY MR. KENNEDY:

2 Q. You had been selling hydrocodones for
3 a decade or more, making millions of dollars, and you
4 didn't understand that; is that your testimony?

5 MS. HENN: Objection. Asked and answered.

6 Lacks foundation.

7 THE WITNESS: In 2005 I had no knowledge and
8 don't recall.

9 MR. KENNEDY: I am going to give you
10 Exhibit 695.

11 (Exhibit No. 695 was marked.)

12 BY MR. KENNEDY:

13 Q. Sir, I'm going to show you --

14 MS. HENN: Counsel, this appears to have
15 been printed without Bates number or confidentiality
16 stamp. So we would just ask, for the record, that
17 those -- the number and the confidentiality
18 designation be read into the record, if you have it.

19 MR. KENNEDY: The Bates numbers?

20 MS. HENN: The Bates number, so the people
21 on the phone know what you're looking at.

22 MR. KENNEDY: These are not Bates numbered.
23 This comes from the U.S. Department of Justice, Drug
24 Enforcement Administration.

25 MS. HENN: Has it not been produced in this

1 litigation?

2 MR. KENNEDY: Well, I can't tell you I've
3 got a memory of all 20 million documents produced, so
4 I really don't know.

5 MS. HENN: Okay.

6 BY MR. KENNEDY:

7 Q. Do you see the DEA logo on
8 Exhibit 695, sir?

9 A. Yes, I do.

10 Q. Does it say, "U.S. Department of
11 Justice, Drug Enforcement Administration"; correct?

12 A. Yes.

13 Q. Do you see the Bates stamp there?
14 They are -- they are not Bates stamped, but a date
15 stamp of July 28, 2004; do you see that?

16 A. Yes.

17 Q. And you were just telling me you
18 don't think you had knowledge of -- with respect to
19 the diversion, the addiction of hydrocodones in 2005.
20 That's what we were talking about; right?

21 MS. HENN: Objection. Asked and answered.

22 BY MR. KENNEDY:

23 Q. Correct, sir? Is that what we just
24 were talking about, your knowledge in 2005; right?

25 A. That's correct.

1 Q. And then in 2005 you were the boss
2 with respect to McKesson's regulation, diversion of
3 controlled substances; correct?

4 MS. HENN: Objection. Lacks foundation.

5 THE WITNESS: In the latter part of 2005, I
6 assumed that responsibility.

7 BY MR. KENNEDY:

8 Q. All right. And this is July '04. So
9 this is -- this is even before that date; right? So
10 this is available before that date; all right?

11 MS. HENN: Objection to form.

12 BY MR. KENNEDY:

13 Q. Go to page 2. 132 at the bottom,
14 page 2 up at the top. The second sentence,
15 "Despite." Does it state:

16 (Reading) Despite their obvious
17 utility in medical practice, as stated
18 above, hydrocodone products are among
19 the most popular pharmaceutical drugs
20 associated with drug diversion,
21 trafficking, abuse and addiction (end
22 of reading)?

23 Is it your testimony you did not know that
24 in 2005?

25 A. Counsel, as I answered, I do not

1 recall having any specific knowledge of hydrocodone
2 or this issue. This is the first time I've seen this
3 document and had no other personal knowledge.

4 Q. Well, you're in charge of Regulatory
5 in 2005; right?

6 MS. HENN: Objection to form.

7 THE WITNESS: I assume --

8 BY MR. KENNEDY:

9 Q. Correct?

10 A. I assumed responsibility for
11 Regulatory in September of 2005.

12 Q. And McKesson is selling millions upon
13 millions of hydrocodones in 2005; are they not?

14 A. I don't know specifically the
15 quantities that we were selling. We sold hydrocodone
16 as one of the controlled substances we provided to
17 our licensed pharmacies.

18 Q. Look at the first bullet. And this
19 is a -- this is in a government available document.
20 Look at the first bullet, "Hydrocodone has an abuse
21 liability similar to morphine."

22 Did you know that?

23 MS. HENN: Objection to form.

24 BY MR. KENNEDY:

25 Q. Did you know that in 2005?

1 A. No, Counsel, I -- as I said, I don't
2 have and did not have any personal knowledge of, you
3 know, hydrocodone or its comparison to morphine.

4 Q. Look at the next bullet, first
5 sentence. Now you're in charge of making sure that
6 hydrocodones as a controlled substance are not being
7 diverted; correct?

8 A. We had the responsibility --

9 Q. I asked you about, were you in charge
10 of that responsibility?

11 MS. HENN: Objection to form.

12 Let the witness finish his answer, please.

13 THE WITNESS: I had responsibility for our
14 regulatory and our compliance, which included
15 guarding against and preventing -- guarding against
16 the diversion of controlled substances.

17 BY MR. KENNEDY:

18 Q. Does the next bullet point in this
19 DEA document say, "Hydrocodone products are
20 associated with significant diversion"? Does it
21 state that?

22 A. Paragraph 2, that's what the document
23 says. And DEA is alleging, yes.

24 Q. You say, "DEA is alleging." Is that
25 what you said? Did you say, "DEA is alleging"?

1 A. This is -- this is their document.

2 Q. When you say "allege," you didn't --
3 there's not much question about that. This is more
4 than an allegation. That's the truth in 2005, from
5 everything you know, sir? Fifteen years in this,
6 that's the truth; is it not?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 THE WITNESS: Counsel, again, I -- as I
10 stated, I do not remember having any specific
11 recollection around discussions either -- or
12 documents around hydrocodone's addictive and its
13 comparison to others.

14 BY MR. KENNEDY:

15 Q. I just want to go back.

16 A. I'm just simply looking at the
17 document and trying to answer your question.

18 Q. I just want to ask you real simple.
19 You used the words, "DEA alleges." Was the problem
20 in 2005 that you and McKesson thought that these were
21 just DEA allegations with respect to hydrocodones and
22 diversion? Did you think these were just
23 allegations?

24 MS. HENN: Objection to form.

25 Mischaracterizing the testimony and lacks foundation.

1 BY MR. KENNEDY:

2 Q. Is that what you thought in 2005,
3 sir?

4 A. Counsel, I was answering your
5 question specific to this document. I don't know.
6 And certainly I'm not sure I can answer the question
7 as you asked it.

8 Q. Next says -- next bullet, first
9 sentence, "Hydrocodone products are associated with
10 significant drug abuse."

11 Did you know that in 2005, as the person who
12 was in charge of Regulatory? Did you know that?

13 MS. HENN: Objection to form.

14 THE WITNESS: Again, I don't recall being
15 specifically aware of a hydrocodone drug abuse issue.

16 BY MR. KENNEDY:

17 Q. The next bullet:

18 (Reading) Poison control data, DAWN
19 medical examiner (ME) data and other
20 ME data indicate that hydrocodone
21 deaths are numerous, widespread and
22 increasing in number (end of reading).

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 (Exhibit No. 693 was marked.)

7 BY MR. KENNEDY:

8 Q. Showing you what has been marked as
9 Exhibit 693. 693, all right, which is No. -497154.

10 Go to the second page, if you would. And I
11 believe this is a document prepared by the DEA and
12 provided to us by McKesson.

13 Do you see the chart on page -155? Do you
14 see that?

15 A. Yes.

16 Q. Now, this is McKesson hydrocodone
17 sales and distributions from October 1, now, to
18 January 31, a four-month period. We've been talking
19 about just 11 days in October.

20 This is a four-month period; do you see
21 that?

22 A. Yes.

23 Q. This is in Florida, just Florida;
24 all right?



1 that's where the DEA gets its number; true?

2 MS. HENN: Objection to form.

3 THE WITNESS: I know that ARCOS is one of
4 the sources of DEA's data. But I don't know that
5 it's exclusive.

6 BY MR. KENNEDY:

7 Q. And tell the jury who provides the
8 DEA with the ARCOS data on your sales. Who provides
9 that to them?

10 A. We submit on a monthly basis, as
11 required by the regulation, the ARCOS data on the
12 sales of controlled substances that are required to
13 be reported.

14 Q. McKesson gives them the numbers on
15 what you're selling them; right?

16 A. We provide the ARCOS data to DEA.

[REDACTED]





[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 BY MR. KENNEDY:

7 Q. And that included, number one,
8 identifying orders of unusual size; correct?

9 MS. HENN: Objection to form.

10 THE WITNESS: In the suspicious order
11 regulation, unusual size is called out.

12 BY MR. KENNEDY:

[REDACTED]

23 Q. Absolutely. And that's more than
24 just making sure you're selling to a pharmacy that's
25 got a license; right? Correct?

1 A. And report to the DEA.

The figure is a horizontal bar chart with 1000 bars. The x-axis is labeled 'Index' and ranges from 1 to 1000. The y-axis is labeled 'Category' and ranges from 1 to 10. The bars are colored grey. The distribution is highly skewed, with most samples falling into categories 1, 2, 5, 6, 7, 8, 9, and 10, while categories 3 and 4 have very few samples.

Category	Approximate Sample Range
1	1-1000
2	1-1000
3	~100-200
4	~100-200
5	1-1000
6	1-1000
7	1-1000
8	1-1000
9	1-1000
10	1-1000

13 BY MR. KENNEDY:

14 Q. You don't remember that that is the
15 reason that you got fined \$13 million?

16 MS. HENN: Objection to form. Lacks
17 foundation.

18 BY MR. KENNEDY:

19 O. You don't remember?

20 A. I don't remember or have any
21 independent knowledge of whether or not any of these
22 pharmacies ever reported to DEA during that time
23 frame.

24 Q. All right. Sir, I wrote down some of
25 the dates of what we have been talking about so we

1 can put it all together here, everything we have been
2 talking about.









11 (Exhibit No. 802 was marked.)

12 MR. KENNEDY: Well, sir, let's -- let me
13 show you Exhibit 686.

14 (Exhibit No. 686 was marked.)

15 BY MR. KENNEDY:

16 Q. 686 does not have Bates numbers.

17 Sir, you indicate you don't have any knowledge of
18 McKesson -- McKesson sending massive amounts around
19 the country of hydrocodone -- excuse me,
20 hydrocodones. This is a Settlement Agreement. Look
21 at that first sentence.

22 (Reading) This is a Settlement
23 Agreement entered into on April 30th,
24 2008, between the United States
25 Department of Justice, through the

1 United States Attorney's Office, for
2 the Districts of Maryland, Middle
3 Florida, Southern Texas, Colorado,
4 Utah, and Eastern California (end of
5 reading).

6 Do you see that?

7 A. I see that.

8 Q. And the Settlement Agreement is with
9 McKesson Corporation; true?

10 A. Yes.

11 Q. You signed this document; did you
12 not?

13 A. Yes, I did.

14 Q. And that's why I'm asking, why is it
15 that you didn't have any knowledge that this was
16 going on across the country? You signed this
17 document; didn't you?

18 MS. HENN: Objection to form.

19 THE WITNESS: I signed this document,
20 Counsel.

21 BY MR. KENNEDY:

22 Q. Let's go to the next page, down to
23 No. 8 on the next page. See where it says, on No. 8,
24 paragraph 8, "The Covered Conduct shall mean the
25 following alleged conduct"? Do you see that?

1 A. Yes.

2 Q. "A: Within the District of
3 Maryland" -- and that's not Florida; right? Can we
4 agree that's not Florida?

5 A. Maryland is not Florida.

6 Q. (Reading) -- from January 2005?

7 through October 2006,
8 McKesson-Landover sold approximately
9 three million dosage units of
10 hydrocodone to New Care Pharmacy in
11 Baltimore and failed to report these
12 sales as suspicious orders to DEA when
13 discovered, as required by and in
14 violation of 21 C.F.R 1301.74(b), and
15 21 U.S.C. 842 (a)(5) (end of reading).

16 Do you see that?

17 A. Yes.

18 Q. That's 150,000 hydrocodones a month,
19 if I did the math right. Do you see that? That
20 would be 30 times the national average?

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. The DEA national average; right? If
24 I did my math right.

25 MS. HENN: Objection to form.

1 BY MR. KENNEDY:

2 Q. Do you see that?

3 A. Again, if using DEA's average, which
4 I can neither support or refute, and the dosage units
5 here, that your math is correct.

6 Q. That's Maryland; right? So let's
7 go -- No. B, that's the Middle District of Florida,
8 and that's probably what we've been talking about;
9 correct?

10 A. Yes.

11 Q. And then go to C. Now we're in the
12 Southern District of Texas; right? And does it
13 state:

14 (Reading) from February to December of
15 2007, McKesson-Conroe sold
16 approximately 2.6 million dosage units
17 of hydrocodone to Mercury Drive
18 Pharmacy and Maswoswe's Alternative
19 Pharmacy and failed to report those
20 sales as suspicious orders to DEA when
21 discovered (end of reading).

22 Did I read that right?

23 A. Yes, you read that correctly.

24 Q. And that's over eight months. And
25 that would be about 150,000 a month, if I did my math

1 right; correct?

2 A. If you divide what that says, that
3 would be correct for the two pharmacies.

4 Q. And, again, if the DEA was correct,
5 and that the national average is about 5,000 a month,
6 what's this? About 30 times? 30 times the national
7 average; right?

8 MS. HENN: Objection to form.

9 BY MR. KENNEDY:

10 Q. Correct?

11 A. Are you referring to the Texas
12 pharmacies?

13 Q. We're on Texas, yes, sir.

14 A. If the math -- but, again, it would
15 be -- there's two pharmacies involved. But your math
16 would be correct.

17 Q. And not one order was reported to the
18 DEA; was it?

19 MS. HENN: Objection to form. Lacks
20 foundation.

21 BY MR. KENNEDY:

22 Q. Is that right?

23 A. I don't have any specific knowledge
24 of what was or wasn't reported to DEA.

25 Q. What does it state here. "Failed to

1 report these sales as suspicious orders to the DEA";
2 does it say that?

3 A. That's what it says. That was the
4 allegation.

5 Q. Did you sign this?

6 A. I did.

7 Q. Let's go to D on the next page. This
8 is Colorado now. It states:

9 (Reading) With respect to Colorado,
10 from September 2005 through November
11 of 2007, McKesson-Aurora sold large
12 quantities of hydrocodone to three
13 Colorado pharmacies (end of reading).

14 Is that what it states with respect to
15 Colorado?

16 A. That is correct.

17 Q. E, now we're in Utah:

18 (Reading) From January 2005 through
19 October 2007, McKesson-Salt Lake City
20 sold approximately 825,000 dosage
21 units of hydrocodone, oxycodone,
22 Fentanyl and Methadone to the
23 Blackfeet Clinic in Browning, Montana
24 (end of reading).

25 Does it state that?

1 A. Yes, that's what it states.

2 Q. And, again, failed to report any of
3 these to the DEA as suspicious orders; true?

4 MS. HENN: Objection to form. Lacks
5 foundation.

6 BY MR. KENNEDY:

7 Q. Correct?

8 MS. HENN: Same objections.

9 THE WITNESS: What is written is that
10 allegation.

11 BY MR. KENNEDY:

12 Q. You signed the document; right?

13 A. I signed the agreement.

14 Q. And, again, just to backtrack a
15 second. The responsibility of McKesson, with respect
16 to suspicious orders, included identifying orders of
17 unusual size; true? Is that true?

18 A. As part of the regulation, size is a
19 factor.

20 Q. Part of your responsibility, is to
21 identify unusual orders of size; correct?

22 MS. HENN: Objection to form.

23 THE WITNESS: We were responsible for
24 reporting suspicious orders, which included unusual
25 size.

1 BY MR. KENNEDY:

2 Q. Sir, I asked you a "yes" or "no"
3 question. And we have a limited amount of time here.
4 And I know you've been instructed to repeat my
5 question in your answer to take up time. But if I
6 asked you a "yes" or "no" question, I want you to
7 answer it "yes" or "no" so we can move forward with
8 this and not waste time having you repeat my question
9 in every answer, as you've been instructed to.

10 All right?

11 MS. HENN: Counsel, I don't appreciate the
12 kind of --

13 MR. KENNEDY: But it's the truth.

14 MS. HENN: -- allegation you're making.

15 MR. KENNEDY: It's the truth, and you know
16 that.

17 MS. HENN: You don't know that. And you're
18 just arguing with the witness and wasting time.

19 MR. KENNEDY: Are you going to deny that
20 that's the truth?

21 MS. HENN: I am --

22 MR. KENNEDY: Are you going to deny that
23 that is the truth of how he has been prepared?

24 MS. HENN: Counsel, you know you have no
25 right to know anything about how he has been

1 prepared. He is here to answer your questions and
2 has been doing that in good faith, and I suggest you
3 move on and ask the question.

4 MR. KENNEDY: Absolutely. Because you know
5 I have no right to know how you have prepared the
6 witness, you know --

7 MS. HENN: Counsel --

8 MR. KENNEDY: -- you can get away with
9 instructing him to repeat my question and every
10 answer to waste our seven hours.

11 MS. HENN: Counsel, you have no basis and no
12 right to make these allegations and waste time in the
13 deposition.

14 Mr. Walker has come from retirement to spend
15 time answering your questions, and he's doing a
16 good-faith job of that. And I suggest we move on
17 from this tantrum and --

18 MR. KENNEDY: It's not a tantrum.

19 MS. HENN: -- pay attention to the job at
20 hand.

21 If you would like to call the Special Master
22 and have him review this transcript, I think he will
23 agree that the witness is doing a fine job of
24 responding to your argumentative questions, and will
25 continue to do that throughout the day.

1 MR. KENNEDY: Nobody answers questions in
2 that fashion unless they are told to do so. I
3 don't -- I don't blame him one bit. He's a gentleman
4 coming here from his retirement and having to answer
5 these questions because of the company that he worked
6 for and what they did to this country.

7 What I am objecting to is the way you have
8 instructed this witness to waste our time.

9 MS. HENN: Counsel --

10 MR. KENNEDY: That's what I am objecting to.
11 So let's be clear.

12 MS. HENN: Are you done with your speech now
13 so we can move on?

14 MR. KENNEDY: I all am done, so let's move
15 on.

16 MS. HENN: Thank you.

17 MR. KENNEDY: I hope, I just hope that he
18 ceases and stops what he is doing.

19 MS. HENN: He's not doing anything of the
20 sort. And I suggest we focus on the task at hand.

21 BY MR. KENNEDY:

22 Q. Sir, let's now go to California, if
23 we could. Does this Settlement Agreement, in
24 California state, that:

25 (Reading) From October of '07 through

1 June of '07, McKesson-West Sacramento
2 suffered the theft of significant loss
3 of controlled substances on 28
4 separate occasions and failed to
5 timely submit required theft and loss
6 reports to the DEA (end of reading)?

7 Is that what it states here? Now, this is
8 California.

9 A. That's what it states.

10 MR. KENNEDY: I want you to look at
11 Exhibit 688.

12 I'm sorry, 687.

13 (Exhibit No. 687 was marked.)

14 MR. KENNEDY: 687 Exhibit starts with Bates
15 -00574724 and ends with -4744.

16 Q. Mr. Walker, have you seen this
17 document before?

18 A. Yes, I have.

19 Q. And this would relate to a meeting of
20 "Directors of Regulatory"? Is that what it says?

21 A. Yes.

22 Q. This would have been in Dallas, March
23 5-6. 2008: true?

24 A Yes

25 O. Do you remember who was present at

1 this meeting?

2 A. I don't remember specifically all the
3 participants. I know that our newly-hired Director
4 of Regulatory Affairs and my Regulatory staff was
5 there. But I don't know who else might have been
6 there.

7 Q. And the purpose of the meeting was
8 what?

9 A. As I recall, the purpose of the
10 meeting was to review with the Regulatory staff and
11 then expanded the overview of the Memorandum of
12 Agreement that we were moving forward with. We
13 hadn't signed it yet, but we were very close. So we
14 had the components.

15 Q. That was the Memorandum of Agreement
16 that we just talked about with the DEA, with the
17 Department of Justice?

18 A. Yes, the same memorandum.

19 Q. And it was signed by you, and it was
20 also signed by Mr. Hambergren, that agreement with
21 the DEA; was it not?

22 A. I'd -- I'd have to look.

23 Q. Let me ask you this. Where -- in
24 relation to the company in 2008, where were you with
25 respect to -- Mr. Hambergren was the CEO?

1 A. Yes, he's the CEO.

2 Q. Where did you sit in relation to the
3 CEO in your responsibility as with the VP of
4 Distribution and Operations? Where did you sit in
5 relation to Mr. Hambergren?

6 A. Probably best described as not very
7 close. But it was several levels, you know, down in
8 the organization.

9 Q. Would you interact with him? You
10 were both in San Francisco; right?

11 A. There were occasions that I
12 interacted with Mr. Hambergren.

13 Q. What committees did you sit on? I
14 know that -- we know your title. But were you a part
15 of any management committees at McKesson? And I'm
16 talking about the '08 period.

17 A. Yes. So in that time frame in my
18 role, I was part of the -- I will use your term --
19 management committee that oversaw -- oversaw the
20 pharmaceutical business.

21 Q. Okay. So the management committee
22 that oversaw the pharmaceutical business. And a
23 significant part of McKesson's business was the
24 pharmaceutical business, I assume?

25 A. Yes.

1 Q. And when -- who all was on the
2 management committee of pharmaceuticals?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. And, again, we're on the 2008 period.

6 A. At a -- at a high level, the
7 president of U.S. Pharma and then individuals that
8 had leadership positions in sales, inventory,
9 vendor-manufacturer relationships, HR, and marketing,
10 I.T. I mean, sort of --

11 Q. Ten members? Twenty members?

12 A. My best recollection is about ten.

13 Q. And their responsibility was -- was
14 what this management committee of U.S. -- this is
15 U.S. pharmaceuticals?

16 A. Yes. U.S. pharmaceuticals.

17 Q. And what was the responsibility of
18 this management committee that you sat on?

19 A. Again, at a high level, it was really
20 to collaborate to provide overall guidance and
21 direction. And there was, you know, the normal
22 planning/budgeting processes that we went through.

23 Q. All right. Let's -- let's go back to
24 this meeting, then, that was -- that was held in 2008
25 with the Directors of Regulatory.

1 If you can go to page -- the Bates in the
2 bottom of -4733. Did you run this meeting?

3 A. Yes, I did.

4 Q. Did you prepare these slide
5 presentations?

6 A. Looking at it, I don't specifically
7 put in the slide presentation. But it was consistent
8 with one that I would do.

9 Q. All right. Well, let's look, then,
10 at this page of the 2008 slide presentation. And
11 this is talking about the 2008 Settlement Agreement
12 that is reached with the Department of Justice and
13 the DEA; correct?

14 A. Correct.

15 Q. And this is in relation to what we
16 have been talking about for the last hour; true?

17 A. Yes.

18 Q. And does this slide presentation
19 state that -- the first -- the first bullet, "Six
20 different McKesson facilities involved"; right?

21 A. Yes.

22 Q. And we went over those six different
23 facilities, I think. Florida, Maryland, Texas, Utah;
24 correct? Those are the ones we went through?

25 A. That's correct.







6 Q. And does it state, Conroe DC -- that
7 would be Texas, Conroe?

8 A. Yes.

23 BY MR. KENNEDY:

24 Q. Sir, at this point in time, these
25 allegations, which are 2004, 2005, 2006, at that

1 point in time were the suspicious order monitoring
2 policies of McKesson national?

3 A. Yes. It was a single system. So the
4 answer is, yes.

5 Q. So the policies and the procedures
6 that led at least to what you considered to be the
7 allegations of these extraordinary sales, those
8 policies and procedures were the same in Maryland,
9 Ohio, West Virginia, Utah, Florida; would that be
10 true?

11 A. Yes.

12 Q. And as the person in charge, sitting
13 on the top of this, did you make every effort to make
14 sure that the implementation of the policies and
15 procedures relating to suspicious order monitoring,
16 that they were being implemented uniformly across the
17 country?

18 MS. HENN: Objection to form.

19 THE WITNESS: Yes, we had a system in place
20 that was reporting regularly to DEA suspicious
21 orders.

22 BY MR. KENNEDY:

23 Q. So the answer would be, yes, you, as
24 the boss, made an effort to make sure that your
25 policies with respect to suspicious orders were being

1 implemented uniformly across the country; true?

2 A. Yes.

3 Q. You didn't want somebody doing
4 something different in California than they were
5 doing in Maryland; did you?

6 A. The system was one system. So the
7 uniform reporting and report generation was the same
8 across the country.

9 Q. And would I be correct that you had
10 meetings amongst the Directors of Regulatory Affairs
11 from different regions, you had meetings and calls to
12 make sure that the policies with respect to
13 suspicious order monitoring were being implemented
14 and used by them uniformly; true?

15 MS. HENN: Objection to form. Lacks
16 foundation.

17 THE WITNESS: Can you clarify the time frame
18 you're referring to.

19 BY MR. KENNEDY:

20 Q. Again, let's -- the entire time that
21 you were the head of -- excuse me. You were the head
22 of Regulatory. You would have meetings and
23 conference calls in an attempt to make sure that your
24 policies with respect to suspicious order monitoring
25 were being implemented uniformly across the country;

1 right?

2 A. Generally I would answer that
3 question, yes, Counsel. The reason I asked you the
4 question about the time frame is at this point this
5 was the initial meeting that I had with newly-hired
6 directors. So prior to that meeting, they would not
7 have been involved in any of the suspicious orders.
8 So I want to be accurate in my response to you.

9 Q. Okay. But from '08 forward, while
10 you were in charge, again, you would have meetings,
11 you would have memos, you would have calls in an
12 attempt to make sure that your policies were being
13 implemented uniformly across the country; true?

14 MS. HENN: Objection to form. Compound.
15 Lacks foundation.

16 THE WITNESS: So subsequent to the 2008
17 agreement with the regulatory team, we had regular
18 conference calls, regular discussions to ensure that
19 we were executing our regulatory responsibilities
20 uniformly across the country; so yes.

21 BY MR. KENNEDY:

22 Q. You don't want Mr. Oriente in the
23 East doing something different from Mr. McDonald in
24 the West, doing something different than Mr. Gustin
25 in the Midwest; true?

1 A. Generally that would be accurate.

2 MS. HENN: Counsel, we have been going about
3 an hour and ten minutes. Take another break.

4 MR. KENNEDY: I about to switch to a new
5 topic. That's good.

6 THE VIDEOGRAPHER: We are going off the
7 record. The time is 11:31 a.m.

8 (Recess taken.)

9 THE VIDEOGRAPHER: We are back on the
10 record. The time is 11:49 a.m.

11 BY MR. KENNEDY:

12 Q. All right. Mr. Walker, it's still
13 Eric Kennedy after our break. I know you might be
14 disappointed, but it's still me.

15 I'm going to switch gears. I want to talk
16 about the 2008 CSMP, the Controlled Substances
17 Monitoring Program. You remember that program?

18 A. Yes.

19 Q. That was a program that McKesson
20 developed and put into place in 2008; is that true?

21 A. Yes, that is correct.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

22 Q. Let me -- let me show you

23 Exhibit 672. And if you keep this exhibit in front

24 of you even after this series of questions, because

25 we're going to refer back to this quite a bit,

1 all right?

2 A. That would be fine.

3 (Exhibit No. 672 was marked.)

4 BY MR. KENNEDY:

5 Q. This is the McKesson's 2008
6 Controlled Substance Monitoring Program; is it not?

7 A. What this document is, is a -- the
8 Operations Manual entry and documentation of how to
9 execute against the Controlled Substance Monitoring
10 Program. That's probably the best way to describe
11 it.

12 Q. Was there any document that McKesson
13 has that is more comprehensive and detailed with
14 respect to your suspicious order monitoring system
15 than this document from the period of 2008 to, let's
16 say, 2014? Any document other than this that is more
17 comprehensive?

18 A. Probably this would be the most
19 comprehensive document.

20 MS. HENN: Counsel, just to clarify the
21 record. You had referred to this as the 2008
22 program, but I see it as a 2013 version. I just want
23 to make sure the record is clear on that.

24 BY MR. KENNEDY:

25 Q. Okay. This is the revised version

1 that comes into play in 2008; correct? The original
2 version is 2008?

3 A. Just a moment, Counsel.

4 MR. KENNEDY: I was -- this is when it's
5 printed, 2013. When it's printed.

6 MS. HENN: If you look on one of the last
7 pages, it will show you the revisions history.

8 MR. KENNEDY: All right.

9 MS. HENN: And the last revision I see is
10 from 11-29-2013.

11 MR. KENNEDY: All right.

12 MS. HENN: Sorry. March 20th, 2013.

13 BY MR. KENNEDY:

14 Q. And this program came into place, as
15 I said before, in 2008; did it not?

16 A. That is correct.

17 Q. And it was revised various times, as
18 we have seen, up through '13; correct?

19 A. Yes.

20 Q. And if I make reference to something
21 here in my questioning that wasn't in existence in
22 2008, you will let me know; all right?

23 MS. HENN: Objection to form.

24 THE WITNESS: I will let you know.

25 ///

1 BY MR. KENNEDY:

2 Q. All right. So this is the program
3 that comes into place, the Controlled Substances
4 Monitoring Program, in 2008; would that be correct?

5 A. Yes. This is the Controlled
6 Substance Monitoring Program overview that we would
7 put in our Operations Manual.

8 Q. And we were talking about this
9 threshold system. And do you see where it says,
10 "Purpose"?

11 A. Yes.

A horizontal bar chart illustrating the distribution of 1200 samples across 12 categories. The x-axis represents the number of samples (0 to 1200), and the y-axis represents the category index (0 to 11). The bars show the following approximate sample counts per category:

Category	Approximate Sample Count
0	1
1	120
2	120
3	120
4	120
5	120
6	120
7	120
8	120
9	120
10	120
11	120

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5 MR. KENNEDY: We will take a look.

6 (Exhibit No. 755 was marked.)

7 BY MR. KENNEDY:

8 Q. Showing you Exhibit 755, Bates
9 -409289 to -299. Is this the Settlement and Release
10 Agreement and Administrative Memorandum and Agreement
11 between McKesson and the Department of Justice and
12 the DEA?

13 A. I understand this to be that, yes.

14 Q. And if you will go to Attachment 6,
15 or Bates No. -298 down at the bottom. Do you see --
16 under the -291, is what we're looking for.

17 And, again, you were a signatory on this
18 agreement? Thank you. Is that correct?

19 A. Yes, I was.

20 Q. And -291, on Bates -291, if you will
21 go to that. And do you see the section, "Obligations
22 of McKesson"?

23 You might want to look at the first four
24 lines. "Obligations of McKesson." And these are the
25 obligations under the agreement that McKesson agreed

1 to with the Department of Justice and DEA; right?

2 Does it state:

3 (Reading) McKesson agrees to maintain

4 a compliance program designed to

5 detect and prevent diversion of

6 controlled substances as required

7 under the CSA and applicable DEA

8 regulations. This program shall

9 include procedures to review orders

10 for controlled substances. Orders

11 that exceed established thresholds and

12 criteria will be reviewed by a

13 McKesson employee (end of reading).

14 Do you see that?

15 A. Yes.

16 Q. So the agreement with the DEA

17 mentions thresholds; correct?

18 A. Yes.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

25 Q. And it states that you're going to

1 make informed decisions at McKesson based upon these
2 established thresholds; true? That's what your
3 program states?

4 MS. HENN: You're referring to Exhibit 672?

5 MR. KENNEDY: Yeah, I'm talking about the
6 program. We're not talking about the --

7 MS. HENN: It's a different exhibit.

8 THE WITNESS: Okay. Okay. Can you
9 repeat --

10 BY MR. KENNEDY:

11 Q. Yes, my question is --

12 A. I'm sorry. I was still --

13 Q. -- your agreement with the DEA talked
14 about thresholds; true?

15 A. Correct.

[REDACTED]



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 Q. All right. And McKesson -- if we
9 look at this program and how it's divided up, there
10 were basically two different groups of customers.
11 One, the big chain pharmacies, the RNAs, the regional
12 national accounts; correct?

13 A. That's one large customer group.

14 Q. And the other major customer group
15 that's defined in your monitoring program were the
16 ISMCs, or the independent small, medium chains;
17 correct?

18 A. That was also included. But that
19 wasn't the totality of every registrant that we
20 provided controlled substance to. So the two groups
21 that you mentioned in addition to that, would be what
22 we called our hospital or MHS group. So these were
23 hospitals, institutions, surgery centers. And then
24 probably the fourth big category was the federal
25 government.

1 Q. All right. I'm going to talk about
2 the two. I want to talk about the big chain
3 pharmacies, the RNAs; all right? And I want to talk
4 about the smaller chains, the independents and the
5 smalls; all right?

6 A. Yes.

The image consists of a series of horizontal grey bars of varying lengths, arranged vertically. The bars are of different widths and have small gaps between them. Some bars are longer than others, and some have small gaps between them.



3 (Exhibit No. 676 was marked.)

4 BY MR. KENNEDY:

5 Q. Let me show you Exhibit -- you
6 were -- you don't think that's accurate, but you
7 were -- you were the boss at this point in time in
8 '08; correct?

9 A. Yes.

10 Q. I'm going to show you Exhibit 676.
11 And that's Bates -542108 to -110.

12 This is an email from Tom McDonald. Do you
13 see that? The first page.

14 A. Yes.

15 Q. And who was Tom McDonald in this time
16 period of 12 -- or excuse me, 2012? Who was he?

17 A. Tom McDonald was the Director of
18 Regulatory Affairs for the Western part of the
19 United States.

20 Q. And so he was, what, one of four
21 directors; true? Or one of five at that point?

22 A. I don't recall specifically whether
23 we had four or six at the time. But one of four or
24 six.

25 Q. And he's sending an email to an

1 extraordinarily large group of people. Can you --
2 are you able to kind of look through that and say
3 this is -- who this group is?

4 A. Based on the names here, this is a
5 combination of our sales and operations teams in the
6 West Region.

7 Q. And you're copied on this; right?
8 Donald Walker, CC.

9 A. Yes, I am.

10 Q. So you would have gotten this; right?

11 A. Yes.

12 Q. Subject, "Ongoing due diligence, new
13 questionnaires and dispensing data." Do you see
14 that?

15 A. Yes.

16 Q. It says high -- importance is high;
17 right?

18 A. Yes.

19 Q. Look to the next page, if you would,
20 -109, all the way toward the bottom, the paragraph
21 that starts with, "Additionally."

22 A. Can I have a moment just to review
23 the rest of the document?

24 Q. Sure.

25 A. I'm not --

1 (Witness reviewing document.)

2 A. Okay.

3 Q. Look at the paragraph. This is
4 Mr. McDonald. You're copied on this. The paragraph
5 that starts, "Additionally."

6 He states:

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

8 BY MR. KENNEDY:

9 Q. And tell the jury, dispensing data
10 from a pharmacy, what is that?

11 A. The data that a pharmacy may or may
12 not provide was data around the quantities of a given
13 pharmaceutical or medicine that they would dispense.
14 So it was a summary document.

15 Q. So dispensing data is going to tell
16 McKesson how much the CVS store on Main Street, how
17 much Oxycontin they are selling; right? That's what
18 it would tell McKesson; correct?

19 A. I can't answer that accurately,
20 Counsel, because your example of a CVS store would
21 not be an example of that.

22 Q. All right. Okay. Take CVS out.

23 A. I'm trying to answer you accurately.

24 Q. Let's talk about an independent
25 pharmacy on Main Street. They provide you with

1 dispensing data. It's going to tell McKesson how
2 much Oxycontin that they are selling, actually
3 dispensing, filling prescriptions and dispensing;
4 that's what dispensing data is?

5 MS. HENN: Objection to form.

6 THE WITNESS: Dispensing data should
7 represent that, yes.

8 BY MR. KENNEDY:

9 Q. So Mr. McDonald, head of the Western
10 Region, in this email he says:

Term	Percentage
GMOs	100%
Organic	65%
Natural	75%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%

11 BY MR. KENNEDY:

12 Q. I understand. We know that to be
13 true, because we're reading the document. I'm asking
14 about your opinion. You were the boss. You were
15 above Mr. McDonald. You were the one that was in
16 charge of the implementation of the policies and
17 procedures at McKesson.

18 Do you agree, Mr. Walker, as being the boss?

19 Do you agree with his statement?

20 MS. HENN: Objection to form.

21 BY MR. KENNEDY:

22 Q. And he states:

The figure consists of three horizontal bars, each composed of a small gray square followed by a longer gray bar. The first bar is the longest, the second is shorter, and the third is the longest again.









7 Q. And he's in charge -- Mr. McDonald is
8 in charge of the Western Region. How many states did
9 that include? What states?

10 A. If there were just four of the DRAs
11 at the time, he would have had the western states,
12 and from Colorado, north to Wyoming, south to
13 Arizona -- I can't remember -- New Mexico west.

14 Q. California?

15 A. California.

16 Q. Arizona?

17 A. California, Arizona, Oregon,
18 Washington, Colorado, New Mexico.

19 Q. He's in charge of thousands of
20 pharmacies, thousands of customers; is he not?

21 A. There -- there were a lot of
22 pharmacies in the west.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 BY MR. KENNEDY:

7 Q. All right. We will look at documents
8 in a minute. But I'm going to write that down.

9 All right.

10 So I wrote dispensing -- I wrote your name,
11 Mr. Walker, "Dispensing data does not include cash
12 payment information." Is that your -- is that your
13 testimony?

14 MS. HENN: Objection to form.

15 THE WITNESS: That was not my testimony.

16 What I said is your question statement was not
17 accurate.

18 BY MR. KENNEDY:

19 Q. If you get dispensing data from a
20 pharmacy, you're going to be able to see cash
21 payments; are you not, sir?

22 A. Not necessarily.

23 Q. In many instances will you be able to
24 see that, sir?

25 A. If -- if the pharmacist chooses to

1 enter a cash payment in their pharmacy terminal
2 system where this data originates, then, yes, it will
3 show up.

4 Q. All right.

5 A. If he chooses not to do that, it
6 won't show up.

7 Q. All right. And so you're getting
8 dispensing data. And if the pharmacist is putting
9 cash payments in, all right, you're going to be able
10 to see cash payments -- correct? -- from what you
11 just said, if the pharmacist is entering it; true?

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. True?

15 A. If the pharmacist enters it into the
16 pharmacy terminal system, we would see that.

17 Q. And a certain percentage of cash
18 payments for opioids for narcotics is evidence of
19 diversion; is it not?

20 MS. HENN: Objection to form.

21 THE WITNESS: The DEA identified cash
22 payment percentage as a potential indicator.

23 BY MR. KENNEDY:

24 Q. All right. And if you get dispensing
25 data, as indicated in this memo, it's going to tell

1 you who the prescribing doctors are; is it not?

2 MS. HENN: Objection to form.

3 THE WITNESS: If the data is complete, we
4 would see the doctors -- generally see the doctors in
5 the dispensing data.

6 BY MR. KENNEDY:

7 Q. And that would allow McKesson to
8 determine whether a small group of doctors is
9 prescribing a large amount of opioids; correct? You
10 would be able to do that if you had the dispensing
11 data; true?

12 MS. HENN: Objection to form.

13 THE WITNESS: I'm not sure I can answer that
14 accurately. Generally, if the physicians are in
15 there and the data was complete, not -- our challenge
16 was, is the data wasn't always complete. So I'm
17 reluctant to say that that is accurate.

18 BY MR. KENNEDY:

19 Q. If you have accurate prescribing
20 data, McKesson would be able to determine whether a
21 small group of doctors is ordering a large percentage
22 of the opioids from that pharmacy; correct? You're
23 able to do that?

24 A. If the data was accurate, yes.

25 Q. And the DEA told you back in '06 that

1 that's one of the things that you should look for;
2 true? Back in '06 they told you?

3 MS. HENN: Objection to form. Lacks
4 foundation.

5 THE WITNESS: Repeat your question, Counsel.

6 BY MR. KENNEDY:

7 Q. And the DEA told you back in 2006
8 that's one of the things you should look for, a small
9 number of doctors ordering a large percent of the
10 opioids from a pharmacy? That's one of the things
11 you should look for?

12 A. My recollection of the document, the
13 documents state that is one of the areas that they
14 outlined.

15 Q. And if you had the doctor's name from
16 the prescribing -- or the prescribing data, you
17 could -- McKesson could research as to whether or not
18 this physician was having problems with any medical
19 board; couldn't you?

20 MS. HENN: Objection to form.

21 BY MR. KENNEDY:

22 Q. If you had that data?

23 A. I believe, Counsel -- I didn't
24 specifically make any type of inquiries myself, but
25 my understanding was, is that we -- you had the

1 ability to identify any doctors if, in fact, there
2 was documentation on state medical board sites.

3 Q. And if you got the dispensing data,

4 [REDACTED]
5 you can now actually see if a pharmacy is purchasing
6 opioids from other distributors, other than just
7 McKesson; correct?

8 MS. HENN: Objection to form. Lacks
9 foundation.

10 THE WITNESS: I don't recall that we had the
11 ability or felt we had the ability to determine
12 multiple distribution -- distributors supplying a
13 pharmacy through dispensing data.

14 BY MR. KENNEDY:

15 Q. Let me ask you this. If the
16 dispensing data says that a particular pharmacy is
17 dispensing, selling 1,000 Oxycontins in a month, and
18 your records say you're selling them only 500, then
19 you can reasonably conclude that they are getting
20 Oxycontins from somebody other than just McKesson;
21 right?

22 MS. HENN: Objection. Calls for
23 speculation.

24 THE WITNESS: Counsel, there are so many
25 variables in pharmacy behavior, in terms of inventory

1 management, again, it's very difficult for me to
2 answer accurately whether that could take place.

3 BY MR. KENNEDY:

4 Q. If you have the dispensing data,
5 McKesson would be able to determine the percentage of
6 controlled substances against total prescriptions?
7 They would be able to calculate that, wouldn't they?

8 MS. HENN: Objection. Lack of foundation.
9 Speculation.

10 THE WITNESS: Counsel, I'm having a
11 difficult time answering the question. I think it's
12 an oversimplification of analysis of the value of
13 this dispensing data.

14 As I stated, it was a very valuable tool to
15 us, but it was a single tool. We had other data
16 points that we needed to understand.

17 BY MR. KENNEDY:

18 Q. Isn't that exactly one of the things
19 that the DEA told McKesson in 2006 you ought to be
20 looking to, the percentage of controlled substances
21 that a pharmacy was selling against its total
22 prescription sales? Isn't that one of the specific
23 items that DEA informed you in 2006 you should be
24 looking at?

25 MS. HENN: Objection. Lack of foundation.

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. My recollection, was that the
4 percentage of controlled substance sales were a point
5 of indication.

6 MR. KENNEDY: All right. So we've got



9 look to another region, all right? Let's look to
10 Exhibit 680.

11 (Exhibit No. 680 was marked.)

12 MS. HENN: Thank you.

13 BY MR. KENNEDY:

14 Q. Exhibit 680 is -492821 to -492823.

15 This is an email from Dave Gustin; correct?

16 A. Yes.

17 Q. Tell the jury who Dave Gustin was?

18 A. Dave Gustin was the Director of
19 Regulatory Affairs, DRA, for the Central Region.

20 Q. And the Central Region, how many
21 states are in the Central Region?

22 A. I don't know specifically the number
23 of states going from memory here, but it's basically
24 the Midwest, stretching down into Kentucky. So Iowa,
25 Nebraska, Minnesota, Illinois, Indiana.

1 Q. Well, between Mr. McDonald now and
2 Mr. Gustin, they probably account for more than half
3 of the country; would that be right?

4 A. Certainly half the geography.

5 Q. Thousands of pharmacies; right?

6 A. There would be a large number of
7 pharmacies in that area.

8 Q. And Mr. Gustin -- now, this is
9 1-16-12. This is about the same time of McDonald's
10 email talking about dispensing data. And can you
11 tell us who's this large group of people that he
12 seems to be sending this email to?

13 A. This appears to be the North Central
14 Region Sales and Operations teams.

15 Q. Look at the next page, if you would.
16 See on the next page, a January 5, 2012, email from
17 Dave Gustin?

18 A. Yes.

19 Q. Another large group of people?

20 A. Yes.

21 Q. In the first paragraph does he state:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. So he's talking about requirements,
10 and he's talking about the Controlled Substances
11 Monitoring Program of 2008; true?

12 A. Yes.

13 Q. And that program applied nationally;
14 did it not?

15 A. Yes, it did.

16 Q. Look at the next page, if you would,
17 page -23. In big capital letters, "Dispensing data."
18 Do you see that?

19 A. Yes.

20 Q. Now, this is Mr. Gustin, and he is
21 the Director of Regulatory Affairs for the entire
22 North Central Region of the United States; true?

23 A. Yes.

24 Q. And he states, and he seems -- maybe
25 he's parrotting Mr. McDonald. But now he is writing

1 to his region:

[REDACTED]

7 BY MR. KENNEDY:

8 Q. All right. Well, look at -- look at
9 your Controlled Substances Monitoring Program, if you
10 would, the program you put in place in 2008, which is
11 Exhibit 672? Back to 672, if you could.

12 MS. HENN: The 2013 version?

13 MR. KENNEDY: Yes.

14 THE WITNESS: I see it.

15 BY MR. KENNEDY:

[REDACTED]

1 BY MR. KENNEDY:

2 Q. Let's go back, then, if we could, to
3 Exhibit 680. This is Mr. Gustin, from the North
4 Central Region; correct?

5 A. Yes.

6 Q. And he's writing his region. And if
7 we look to bullet point 2, he states:

[REDACTED]



[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

24 MR. KENNEDY: Let's look at 681,

25 Exhibit 681.

1 (Exhibit No. 681 was marked.)

2 BY MR. KENNEDY:

3 Q. Showing you what has been marked as
4 Exhibit 681, which is -490953 to -54. Now, this is

██████████

██████████

7 we have an email by Joe Lumpkin.

8 Who was Joe Lumpkin?

9 A. Joe Lumpkin was one of two of our
10 DRAs that we assigned to the Northeast Region.

11 Q. And, now, on November 30, 2012, he
12 sends an email to a large group of people; does he
13 not?

14 A. Yes.

15 Q. And he says, "Northeast Team," right,
16 at the beginning?

17 A. Yes.

18 Q. And he says, "As of December 1,
19 please be aware it is required for any ISMC" -- and
20 that would be the independent small, medium chains;
21 right?

22 A. Yes.

23 Q. He says:

██████████

██████████



16 BY MR. KENNEDY:

17 Q. And these are exactly the things that
18 you told us the DEA said to look out for in 2006;
19 right?

20 MS. HENN: Objection. Lacks foundation.

21 BY MR. KENNEDY:

22 Q. It's now 2012. The DEA said to
23 McKesson in 2006, these are some of the things to
24 look out for?

25 MS. HENN: Same objection.

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. I'm not -- I'm not sure I understand
4 your question, Counsel. The DEA outlined the items
5 such as this in 2006, that is correct.

6 Q. And my point is, sir, it's six years
7 later -- it's 2012 -- and the entire Eastern Region
8 is saying, as of December 1, 2012, six years after
9 these have been outlined by the DEA, we're going to
10 start doing this; correct?

11 MS. HENN: Objection. Mischaracterizes the
12 document. Lack of foundation.

13 THE WITNESS: I wouldn't agree with that
14 statement. We had a number of tools we used
15 throughout the time that we executed CSMP.

16 BY MR. KENNEDY:

17 Q. Sir, other than the dispensing data,
18 where are you going to get the names of the doctors
19 prescribing medications? Where are you getting the
20 names?

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. Tell us.

24 A. I'm not aware of all the potential
25 sources, but -- that we could get for, you know,

1 doctors prescribing.

2 Q. Other than the dispensing data, where
3 are you going to find out what's getting paid for in
4 cash, sir? Like the DEA said six years earlier you
5 ought to look for, where are you going to find that
6 information without the dispensing data?

7 MS. HENN: Objection to form. Calls for
8 speculation.

9 THE WITNESS: I really don't know. I
10 mean --

11 BY MR. KENNEDY:

12 Q. Tell me, how are you going to run
13 percentages of controlled substances at a particular
14 pharmacy versus total prescriptions without
15 dispensing data, sir? Tell me that. Where are you
16 going to get it?

17 MS. HENN: Objection to form.

18 THE WITNESS: Again, I would -- I would
19 speculate. But I would like to clarify that DEA's
20 guidance in 2006 was percentage of sales of
21 controlled substances to total pharmacy sales.

22 BY MR. KENNEDY:

23 Q. And where are you going to get that
24 information other than dispensing data?

25 A. We would have that information from a

1 sales standpoint.

2 Q. Your sales standpoint, not the total
3 sales; correct? Your sales --

4 MS. HENN: Objection. Calls for
5 speculation.

6 BY MR. KENNEDY:

7 Q. -- but not the total sales of a
8 pharmacy; true?

9 MS. HENN: Calls for speculation.

10 THE WITNESS: Again, we -- we could look at
11 the sales record as a percentage of sales to a given
12 pharmacy.

13 BY MR. KENNEDY:

14 Q. McKesson's data, not the pharmacy's;
15 true?

16 MS. HENN: Objection to form.

17 BY MR. KENNEDY:

18 Q. True?

19 A. This was McKesson's data.

20 Q. Right. You can't do it for the
21 pharmacy because you don't know how many different
22 folks they are buying from; right?

23 MS. HENN: Objection to form. Calls for
24 speculation.

25 ///

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. Again, I don't know that I can answer
4 because there's a number of different tools that we
5 could use to understand if a pharmacy was just our
6 customer.

7 Q. Tell me where in 2012, without the
8 dispensing data, you can find out the total amount of
9 oxycodone being sold by a particular pharmacy? Tell
10 me.

11 MS. HENN: Objection to form. Calls for
12 speculation.

13 THE WITNESS: I don't know.

14 BY MR. KENNEDY:

The figure is a horizontal bar chart with 10 categories on the y-axis and 1000 samples on the x-axis. Each bar's length indicates the frequency of a sample belonging to a specific category. The bars are colored in a gradient from light gray to dark gray.

Category	Approximate Sample Range
1	100-200, 300-400, 500-600, 700-800
2	100-200, 300-400, 500-600, 700-800
3	100-200, 300-400, 500-600, 700-800
4	200-300, 400-500, 600-700, 800-900
5	100-200, 300-400, 500-600, 700-800
6	100-200, 300-400, 500-600, 700-800
7	200-300, 400-500, 600-700
8	200-300, 400-500, 600-700, 800-900
9	100-200, 300-400, 500-600, 700-800
10	100-200, 300-400, 500-600, 700-800





The figure consists of a sequence of 20 horizontal bars, each featuring a two-part design. The first part is a long, thin grey rectangle extending across most of the bar's width. The second part is a shorter, thicker grey rectangle attached to the right end of the first. The length of the first part varies from one bar to the next, creating a visual pattern where some bars appear longer than others.

20 MS. HENN: I think we are going to have to
21 go off the record.

22 THE VIDEOGRAPHER: We are going off the
23 record. The time is 12:44 p.m.

24 (Lunch recess taken at 12:44 p.m.)

25 --000--

1 AFTERNOON SESSION

1:19 P.M.

2 --000--

3 THE VIDEOGRAPHER: We are back on the
4 record. The time is 1:19 p.m.

5 BY MR. KENNEDY:

6 Q. All right. Mr. Walker, we've talked
7 a bit about the independents, the small, medium, the
8 smaller chains. I want to switch gears now and talk
9 to you about what McKesson called the RNAs, or the
10 regional national accounts; all right?

11 A. Yes.

12 Q. You're familiar with RNA, regional
13 national account terminology?

14 A. The -- yes, I am. The correct
15 terminology is retail national account.

16 Q. I'm sorry. Those would be the big
17 chains?

18 A. Big chains.

19 Q. The CVS, the Walgreens, the Walmarts,
20 the Rite Aids; correct?

21 A. That size chain, yes.

22 Q. Those are big customers; we agree?
23 The big chains were big customers to McKesson?

24 A. Yes.

25 Q. Probably over a billion dollars worth

1 of business with big -- big national pharmacies?

2 MS. HENN: Objection. Lacks foundation.

3 THE WITNESS: I don't recall the specific
4 sales volume, but they are large -- they were large
5 customers.

6 BY MR. KENNEDY:

7 Q. I mean, would you disagree if I were
8 to say that probably the majority of McKesson's
9 controlled substance sales were being made to the big
10 retail national accounts?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 THE WITNESS: I actually cannot say because
14 it would be speculative, just due to the business
15 models of particularly some of the hospital accounts.

16 BY MR. KENNEDY:

17 Q. All right. Anyway, the big national
18 accounts made up 16,000-plus individual pharmacies;
19 does that sound right?

20 MS. HENN: Objection to form.

21 THE WITNESS: I don't recall specifically
22 the number of pharmacies that were involved in that
23 segment.

24 BY MR. KENNEDY:



The figure is a horizontal bar chart with 1000 bars. The x-axis is labeled 'Index' and ranges from 1 to 1000. The y-axis is labeled 'Category' and ranges from 1 to 10. The bars are gray and have black outlines. The lengths of the bars vary significantly, indicating the frequency of each sample across the different categories. For example, Category 1 has the longest bar, while Category 3 has very short bars.

Category	Approximate Sample Range
1	1-1000
2	100-200, 400-500
3	100-200, 400-500
4	100-200, 400-500
5	100-200, 400-500
6	100-200, 400-500
7	100-200, 400-500
8	100-200, 400-500
9	100-200, 400-500
10	100-200, 400-500

13 BY MR. KENNEDY:

14 Q. Now, with respect to threshold
15 increases. We talked about threshold increases in
16 the smaller chains. Let's talk about threshold
17 increases with respect to the big chains.

18 From time to time McKesson would increase
19 thresholds for pharmacies that were part of a large
20 retail account; correct?

21 MS. HENN: Objection to form.

22 THE WITNESS: Yes, we -- we would increase
23 thresholds.

24 BY MR. KENNEDY:

Golkow Litigation Services



A horizontal bar chart illustrating the distribution of 15 data series across four distinct categories. The bars are rendered in various shades of gray, with the length of each bar representing the magnitude of the data series. The categories are as follows:

- Category 1: Contains 10 bars, ranging from approximately 10% to 100%.
- Category 2: Contains 3 bars, all of which are near 100%.
- Category 3: Contains 2 bars, both of which are near 100%.
- Category 4: Contains 1 bar, which is at 100%.

The bars are arranged in a descending order of length within each category, starting from the longest bar in Category 1 on the left and ending with the shortest bar in Category 4 on the right.

17 Q. Who is Elaine Thomet, if I'm saying
18 that right?

19 A. I'm sorry. Can you spell the last
20 name.

21 O. T-h-o-m-e-t.

22 A. Thomet

23 Q. Thomet. I am very sorry. I wasn't
24 even close.

25 Who is she or who was she in this period of

1 '08 to, let's say, '14, 2014?

2 A. My recollection is Elaine and her
3 responsibilities during that time frame, she worked
4 in our retail national account support team. She was
5 a -- as I understood it -- I don't remember her
6 title -- was primarily a liaison, you know, from the
7 retail national account support team into operations
8 and others.

9 Q. Okay. She would liaison into
10 regulatory?

11 A. On occasion, I believe that's
12 correct.

13 MR. KENNEDY: Let's look at Exhibit 677.

14 (Exhibit No. 677 was marked.)

15 MR. KENNEDY: And that is Bates -52132 to
16 -375.

17 Q. I want to look at an email, the top
18 email on the first page, -72.

19 A. I haven't seen this document before.
20 Could I just --

21 Q. Sure.

22 A. -- have a moment to familiarize
23 myself?

Q. Please.

25 A. Thank you.

1 (Witness reviewing document.)

2 A. Okay.

3 Q. If you want to look -- look to page
4 -74. That would be the third page in.

5 And you remember, we've had a discussion
6 about dispensing data and whether or not that was
7 required for an increase in a drug threshold for the
8 smaller independent accounts. Do you recall that
9 discussion we had? Correct?

10 A. I'm sorry. Repeat your question.

11 Q. We've -- we've had a discussion --
12 I've asked you about the requirement for dispensing
13 data in -- when increasing the threshold of an
14 independent or smaller chain. You recall that
15 discussion?

16 A. Yes.

17 MS. HENN: Objection to form.

18 BY MR. KENNEDY:

19 Q. So I want to have that discussion now
20 with respect to the regional national accounts.

21 If you look to page -74, down at the bottom,
22 you will see a November 1, 2012, email, it looks like
23 from Perry Anderson, where it says:

24 (Reading) Hi, Dan, quick question.

25 See Frank's email below regarding CSMP

1 threshold adjustments (end of
2 reading).

3 That's Controlled Substance Monitoring
4 Program; right?

5 A. Yes.

6 Q. And they are asking about threshold
7 adjustments. And he says, "Is it common -- common
8 practice in RNA" -- that would be the big chains;
9 right? Right? RNA?

10 A. Yes.

11 Q. (Reading) Is it common practice
12 in RNA to change thresholds without
13 asking for this similar backup, or is
14 it more or less done by RNA support
15 team behind the scenes for RNA
16 accounts (end of reading)?

17 Now, go back to -74. And here seems to be
18 the response. Dan Jeffries responds:

19 (Reading) We do -- we adjust at the
20 request of the customer, but we don't
21 ask for dispense data (end of
22 reading).

23 Do you see that?

24 A. Yes.

25 Q. He's talking about the regional

1 national accounts. Was that the policy -- and it's
2 2012 -- that with respect to increases in the
3 thresholds for pharmacies that were a part of the big
4 chains, you did not ask for dispensing data?

5 MS. HENN: Objection to form.

6 THE WITNESS: Generally we did not ask for
7 any dispensing data from our retail national account
8 pharmacies.

9 BY MR. KENNEDY:

10 Q. Go to page -72, the first page. Now,
11 this is an email from Elaine Thomet on 11-2-12. And
12 she says:

13 (Reading) If it helps, I will add some
14 clarification. What Frank may not
15 understand is that with RNA, the big
16 accounts, we are able to establish the
17 regulatory relationship with their
18 headquarters and not at store level
19 (end of reading).

20 Now, that's what we were talking about. You
21 were addressing the headquarters as opposed to the
22 individual stores when it came to the big national
23 accounts; true?

24 A. We used the headquarters.

25 Q. She then says:

(Reading) After their thresholds have been initially set up, based on their required usage data or historical data, if they were a customer back when we implemented the CSMP, then any time they exceed their threshold, we review it and working with their headquarters and our regulatory team, determine if the store should be allowed an increase. If the HQs agreed, then the presumption is made that they have done their due diligence. It also means that we are not talking to the direct purchaser -- that's the individual pharmacy -- but, rather, a representative from headquarters, preferably in Regulatory Loss Prevention, Asset Control, et cetera (end of reading).

Do you see that?

21 A. Yes.

22 Q. And was that basically then the
23 practice? If headquarters said a threshold increase
24 is okay, there was at least -- in the words of
25 Ms. Thomet, there was a presumption that the

1 headquarters of the national chain had done their due
2 diligence -- had done their due diligence; is that
3 correct?

4 A. It is -- it is correct that we
5 utilized the retail national chains' headquarters
6 regulatory and oversight groups to assist us in
7 ensuring that any threshold increases were
8 appropriate.

9 Q. And you would assume that they did
10 their due diligence when saying a threshold increase
11 is okay, according to -- at least to Elaine Thomet?

12 A. Based -- based on our discussions
13 with headquarters and understanding what their
14 internal procedures were and how they conducted
15 oversight of their pharmacies, yes.

16 Q. No prescribing data was required to
17 grant a threshold increase for the pharmacy at a
18 large chain; correct? We just went through that.
19 True?

20 A. No.

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. And so McKesson, when increasing the
24 threshold of a pharmacy at a large chain, had no
25 direct knowledge of the physicians who were writing

1 the prescriptions at the pharmacies for the large
2 national accounts; true?

3 A. That is -- that is correct.

4 Q. You weren't able to check to see if
5 any of these physicians had an issue with a medical
6 board in the large national chains, correct, because
7 you didn't have their identity? Couldn't do that;
8 true?

9 MS. HENN: Objection to form. Calls for
10 speculation.

11 BY MR. KENNEDY:

12 Q. Correct?

13 A. It is probably more accurate to state
14 that we did not have the detail of their -- of their
15 prescriptions and the items that would be included in
16 that prescription data.

17 Q. All right. And that would include
18 the identity of the doctor; correct?

19 A. Presumably, yes.

20 Q. It would include the data that would
21 allow you to accurately run percentages on controlled
22 purchases versus non-controlled purchases; correct?

23 MS. HENN: Objection to form.

24 THE WITNESS: We wouldn't have that ability.

25 ///



[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

7 Q. And the DEA had informed McKesson,
8 had they not, that a list of pain clinics were a big
9 problem in our country? They had told you that; had
10 they not?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 THE WITNESS: In a prior meeting and some
14 communications, the DEA identified pain clinics.

15 MR. KENNEDY: Let me show you Exhibit 752.

16 (Exhibit No. 752 was marked.)

17 MR. KENNEDY: 752 is Bates -498169 to -183.

18 Q. This is an email from you; is it not?

19 A. Yes.

20 Q. Dated May 2nd, 2012; is that right?

21 A. Yes.

22 Q. And it looks like you're sending it
23 out to a variety of the Directors of Regulatory
24 Affairs and folks in somewhat management positions as
25 it relates to Regulatory Affairs; right?

1 MS. HENN: Counsel, let me just ask the
2 videographer, could you please close the door. Thank
3 you.

4 Could you go ahead and repeat that. I'm
5 sorry.

6 MR. KENNEDY: Yes.

7 Q. This email is being sent out by you
8 in 2012, it looks like, to the DRAs, the Directors of
9 Regulatory Affairs, and -- maybe just Directors of
10 Regulatory Affairs; right?

11 A. It appears to be restricted to the
12 regulatory team.

13 Q. And if you want to look at -174.
14 And, again, this is something -- is this a slide,
15 sir, that you would have prepared?

16 A. Yes.

17 Q. And at -174, in your slide show, "How
18 the DEA sees it." Does it state:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]







[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 MS. HENN: Objection. Asked and answered.

7 BY MR. KENNEDY:

8 Q. Is that your slide?

9 A. This is -- this is a slide that I
10 created.

[REDACTED]

15 Q. So the big chain pharmacies represent
16 16,000 individual pharmacies. And I can't remember
17 if we agreed to that number. Does that sound about
18 right, 16,000 individual pharmacies for the big
19 national chains?

20 MS. HENN: Objection to form. Lacks
21 foundation.

22 THE WITNESS: I didn't -- I didn't agree or
23 disagree. I just don't know.

24 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 BY MR. KENNEDY:

11 Q. Well, let me ask, did McKesson ever

12 think that -- let's say, for example, did they ever

13 think that CVS would report themselves to the DEA?

14 A. I'm not sure I understand that

15 question.

16 Q. Did McKesson ever believe that CVS,

17 for example, CVS headquarters, would report one of

18 their own pharmacies to the DEA?

19 A. I can't answer the question. I

20 don't -- I don't know.

21 Q. I mean, did CVS ever sit there and

22 say, well, we think that CVS headquarters will

23 contact the DEA and tell them we have a pharmacy in

24 West Virginia that is violating the law, and we think

25 you should close them down? Do you think that they

1 would ever do that?

2 MS. HENN: Objection to form. Calls for
3 speculation.

4 THE WITNESS: Again, I can't answer what CVS
5 would or would not do with information that they
6 received.

7 BY MR. KENNEDY:

The image consists of a sequence of horizontal grey bars of different lengths, arranged vertically. Some bars have small square markers placed near their left or right ends. The markers are also grey and vary in size. The overall pattern suggests a repeating or sequential process.

12 MR. KENNEDY: Give me 684.

13 (Exhibit No. 684 was marked.)

14 MR. KENNEDY: I am going to show you

15 Exhibit 684, which is McKesson -513746.

16 BY MR. KENNEDY:

Q. This is an email from Elaine Thomet.

18 And I believe her title was Director of RNA Support

19 Solutions. Does that sound right?

20 A. Hang on just a moment. Let me take a
21 real quick look

22 To answer your first question, her title is
23 Director of Business Process

24 Q. Oh, right. So she would understand
25 the process of what you folks were doing? That's

1 kind of what her job was, the process?

2 A. I believe that she understood our
3 processes.

4 Q. She sends an email on January 2,

The image consists of a vertical sequence of approximately 20 horizontal grey bars. The bars are arranged from top to bottom. At the top, there are three very short, separate grey segments. Below them, the bars increase in length and number. There are two longer bars, one on the left and one on the right. Following these are several pairs of bars, each pair consisting of a shorter bar on the left and a longer bar on the right. As the sequence continues downwards, the gaps between the pairs of bars decrease, and eventually, there is a single, extremely long bar that spans most of the width of the frame. The bars are a uniform grey color and have thin black outlines.











23 MR. KENNEDY: Let me show you Exhibit 685.

24 (Exhibit No. 685 was marked.)

25 MR. KENNEDY: 685 is Bates -498295 to -307.

1 Q. Do you remember this document?

2 A. Yes, I do.

3 Q. And this is a PowerPoint that was put
4 together for presentation to the DEA; true?

5 A. The date of this document is -- and
6 my understanding of this document, based on the date
7 here, is that it was a document that we put together
8 for a review with various DEA field offices and DEA.

9 Q. Did you prepare this?

10 A. I prepared the original, yes.

11 Q. Go to page -302, if you would. See
12 where it says, "Level 1 Review"?

13 A. Yes.

14 Q. That's what we've been talking about
15 with respect to the large chain pharmacies; right?

16 A. Yes.

[REDACTED]



A horizontal bar chart illustrating the distribution of 1000 samples across 12 different categories. The x-axis represents the number of samples, ranging from 0 to 1000. The y-axis lists the categories. Each bar is composed of two segments: a shorter segment on the left and a longer segment on the right, representing two distinct components or distributions within each category.

Category	Sample Count (Left Segment)	Sample Count (Right Segment)
1	100	900
2	100	900
3	100	900
4	100	900
5	100	900
6	100	900
7	100	900
8	100	900
9	100	900
10	100	900
11	100	900
12	100	900

13 MR. KENNEDY: Give me 682.

14 (Exhibit No. 682 was marked.)

15 MR. KENNEDY: Let me show you Exhibit 682.

16 Q. This is a graph of data that we put
17 together, all right? And it is based upon -- I will
18 tell you, it is based upon McKesson's transaction
19 data and sales that they provided to us. All right?

20 And so let me ask you, Rite Aid, was that a
21 big national account, one of the big retail RNA
22 accounts at McKesson?

23 A. Rite Aid was and is a large customer
24 of McKesson.





3 MS. HENN: And, Counsel, I will just note
4 for the record that this data is all produced highly
5 confidential, and this should be marked when you
6 create exhibits with that information.

7 So we will ask that the court reporter mark
8 this 682 as highly confidential.

9 BY MR. KENNEDY:

The figure consists of 15 horizontal bars, each preceded by a small gray square marker. The bars represent different data points, with their lengths varying significantly. The first bar is the longest, followed by the third, fourth, and fifth bars. The eighth bar is the shortest, and the twelfth bar is also relatively short. The other bars fall in between in terms of length.

19 MR. KENNEDY: Give me 678.

20 (Exhibit No. 678 was marked.)

21 BY MR. KENNEDY:

22 Q. I am going to show you Exhibit 678,
23 which we don't have Bates numbers on. Let me give
24 you this. It's 445881-4.

25 If you go down to the bottom, this is an

1 email by Elaine Thomet again, July 17, 2014. I want
2 to see if you agree with this. Do you see the second
3 page?

4 A. Hang on just a moment. Let me just
5 take a quick look.

6 Okay. Counsel, you directed me to the
7 second page?

8 Q. Yes. Look at the second page, the
9 big letters. I mean, you just looked at it. She
10 is -- she's talking about setting up informational
11 phone calls; is she not?

12 A. Yes.



1 MS. HENN: Objection to form. Lacks
2 foundation.

3 BY MR. KENNEDY:

4 Q. You knew that; did you not?

5 A. I was aware CVS had paid some
6 penalties. I don't recall the amount nor do I recall
7 the events or the issues.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 Q. And proxy means you are giving
14 someone else authority to act for you; is that what
15 it means?

16 MS. HENN: Objection to form. Calls for
17 speculation.

18 THE WITNESS: Generally, I would understand
19 that.

20 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1 for this educational webinar?

2 MS. HENN: Objection to form.

3 BY MR. KENNEDY:

4 Q. Is that right?

5 MS. HENN: Mischaracterizes the document.

6 BY MR. KENNEDY:

7 Q. 2014?

8 A. The document is dated in 2014.

[REDACTED]

1 MS. HENN: Mischaracterizes the document.

2 THE WITNESS: I think better -- a better
3 characterization there is that it was eight years
4 after DEA identified issues with Internet pharmacies.
5 They didn't reveal all of this -- these issues.

6 And, frankly, as we evolved our program and
7 gained additional information and additional
8 knowledge and ability to utilize data, we expanded
9 our enforcement and -- well, not enforcement, but our
10 oversight effort in every way that we could.

11 BY MR. KENNEDY:

Category	Number of Samples
1	~150
2	~950
3	~950
4	~950
5	~850
6	~850
7	~950
8	~950
9	~950
10	~950

23 BY MR. KENNEDY:

24 Q. And it took you eight years?

25 MS. HENN: Same objection.

1 BY MR. KENNEDY:

2 Q. Eight years to modify your program
3 after being told by the DEA this is important
4 information to have in identifying suspicious orders
5 and diversion; correct?

6 MS. HENN: Objection. Lacks foundation.

7 Mischaracterizes the documents.

8 BY MR. KENNEDY:

9 Q. Is that right, sir, eight years to
10 develop it?

11 A. It is eight years between 2006 and
12 2014. But it is not correct that DEA identified all
13 the issues and all the information that we have
14 discussed in terms of prescription data. And during
15 that time frame, prescription data resources and
16 capabilities increased significantly with technology.

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 BY MR. KENNEDY:

14 Q. Sir, let me ask you this. You're

15 familiar with the Controlled Substance Act of 1970;

16 is that right?

17 A. Yes.

18 Q. And then the regulations we've talked

19 about after that relating to suspicious order

20 monitoring that came into effect, I think, in 1971?

21 We spoke about that regulation; true?

22 A. Yes, I'm familiar with that.

23 Q. Did the United States Congress ever

24 say that McKesson could give the pharmacies and the

25 big national accounts their proxy and allow them to

1 monitor themselves? Did Congress ever state that?

2 MS. HENN: Objection to form. Calls for
3 speculation.

4 THE WITNESS: Ask the question again,
5 Counsel. I'm not sure I understand what you're
6 asking.

7 BY MR. KENNEDY:

[REDACTED]

1 BY MR. KENNEDY:

2 Q. Sir, a pharmacy is not a distributor;
3 correct?

4 MS. HENN: Objection to form.

5 BY MR. KENNEDY:

6 Q. With respect to what we're talking
7 about, some of the pharmacies would distribute to
8 themselves. But outside of that, what we're talking
9 about is, let's say, pharmacies that are not
10 self-warehousing, they have a duty and a
11 responsibility under the law as a pharmacy; correct?

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. Is that right?

15 MS. HENN: Lacks foundation.

16 THE WITNESS: I'm not familiar with pharmacy
17 legal requirements. I understand distributor.

18 BY MR. KENNEDY:

19 Q. All right. But didn't you just tell
20 us you, as a distributor, were relying upon the
21 pharmacy and what they were required to do under the
22 law?

23 MS. HENN: Same objections.

24 BY MR. KENNEDY:

25 Q. And now you don't know what their

1 requirements are?

2 A. What I was answering was the chains
3 that we're discussing were self-warehousing chains
4 and had a distributor registration as well as a
5 pharmacy registration.

A horizontal bar chart illustrating the distribution of 1000 samples across 10 categories. The x-axis represents the number of samples, ranging from 0 to 1000. The y-axis represents the category index, ranging from 0 to 9. The distribution is highly skewed, with most categories having a large number of samples. Categories 0, 1, 2, 4, 5, 6, 7, 8, and 9 each contain a single long bar extending to the right edge of the plot. Category 3 contains three shorter bars, indicating multiple distinct clusters within that category.

16 BY MR. KENNEDY:

17 Q. You understand that the
18 responsibilities under the law for a pharmacy to
19 prevent a diversion is different than the
20 responsibilities under the law of a distributor?
21 They are different; correct?

22 A. I don't understand specifically the
23 regulations associated with pharmacy. I've never
24 reviewed them. But generally I understand that they
25 are different.

1 Q. Right. And the way Congress set this
2 up, because they did not want a crisis, is they gave
3 responsibilities to the distributors, and they gave a
4 separate responsibility to the pharmacies, a belt and
5 a suspenders? It wasn't one or the other. Congress
6 wanted both to have responsibilities to prevent the
7 diversion of dangerous drugs into the communities;
8 right? A separate set of responsibilities for each;
9 correct?

10 MS. HENN: Objection to form.

11 THE WITNESS: Again, I -- I don't know what
12 Congress's intent necessarily was. I understand the
13 regulation.

14 BY MR. KENNEDY:

15 Q. And you understand the regulation
16 gave a responsibility and a set of responsibilities
17 to the two different entities? Distributors, you've
18 got your jobs, and pharmacies, you have your job;
19 correct?

20 A. I understand the distributor
21 responsibilities.

22 Q. Nowhere did it ever say that if the
23 pharmacy has responsibility, us as distributors, we
24 don't have any responsibility to prevent diversion?
25 That has never been stated anywhere; correct?

1 MS. HENN: Objection to form.

2 THE WITNESS: Again, I -- the regulations
3 are very clear what our responsibilities are.

4 MS. HENN: Counsel, is this another good
5 time for a break? It's been an hour.

6 MR. KENNEDY: Give me five minutes.

7 MS. HENN: Are you comfortable going five
8 minutes?

9 THE WITNESS: That's fine.

10 MR. KENNEDY: Let me show you Exhibit 674,
11 if I could.

12 MS. HENN: Thank you.

13 (Exhibit No. 674 was marked.)

14 BY MR. KENNEDY:

15 Q. This is Bates -507218 to -507220.

16 This is an email from Michael Oriente, if you look at
17 the top. Who is Michael Oriente?

18 A. Michael Oriente was -- was and is the
19 Director of Regulatory Affairs for the East Region --
20 Northeast Region.

21 Q. So a big responsibility. He's one of
22 four/six people; correct?

23 A. Yes, at that point in time.

24 Q. And at this point in time, he is also
25 responsible for managing and monitoring some of the

1 large national chains; true?

2 A. Yes.

3 Q. And this is April of 2011. And does
4 he state, "Dave" -- and he's sending an email to Dave
5 Gustin, who is another Regulatory Affairs person;
6 right? He's in the Midwest; right?

7 A. Yes.

8 Q. He also has some responsibility for
9 these big national chains; right?

10 A. Yes.

11 Q. And does he state, "Dave, can you ask
12 RNA" -- and that's the regional national account
13 portion of McKesson; right?

14 A. Yes.



[REDACTED]

5 Q. And do you know he was responsible
6 for CVS for a certain portion of time; did you know
7 that?

8 A. I don't recall.

9 Q. He was in charge of Rite Aid for a
10 certain portion of time; do you know that?

11 A. I do recall he had responsibility for
12 Rite Aid.

13 Q. Kroger's?

14 A. Again, I don't remember all the ones
15 that he had.

16 Q. Costco; do you remember that?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: Again, I don't -- I don't
20 recall specifically.

21 BY MR. KENNEDY:

A horizontal bar chart illustrating the distribution of 1500 samples across 12 distinct categories. The categories are represented by the 12 bars, each starting with a small gray square marker. The lengths of the bars indicate the number of samples assigned to each category. Category 1 has the longest bar, extending slightly beyond the 1500 mark. Categories 2, 3, 6, 7, 8, 9, 10, 11, and 12 also have bars that extend beyond the 1500 mark, while categories 4 and 5 have shorter bars.

Category	Approximate Sample Count
1	1550
2	1450
3	1400
4	1350
5	1300
6	1580
7	1520
8	1540
9	1560
10	1570
11	1590
12	1530

16 BY MR. KENNEDY:

17 Q. Well, at this point in time -- maybe
18 there's been change, maybe people are moving around,
19 but this man, in charge of CVS and Rite Aid and
20 Costco and Krogers, he doesn't even know who to call;
21 right?

22 MS. HENN: Objection.

23 BY MR. KENNEDY:

24 Q. At this point he doesn't even know
25 who to call?

1 MS. HENN: Objection to form. Lacks
2 foundation.

3 BY MR. KENNEDY:

4 Q. Isn't that what this is saying at
5 this moment in time?

6 A. No, that's not accurate. I don't
7 believe that this is that at all. I think he is
8 ensuring that he has right information.

9 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Term	Percentage
GMOs	~85%
Organic	~80%
Natural	~75%
Artificial	~65%
Organic	~60%
Natural	~55%
Artificial	~50%
Organic	~45%
Natural	~40%
Artificial	~35%

9 Q. Well, not so much interaction that
10 Mr. Oriente even knows who to call; right?

11 MS. HENN: Objection to form.

12 THE WITNESS: Again, I think it's simply, as
13 I read this and understand the question, is more of
14 an update and clarification of who the contact people
15 are.

16 MS. HENN: Go off the record.

17 THE VIDEOGRAPHER: We are going off the
18 record. The time is 2:29 p.m.

19 (Recess taken.)

THE VIDEOGRAPHER: We are back on the record. The time is 2:46 p.m.

22 BY MR. KENNEDY:

23 Q. Mr. Walker, we have been talking
24 about the large national --

25 THE VIDEOGRAPHER: Sorry, Counsel, your

1 microphone.

2 MR. KENNEDY: Oh, yeah.

3 Q. All right. Let me start all over.

4 Mr. Walker, we have been talking about the large
5 national accounts, and I want to talk specifically
6 about CVS; all right?

7 A. Okay.

8 Q. CVS was a large national account;
9 were they not?

10 A. CVS is a large national retail chain.

11 Q. More than that, CVS, certainly while
12 you were at McKesson, was -- they were McKesson's
13 largest customer; were they not?

14 MS. HENN: Objection to form. Lacks
15 foundation.

16 THE WITNESS: I don't recall specifically
17 where they were. They were a large customer, but we
18 were not the sole supplier. So I don't know exactly
19 what their position was in our business.

20 BY MR. KENNEDY:

21 Q. Well, you know that in the 2010,
22 2012, 2014 era, they were a customer purchasing in
23 excess of \$10 billion --

24 MS. HENN: Objection to form. Lacks
25 foundation.

1 BY MR. KENNEDY:

2 Q. -- from McKesson? Did you know that?
3 \$10 billion?

4 A. I don't have any specific knowledge
5 of what their sales volume was then.



This figure displays a horizontal bar chart with 15 data series. The bars are arranged in three distinct groups. The first group contains 10 bars of varying lengths, the second group contains 4 bars, and the third group contains a single long bar. Each bar is rendered as a solid grey rectangle, and a small vertical tick mark is positioned at the left end of each bar.

19 MR. KENNEDY: We will go through the
20 refusals. We will do that at one at a time.

21 Let's start with 698. Let's start in 2008
22 and your discussions with CVS and trying to get them
23 involved with your monitoring program.

24 (Exhibit No. 698 was marked.)

25 MR. KENNEDY: -627161 to -162.

1 THE WITNESS: Can I have a minute to review.

2 I just --

3 MR. KENNEDY: Please. Please.

4 THE WITNESS: -- haven't seen the document
5 before.

6 (Witness reviewing document.)

7 THE WITNESS: Okay.

8 BY MR. KENNEDY:

9 Q. All right. Let's start at the
10 bottom. That's the first email in time. This is
11 from Michael Oriente, an email; correct?

12 A. Yes.

13 Q. And he was one of the Directors of
14 Regulatory Affairs, who at that time was monitoring
15 the CVS stores; would that be accurate?

16 A. I believe that's correct.

17 Q. And it's April 24, 2008. This is
18 about the time that you're beginning the
19 implementation of the monitoring program at McKesson;
20 true?

21 A. Yes, we were implementing.

22 Q. And this is an email to you; right?

23 A. It's addressed to me.

24 Q. And he is recapping a call with CVS
25 on that day; right?

1 A. Yes.

2 Q. And he starts off, "Don" -- and
3 that's you. And he states:













[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

25 Q. And, sir, you were -- you were in

1 charge of all the regulatory during this period, were
2 you not, 2010, 2011, and 2012? You were in charge --

3 A. Yes.

4 Q. -- correct?

[REDACTED]

24 MR. KENNEDY: We were talking about CVS, I
25 believe, in April of '08. Let's go four months

1 later, in July of '08.

2 THE REPORTER: What number is that?

3 MR. ASQUITH: 699.

4 (Exhibit No. 699 was marked.)

5 BY MR. KENNEDY:

6 Q. I'm going to ask you about page -70?

7 MS. URQUHART: Could we get a Bates number?

8 MR. KENNEDY: -627168 to -172.

9 Q. On page -170 --

10 A. Can you just -- I haven't seen this
11 document. I am not familiar with it at all.

12 Q. Okay. All right.

13 (Witness reviewing document.)

14 A. Okay.

15 Q. Go to page -170, please. Do you see
16 there, there is an email from Mr. Oriente, dated
17 July 22, 2008. And this email is to you; correct?

18 A. Yes.

19 Q. And you're responsible for Regulatory
20 at that point in time; are you not?

21 A. Yes, I'm still responsible for
22 Regulatory.

23 Q. And it says:



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

7 Q. Well, let me ask you this. What do
8 you think Viper was monitoring? Was it monitoring
9 controlled substances?

10 MS. HENN: Objection. Calls for
11 speculation.

12 BY MR. KENNEDY:

13 Q. Or you just don't have any idea?

14 A. I can't speculate, because I just
15 don't know.

16 Q. Well, this whole email is about the
17 Controlled Substances Monitoring Program; isn't it?

18 A. Yes, it is.

19 Q. And it says that CVS has got a
20 monitoring program. Do you think they are monitoring
21 something other than controlled substances?

22 A. Again, I don't have any -- any
23 specific knowledge or -- other than to speculate that
24 that's about controlled substances.

25 Q. So you think that they're talking

1 about monitoring toothbrushes?

2 MS. HENN: Objection to form. Asked and
3 answered. Calls for speculation.

4 THE WITNESS: Counsel, I'm trying to be
5 clear that I did not and do not understand what Viper
6 monitored, and, therefore, I can't answer your
7 question specifically whether it did or did not
8 include anything other than controlled substances or
9 whether -- you know, what it oversaw.

10 BY MR. KENNEDY:

11 Q. Well, let me -- this is an email to
12 you. You're in charge of Regulatory, which relates
13 to controlled substances; right?

14 A. Yes.

15 Q. The topic -- or the subject of the
16 email is your Controlled Substances Monitoring
17 Program; correct? Correct?

18 A. Yes.

19 Q. They are talking about thresholds and
20 Threshold Change Requests relating to controlled
21 substances; are they not?

22 A. Yes.

23 Q. Right? They are talking about
24 thresholds in relationship to controlled substances;
25 are they not?

1 A. The discussion is around thresholds
2 and controlled substances.

3 Q. And so where it says they have a
4 monitoring program at CVS, isn't it real easy to
5 conclude that they are talking about monitoring of
6 controlled substances when you read this?

7 MS. HENN: Objection to form. Asked and
8 answered. Calls for speculation. Guess.

9 THE WITNESS: Counsel, I am trying to
10 testify to that which I know. I do not know exactly
11 what Viper monitored.

12 BY MR. KENNEDY:

13 Q. All right. And you can't put all of
14 the content of this email together and conclude that
15 Viper is monitoring controlled substances? You can't
16 do that; is that what you're telling us? Under your
17 oath, on the record, you can't put all that together
18 from this email that you received?

19 MS. HENN: Objection to form. Asked and
20 answered. Calling for speculation.

21 THE WITNESS: Very clearly, I can only
22 testify to that which I absolutely know.

23 BY MR. KENNEDY:

[REDACTED]

[REDACTED]













5 MR. KENNEDY: Mark this, please.

6 THE REPORTER: 803.

7 (Exhibit No. 803 was marked.)

8 MR. KENNEDY: I show you Exhibit 700.

9 (Exhibit No. 700 was marked.)

10 BY MR. KENNEDY:

11 Q. I show you Exhibit 700, which is
12 -555948 to -950.

13 (Witness reviewing document.)

14 Q. You get an email from Elaine Thomet,
15 August 26, '08. We're still talking about CVS, and
16 it is -- you are copied on this email; are you not?

17 A. Yes, I am.

18 Q. And it says:

19 (Reading) Team, here's the recap from
20 our meeting with Don this morning (end
21 of reading).

22 And Don is you; right?

23 A. Yes.

24 Q. And it says:














12 MR. KENNEDY: All right. Let's go forward,
13 then, a couple months into this, in November of '08,
14 and look at 701.

15 (Exhibit No. 701 was marked.)

16 BY MR. KENNEDY:

17 Q. I'm looking at the Elaine Thomet's
18 email, November 12 of 2008, to you and others. But
19 it's sent to you.



10 BY MR. KENNEDY:

11 Q. And you don't know what Viper is;
12 right?

13 A. I don't remember what Viper is.

14 Q. Did anybody ever know what Viper was?

15 A. I don't know.

16 Q. You don't know.

17 Would you be surprised to know that Viper is
18 not a Controlled Substance Monitoring Program for any
19 controlled substances that CVS purchased from
20 McKesson?

21 MS. HENN: Objection to form. Lack --

22 BY MR. KENNEDY:

23 Q. Would that be surprising to you?

24 MS. HENN: Objection to form. Lacks
25 foundation.

1 THE WITNESS: Again, I don't have any
2 knowledge of Viper, how CVS used Viper, what it did.
3 I just can't answer your question.

4 BY MR. KENNEDY:

The image consists of a sequence of horizontal grey bars arranged vertically. Each bar is preceded by a small, separate vertical grey bar of the same shade. The length of the horizontal bars varies significantly, with some being very short and others extending almost to the right edge of the frame. The overall pattern creates a sense of rhythmic repetition with varying dynamics.

11 MR. KENNEDY: Let's go to Exhibit 702.

12 (Exhibit No. 702 was marked.)

13 MS. HENN: Thank you.

14 MR. KENNEDY: This is an email from Ned.

15 MS. URQUHART: Could we get the Bates
16 number, please.

17 MR. KENNEDY: -627150 to -158.

18 Q. This is from Ned McKenna of McKesson;
19 correct?


20 A. Yes.

21 Q. And it's being sent to CVS; correct?

22 A. Yes.









The figure consists of three horizontal grey bars. The top bar is the longest, spanning from approximately day 0 to day 10. The middle bar is slightly shorter, spanning from approximately day 0 to day 15. The bottom bar is the shortest, spanning from approximately day 0 to day 10. Each bar has a small vertical tick mark at its left end.

4 MR. KENNEDY: Let's look how that worked,
5 all right? Give me 703, please.

6 (Exhibit No. 703 was marked.)

7 MR. KENNEDY: This is Exhibit 703, -535756
8 to -901.

9 Q. I'm going to start with the bottom
10 email. That's from Dave Gustin. All right?

11 A. Okay.

12 Q. And the subject is, "Hydrocodone
13 Increase." We know what hydrocodone is, right, a
14 controlled substance? Right?

15 A. Yes.

16 Q. And it says:

Term	Percentage
Climate change	100%
Global warming	100%
Green energy	100%
Carbon footprint	100%
Sustainable development	100%
Renewable energy	100%
Eco-friendly	100%

23 What does that stand for?

24 A. I don't know.

Q. That's related to the hydrocodone;

1 right? So you're going to increase the hydrocodone
2 THD for WM. Is that Walmart?

3 A. I believe so.

Figure 1. The three panels show the effect of the parameter α on the mean value of the function $\hat{f}_n(x)$ for different values of n . The left panel shows the case $n=1$, the middle panel $n=2$, and the right panel $n=3$. The x-axis ranges from -1 to 1, and the y-axis ranges from 0 to 1. The curves are bell-shaped and centered at $x=0$.

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

ANSWER The answer is 1000.

[View Details](#) | [Edit](#) | [Delete](#)

ANSWER The answer is **100**.

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or email him at john.smith@researchinstitute.org.

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

ANSWER The answer is 1000. The area of the rectangle is 1000 square centimeters.

For more information about the study, please contact Dr. Michael J. Hwang at (310) 206-6500 or via email at mhwang@ucla.edu.

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

[View Details](#) | [Edit](#) | [Delete](#)

© 2013 Pearson Education, Inc.

[View Details](#) | [Edit](#) | [Delete](#)

10 of 10

[View Details](#) | [Edit](#) | [Delete](#)

For more information about the study, please contact Dr. Michael J. Hwang at (310) 794-3000 or via email at mhwang@ucla.edu.

Polkow Litigation Services

This figure is a horizontal bar chart with 15 data series. The bars are arranged in three groups of five. Each bar is a solid gray color with a thin black outline. The lengths of the bars differ greatly between the three groups, suggesting a significant difference in the values represented by each group.

Group	Bar 1	Bar 2	Bar 3	Bar 4	Bar 5
Group 1	Very Short	Medium Short	Medium Long	Very Long	Extremely Long
Group 2	Medium Short	Medium Long	Very Long	Extremely Long	Extremely Long
Group 3	Medium Short	Medium Long	Very Long	Extremely Long	Extremely Long

20 Now we're two years later with CVS; all right?

21 Exhibit 704.

22 (Exhibit No. 704 was marked.)

23 MR. KENNEDY: -512900 to -01 and then -02.

24 Q. If you will go to page -- the first
25 page, -900, Exhibit 704, the bottom email. That's

1 from Rhonda Fargo, that bottom email?

2 A. The bottom of -900?

3 Q. Yes.

4 A. Yes.

5 Q. And now it's February of 2010, two
6 years after the CSMP has been put into place. And
7 she's sending an email to different directors in
8 Regulatory Affairs; correct?

9 A. Yes.

10 Q. She says:





[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

6 MS. HENN: Objection to form. Lacks
7 foundation.

8 Counsel, we're over an hour. Take a five-,
9 ten-minute break.

10 THE VIDEOGRAPHER: We are going off the
11 record. The time is 3:51 p.m.

12 (Recess taken.)

13 THE VIDEOGRAPHER: We are back on the
14 record. The time is 4:07 p.m.

15 MR. KENNEDY: I show you Exhibit 713, which
16 is Bates -627066.

17 (Exhibit No. 713 was marked.)

18 BY MR. KENNEDY:

19 Q. Do you see that email? I just wanted
20 to look at the last sentence in that email.

21 A. I see the email there.

22 Q. You're right. Do you see that
23 last --

24 A. The last sentence at the bottom?

25 Q. Yes. Ned is from -- Ned is from

1 McKesson?

2 A. Ned is from McKesson.

This figure displays 15 data series represented by horizontal bars. The bars are colored in a uniform gray with a thin black border. They are positioned in a staggered, non-overlapping manner across three distinct horizontal groups. The first group contains 10 bars, the second group contains 4 bars, and the third group contains a single bar. The length of each bar varies, indicating the magnitude of the corresponding data point.

18 MR. KENNEDY: All right. And give me

19 Exhibit 706, please.

20 (Exhibit No. 706 was marked.)

21 MR. KENNEDY: 706, Bates -620748 to -49.

22 Q. I want to look at the second email
23 down from Ned McKenna to Brian Whalen. And you are
24 copied. And this is August 6, 2010. All right?

35 λ ν₀ G

1 Q. And does that email -- and it's CVS
2 Action Plans. That's the subject; true? Do you see
3 that?

4 A. Yes.

5 Q. And it states:

[REDACTED]



10 Q. This is 2010, two years after the
11 original CSMP; is it not, sir?

12 A. Two years after we implemented.

20 MR. KENNEDY: Let's look at the CVS program
21 and where it led to; all right? Give me Exhibit 708,
22 please.

23 (Exhibit No. 708 was marked.)

24 BY MR. KENNEDY:

25 Q. The metadata indicates that this is

1 from February 8 of 2010.

2 THE VIDEOGRAPHER: Sorry, sir. I think
3 you're hitting the --

4 THE WITNESS: Oh, did it again.

5 BY MR. KENNEDY:

.8 MR. KENNEDY: 710, Exhibit 710.

19 (Exhibit No. 710 was marked.)

20 MS. HENN: Are we done with 708?

21 MR. KENNEDY: Yes.

22 MS. HENN: Okay.

23 BY MR. KENNEDY:

24 Q. Do you see the email -- the email is
25 from Tom McDonald, 2-8-2010; do you see that?

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

11 MR. KENNEDY: That's 2010. Let's go two

12 years forward and look at CVS and see how the

13 threshold system was working.

14 Let's go to 2012, Exhibit 709.

15 (Exhibit No. 709 was marked.)

16 BY MR. KENNEDY:

17 Q. This is from Tom McDonald. Tom

18 McDonald, at this point in time, he was the Director

19 of Regulatory Affairs and was responsible for CVS;

20 was he not?

21 MS. HENN: Objection to form. Lacks

22 foundation.

23 BY MR. KENNEDY:

24 Q. 2012.

25 A. I believe in 2012 Tom McDonald was --

1 oversaw CVS.

The image consists of a vertical column of horizontal grey bars. The bars are arranged from top to bottom, with their lengths decreasing as they move upwards. At the very top, there is a very short bar. Below it, there is a slightly longer bar. This pattern continues, with each subsequent bar being progressively longer than the one above it. By the time we reach the bottom of the image, the bars have grown significantly in length, with the longest bar spanning almost the full width of the frame. The bars are all the same shade of grey and have thin black outlines.



23 Q. And oxycodone, sir, was at the center
24 of the opioid crisis in this country by 2012; was it
25 not?

1 A. In 2012 oxycodone had been identified
2 as a controlled substance that was being abused.

3 Q. Not "a." "The."

4 You know well that by 2012 oxycodone was in
5 the middle of the opioid crisis; was it not?

6 A. It was one of the controlled
7 substances that was of concern being abused.

8 Q. Let me ask you: Not one of; was
9 oxycodone the number one addict and killer in the
10 United States with respect to this opioid crisis by
11 2012? Number one; was it not, sir?

12 MS. HENN: Objection to form. Asked and
13 answered. And lacks foundation.

14 THE WITNESS: I can't answer its position.
15 What I can absolutely assure you is that there were
16 other controlled substances that were of concern
17 across the country for abuse.

18 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



The figure consists of 15 identical horizontal bars arranged vertically. Each bar is composed of two parts: a small, solid gray square on the left and a much longer, solid gray bar extending to the right. The length of the long bar varies slightly from one bar to the next, creating a subtle visual pattern.

18 Q. And, sir, the law says you stop
19 shipping until you do your due diligence; isn't that
20 what the law says?

21 MS. HENN: Objection to form. Lack of
22 foundation.

23 BY MR. KENNEDY:

24 O. Right?

25 A. No, that --

1 Q. This is 2012.

2 A. Can I finish, Counsel.

3 MS. HENN: Yes, you can.

4 BY MR. KENNEDY:

5 Q. My question is --

6 MS. HENN: Counsel, he would like to finish
7 his answer.

8 MR. KENNEDY: I didn't finish my question.

9 Q. Isn't that the law in 2012, you don't
10 ship if you have a concern?

11 MS. HENN: Mr. Walker, do you need the prior
12 question back so you can answer?

13 MR. KENNEDY: It's the same question.

14 THE WITNESS: I think I can answer the
15 question.

16 MS. HENN: Okay.

17 THE WITNESS: Counsel, there is no
18 regulation to stop shipping controlled substances.
19 The regulation requires that we report suspicious
20 orders.

21 MR. KENNEDY: We're going to write this one
22 down.

23 Q. How long has that been your view? In
24 2007 -- let's start with 2007 -- was McKesson
25 required to not ship until it did its due diligence

1 on potentially suspicious orders? Was that required
2 in 2007?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. Don't ship until we do our due
6 diligence?

7 MS. HENN: Objection to form. Lack of
8 foundation.

9 BY MR. KENNEDY:

10 Q. Was that required of McKesson in
11 2007, do not ship until we do our due diligence?

12 MS. HENN: Same objection.

13 THE WITNESS: There is no regulatory
14 requirement to not ship. There is a regulatory
15 requirement to report.

16 BY MR. KENNEDY:

17 Q. All right. And did the DEA tell you
18 in 2006 that you are required not to ship until you
19 do your due diligence on a potentially suspicious
20 order? Did they tell you that in '06 in a letter to
21 McKesson?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 BY MR. KENNEDY:

25 Q. Did they tell you that in '06 in a

1 letter to McKesson?

2 A. In 2006 their guidance and direction
3 was, do not ship. And the requirement is at the
4 point that we determine an order to be suspicious.

1 (Exhibit No. 707 was marked.)

2 BY MR. KENNEDY:

3 Q. A PowerPoint prepared by you?

4 MS. URQUHART: Could we get the Bates
5 number, please?

6 MR. KENNEDY: Pardon me?

7 MS. URQUHART: Could we get the Bates
8 number, please?

9 MR. KENNEDY: Just don't interrupt my
10 question, and I will be right back with you,
11 all right?

12 Q. 707, Exhibit 707, is a PowerPoint,
13 "CVS - Regulatory PowerPoint"; is it not?

14 THE WITNESS: This is a -- appears to be a
15 PowerPoint presentation from McKesson to CVS.

16 BY MR. KENNEDY:

17 Q. So my answer is, "Yes"? Is the
18 answer to my question, "Yes"?

19 MS. HENN: Objection to form.

20 THE WITNESS: It's a McKesson PowerPoint.
21 You asked if it was a CVS PowerPoint. It's a
22 McKesson PowerPoint.

23 BY MR. KENNEDY:

24 Q. Does it say, "CVS - Regulatory
25 Review"?

1 A. It's a CVS regulatory review.

2 Q. Prepared by you?

3 A. Yes.

4 Q. Bates No. -497980 to -89. This is

5 March of 2012? Is that correct?

6 A. Yes, that's the date on the document.

[REDACTED]

18 Q. And the DEA had been talking to you
19 about this being important since 2006; right?

20 MS. HENN: Objection to form. Lack of
21 foundation.

22 THE WITNESS: The DEA had identified
23 prescribing doctors as an area of focus.

24 BY MR KENNEDY:

Golkow Litigation Services







19 Q. And -- and the DEA had been telling
20 you since 2006, this is important information to have
21 to identify diversion; correct?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 BY MR. KENNEDY:

Q. It's six years later.

1 A. DEA had identified cash sales as a
2 potential indicator.





The image consists of a series of horizontal bars of varying lengths and positions. The bars are rendered in a light gray color. Some bars are positioned near the top of the frame, while others are centered or near the bottom. The lengths of the bars also vary significantly, from very short segments to long, continuous spans across the width of the frame.

19 BY MR. KENNEDY:

20 Q. Let's switch topics. We will talk
21 about sales, McKesson, sales and promotion as it
22 related to the Controlled Substances Monitoring
23 Program.

24 Can we agree that sales should have nothing
25 to do with the Controlled Substances Monitoring

1 Program, should not have anything to do with it? Do
2 you agree with that?

3 A. Can I clarify, Counsel. Are you
4 referring to our sales force?

5 Q. Your sales force, your sales
6 strategy, your sales goal should have nothing to do
7 with your job as the head of Regulatory to monitor
8 controlled substances?

9 MS. HENN: Objection to form. Compound.

10 THE WITNESS: I would not agree that our
11 sales force should not be involved in the Controlled
12 Substance Monitoring Program. I would agree that
13 sales never influenced our decisions around our
14 regulatory responsibilities.

15 BY MR. KENNEDY:

16 Q. Okay. Well, let's look at that.
17 Let's look at that.

18 First of all, how many sales reps -- did you
19 know how many national sales reps McKesson had,
20 regional sales manager? Hundreds?

21 A. I'm going to -- it would be a guess
22 that we had -- it would probably be less -- you know,
23 150 or less. I really don't remember exactly.

24 Q. And the First Service -- the sales
25 assistants, the First Service folks that were located

1 down in Texas, I think I've read there were a hundred
2 sales assistants down in Texas; do you recall that?
3 First Service.

4 MS. HENN: Objection. Objection to form.

5 THE WITNESS: Counsel, our -- it's called
6 Service First.

7 MR. KENNEDY: I'm sorry.

8 THE WITNESS: Our Service First organization
9 was not just a sales support organization. It was
10 really a customer -- customer service call center.

11 BY MR. KENNEDY:

12 Q. You had the Regional Sales Managers.
13 How many District sales folks above the -- above the
14 Regional Sales Managers were there? If there's 100
15 to 150 Sales Managers, how many District sales folks
16 were above them?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: I don't remember specifically
20 how many there were.

21 BY MR. KENNEDY:

22 Q. How many marketing folks were there,
23 people that had put together the marketing sales
24 programs above the -- let's say the District Sales
25 Manager? How many were those in that department,

1 let's say, nationally?

2 MS. HENN: Objection to form.

3 THE WITNESS: Our marketing group was not
4 based in the field. We had a marketing group that
5 was headquartered. I don't remember what the
6 specific number of marketing people we had. I
7 would -- I would estimate, and it would be a pure
8 estimation, it was probably 35.

9 BY MR. KENNEDY:

10 Q. So you maybe have 150 Sales Managers
11 across the country, and you've got District Sales
12 Managers above them. McKesson has got 35 people
13 working in marketing. Is that in San Francisco?
14 Would that be here?

15 A. Yes. All the marketing at the time
16 was at our headquarters in San Francisco.

17 Q. And you've got a hundred customer
18 service reps sitting at a call center. They were
19 down in Texas; right?

20 MS. HENN: Objection to form. Lacks
21 foundation.

22 THE WITNESS: Our Service First organization
23 was based in Texas, and we also had a satellite --
24 and at that time I think we had a satellite in
25 Phoenix that, again, I can't remember specifically

1 how many people were there.

2 BY MR. KENNEDY:

3 Q. And I'm -- I'm -- for what we've
4 said, I'm counting up close to -- close to 300 people
5 in marketing and sales at McKesson; would that be
6 about right?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 THE WITNESS: Again, I'm concerned about
10 guessing on the numbers.

11 MR. KENNEDY: All right.

12 THE WITNESS: But it's --

13 BY MR. KENNEDY:

14 Q. Well, one thing you're not guessing
15 on back in 2006 or '7, in Regulatory, watching
16 opioids, there was three; right? Three people?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 BY MR. KENNEDY:

20 Q. Three?

21 A. That -- that's not accurate because
22 our Field Operations Team, our Distribution Center
23 Managers, and their second in command were also very
24 heavily involved in regulatory compliance.

25 Q. Five hours ago didn't we look at a

1 slide you presented to the DEA and said, prior to
2 2008 our regulatory team had three people?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. You, Mr. Hilliard, and another
6 gentleman. Isn't that the representation to the DEA
7 on the slide that we looked at six hours ago?

8 MS. HENN: Objection to form.

9 Mischaracterizing the document.

10 THE WITNESS: What I was representing in
11 that document was what our Regulatory Affairs staff
12 group was. Again, we very strongly utilized our
13 Field Operations Teams in terms of our regulatory
14 compliance, and ensured that at a local level we had
15 oversight.

16 BY MR. KENNEDY:

17 Q. Sir, McKesson paid a \$13 million fine
18 in 2008; correct?

19 A. We paid -- as a result of the
20 agreement, we paid a penalty of \$13 million.

21 Q. So the answer would be "Yes"; right?

22 MS. HENN: Objection to form. Asked and
23 answered.

24 BY MR. KENNEDY:

25 Q. Would the answer be "Yes"?

1 A. We paid the \$13 million penalty.

2 Q. The answer would be "Yes"; correct?

3 MS. HENN: Objection to form. Asked and
4 answered.

5 BY MR. KENNEDY:

6 Q. It's a "yes" or "no." The answer
7 would be, yes, you paid a \$13 million fine; true?

8 A. We paid a \$13 million penalty.

9 Q. Okay. Maybe I -- would I be
10 correct -- it's kind of a "yes" or "no." Simple.
11 Would I be correct you paid a \$13 million penalty in
12 2008?

13 A. That's correct.

14 Q. Leading up to that, prior to 2008,
15 you folks began to meet and discuss the creation of a
16 new monitoring program; did you not?

17 A. Internally?

18 Q. Yes.

19 A. Yes.

[REDACTED]



[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

13 MR. KENNEDY: Give me 722, please.

14 (Exhibit No. 722 was marked.)

15 BY MR. KENNEDY:

16 Q. You have seen this document before;

17 haven't you, sir?

18 A. Give me a minute. I don't think

19 I've -- certainly, if it's an email that I generated.

20 But I don't remember having seen it.

21 Q. Bates No. -543914 to -16.

22 A. Okay.

23 Q. Go to the last page, -916, because

24 this is where this exchange begins.

25 Okay. You see the email from Gary Hilliard?

1 And this is October 23, 2006. This is during the
2 period when you're trying to put together your
3 monitoring program; correct?

4 A. Yes, this would be during the time
5 frame we were creating the IT development for --

6 Q. And Gary Hilliard --

7 MS. HENN: Did you finish your answer, sir?

8 THE WITNESS: The IT development program for
9 the CSMP.

10 MS. HENN: Thank you.

11 BY MR. KENNEDY:

12 Q. Gary Hilliard, at that point he is
13 the Director of Regulatory Affairs; right?

14 A. I believe Gary's title at the time
15 was Regulatory. He's on the Regulatory staff, and I
16 believe that title is correct.

17 Q. He states in this email -- do you
18 know Sharon Mackarness? Who that is?

19 A. I'm familiar with the name. Sharon
20 Mackarness was one of our -- the McKesson I.T.
21 associates who was responsible for pieces of
22 development and interface with CSMP.

23 Q. This is a year-and-a-half before your
24 monitoring program goes into place; true?

25 MS. HENN: Objection to form.

1 Mischaracterizes the evidence.

2 THE WITNESS: October 2006. We implemented
3 in the spring of 2008. So roughly that time frame.

4 BY MR. KENNEDY:

5 Q. It states:

[REDACTED]

Term	Percentage
GMOs	100%
Organic	75%
Natural	70%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%
Organic	100%
Natural	100%
Artificial	100%

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. That's basically what she's saying?

15 She's responding, and she's asking some I.T.

16 questions about the establishment of the program?

17 A. It appears that she is asking
18 questions to get the information she needs for system
19 design.

20 Q. And she is -- again, she's
21 referencing a meeting that occurred that morning,
22 October 26, 2006; right?

23 A. Yes.

24 Q. And go to the earlier page, -15. The
25 same day Sharon McGinnis -- Mackarness, excuse me,

1 from I.T. at McKesson, she writes an email to Gary
2 Hilliard; correct?

3 A. At the bottom of the page, yes.

4 Q. And she copies two other folks.

5 VanderWerf; correct?

6 A. Yes.

7 Q. And she says, "Gary," right? Gary?

8 A. Yes.

9 Q. In the second paragraph she says,
10 "JD," and that's probably referencing Jean-Dou up
11 ahead? Up above, JD?

12 A. Yes.

13 Q. Do you know JD, who he was?

14 A. Another I.T. individual.

The figure is a horizontal bar chart with 1000 bars. The x-axis is labeled 'Index' and ranges from 1 to 1000. The y-axis is labeled 'Category' and ranges from 1 to 10. The bars are gray and represent the frequency of each sample belonging to a specific category. The distribution is highly skewed, with most samples belonging to categories 1, 2, 5, 6, 7, 8, 9, and 10, while categories 3 and 4 have very few samples.

Category	Approximate Sample Range
1	1-1000
2	1-1000
3	~100-200, ~400-500
4	~100-200, ~400-500
5	1-1000
6	1-1000
7	1-1000
8	1-1000
9	1-1000
10	1-1000









23 MS. HENN: Objection to form. Lacks
24 foundation.
25 ///

1 BY MR. KENNEDY:

2 Q. Isn't that true, sir?

3 A. I'm not sure I understand the
4 question as asked.

5 Q. Well, we will go through some detail,
6 then.

7 First of all, you knew and understood that
8 the salespeople at McKesson were paid on commission;
9 did you not?

10 A. Our sales force was -- has a
11 portion -- my understanding is a portion of their
12 compensation, there was variable compensation
13 associated with various programs.

14 Q. The more they sold, the more money
15 they made, very simple; isn't that true?

16 MS. HENN: Objection to form. Lacks
17 foundation.

18 THE WITNESS: To my knowledge, that's not
19 accurate. It wasn't -- it's not that simple of a
20 calculation or process.

21 BY MR. KENNEDY:

22 Q. In fact, didn't you know and
23 understand that a salesperson could double, could
24 double their annual income based upon sales?

25 A. I don't have any specific knowledge

1 on what the percentages or the proportions were.

[View Details](#) | [Edit](#) | [Delete](#)

[View Details](#) | [Edit](#) | [Delete](#)

For more information about the study, please contact Dr. Michael J. Hwang at (319) 356-4000 or via email at mhwang@uiowa.edu.

[View Details](#) | [Edit](#) | [Delete](#)

[View Details](#) | [Edit](#) | [Delete](#)

—
—

ANSWER The answer is (A). The first two terms of the sequence are 1 and 2. The third term is 1 + 2 = 3. The fourth term is 2 + 3 = 5. The fifth term is 3 + 5 = 8. The sixth term is 5 + 8 = 13. The seventh term is 8 + 13 = 21.

[View Details](#) | [Edit](#) | [Delete](#)

For more information about the study, please contact Dr. John D. Cawley at (609) 258-4626 or via email at jdcawley@princeton.edu.

[View Details](#) | [Edit](#) | [Delete](#)

17 BY MR. KENNEDY:

18 Q. All right. Salespeople also got paid
19 if they brought in a new pharmacy, a new customer
20 into McKesson; didn't they? They also got paid if
21 they did that; true?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 THE WITNESS: Again, I don't have any
25 specific knowledge of what they were paid. But I

1 believe there was compensation associated with new
2 business.

3 BY MR. KENNEDY:

4 Q. And, sir, before McKesson -- under
5 their 2008 program, before McKesson would sell
6 opioids to a pharmacy, they went through an
7 on-boarding process; did they not?

8 A. Yes.

A series of horizontal gray bars of varying lengths, each preceded by a small gray square, representing redacted portions of the transcript. There are approximately 15 such entries, indicating significant amounts of information have been withheld from view.



[REDACTED]

7 Q. And McKesson knew and you knew and
8 the salespeople knew that if we bring in a new
9 customer, number one, I'm going to get a bonus as a
10 salesperson for bringing in a new customer, and,
11 number two, my sales are going to increase if I get a
12 new customer, and I'm going to make more money; you
13 all knew that, right?

14 MS. HENN: Objection to form.

15 BY MR. KENNEDY:

16 Q. You knew that?

17 A. Again, I think that's oversimplifying
18 the sales force compensation.

19 Q. Now, also built right into your
20 program for the salespeople, you told us -- we've

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]







19 MR. KENNEDY: Let's look at Exhibit 730.

20 I'm going to withdraw that exhibit. Give me
21 732, please.

22 (Exhibit No. 732 was marked.)

23 BY MR. KENNEDY:

24 Q. Do you see this email? This is from
25 you dated 9-17-13; do you see that?

1 A. Yes.

2 Q. And the next page says, "Controlled
3 Substances Regulatory Org Structure." Do you see
4 that?

5 A. Yes.

6 Q. This is created by you?

7 A. Yes.

8 Q. And this is 2013. And if you go to
9 page -500. Do you see that? Look at the second
10 bullet point. Do you see that second bullet point?

11 A. Yes.

12 Q. In 2013 you write:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

8 BY MR. KENNEDY:

9 Q. And, sir, over and above these
10 salespeople that we're talking about, you had -- you
11 had marketing people at McKesson; did you not? We
12 have talked about them.

13 MS. HENN: Objection to forms. Lacks
14 foundation.

15 BY MR. KENNEDY:

16 Q. There were marketing people at
17 McKesson; were there not?

18 A. Yes, there was a marketing
19 department.

20 Q. And while you were trying to control
21 the flow of opioids into the communities and the
22 pharmacy, the marketing people were trying to sell
23 more opioids; were they not?

24 MS. HENN: Objection to form. Lacks
25 foundation.

1 THE WITNESS: No, that's not accurate.

2 MR. KENNEDY: 720.

3 (Exhibit No. 720 was marked.)

4 BY MR. KENNEDY:

5 Q. The first email in time is number one
6 at the bottom. That's where it starts in time.
7 -543462 to -63.

8 This is an email from Scott Mooney, and this
9 is to you, January 16 of 2008, importance high. It
10 states:

A horizontal bar chart illustrating the percentage of respondents who have heard of different topics. The y-axis lists 15 topics, each preceded by a small gray square. The x-axis represents the percentage scale from 0% to 100%, with major tick marks at 0, 50, and 100. Each topic has a corresponding horizontal bar indicating its percentage value.

Topic	Percentage (%)
Healthcare	95
Technology	88
Finance	92
Politics	90
Entertainment	85
Science	80
Food	75
Sports	70
Business	82
Environment	78
Art	72
History	68
Culture	74
Literature	65
Music	71
Mathematics	62



11 Q. Now I want to go to two months later.

12 Tell the jury what fentanyl is?

13 A. Fentanyl is a Schedule 2 narcotic.

14 Q. And is it the most powerful,

15 dangerous of all the narcotics you sell?

16 MS. HENN: Objection to form. Lacks
17 foundation.

18 BY MR. KENNEDY:

19 Q. Is that true, sir?

20 A. I do not know. I know it's a very
21 powerful pain control narcotic.

22 MR. KENNEDY: 714.

23 (Exhibit No. 714 was marked.)

24 BY MR. KENNEDY:

25 Q. There's an email down at the bottom.

1 Kenneth Ball. And this is two years after you're
2 saying we've got to discuss promos. And he states:



3 Q. Let's look to 2012, two years later,
4 two years after that 7-19.

5 A. Again, Counsel, we would not have
6 changed any thresholds on any of our customers in
7 support of any promotions.

8 Q. Mr. Walker, you got fined
9 \$150 million in 2018 for changing thresholds; didn't
10 you?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 BY MR. KENNEDY:

14 Q. Is that true? Did you get fined
15 \$150 million in 2018, McKesson?

16 A. I wasn't with McKesson at the time.
17 I understand that McKesson paid \$150 million.

18 (Exhibit No. 719 was marked.)

19 BY MR. KENNEDY:

20 Q. Let's go to 719. We're still on



A horizontal bar chart illustrating the distribution of 1000 samples across 12 categories. The x-axis represents the number of samples (0 to 1000), and the y-axis represents the categories. The bars are colored grey.

Category	Approximate Sample Count
1	200
2	100
3	250
4	300
5	100
6	100
7	100
8	100
9	100
10	100
11	100
12	100

15 BY MR. KENNEDY:

Q. Let's go to 2013, a year later.

17 MS. HENN: Could we just get information
18 about how much time is on the record at this point?

19 MR. KENNEDY: I'm going to finish these, and
20 then we are done.

21 MS. HENN: Yeah, I just want to check.

22 MR. KENNEDY: Five minutes left.

23 MS. HENN: Good. But let's get --

24 MR. KENNEDY: As soon as I wrap this up.

25 MS. HENN: How much time?

1 THE VIDEOGRAPHER: I think it is ten minutes
2 left.

3 MS. HENN: Okay.

4 (Exhibit No. 721 was marked.)

5 BY MR. KENNEDY:

6 Q. Let's go to the next. It's 2013.

The image consists of a series of horizontal grey bars of varying lengths, arranged vertically. The bars are composed of multiple segments, with some having small gaps between them. The lengths of the bars vary significantly, with some being very long and others very short. The overall pattern is a dense, horizontal bar chart.





5 Q. Do you know how many people
6 hydrocodone was killing a year at the time of this --
7 of this promotion in 2013? Do you know that?


8 A. No, I don't have any specific
9 information on that.


10 MR. KENNEDY: Let's look at 718. We are
11 still in 2013.

12 (Exhibit No. 718 was marked.)

13 BY MR. KENNEDY:

14 Q. This is Exhibit 718, -546932 to -34.





[REDACTED]

[REDACTED]

[REDACTED]

4 BY MR. KENNEDY:

5 Q. And, sir, when you say you are not
6 going to change thresholds without justification, let
7 me ask you very clearly, isn't it true that McKesson
8 got fined \$150 million in a 2018 agreement based upon
9 conduct, increasing thresholds without
10 documentations, during this very time period, 2012,
11 2013, 2014?

12 MS. HENN: Objection to form. Lacks
13 foundation.

14 BY MR. KENNEDY:

15 Q. Do you recall that?

16 A. Counsel, as I -- as I answered, the
17 agreement or document of 2014 or '15, whatever it
18 was, I was not with the company. I have no specific
19 knowledge of the settlement.

20 I do know that McKesson paid 150. I do not
21 understand or have reviewed the details of that
22 settlement.

23 MS. HENN: Counsel, I think we're about at
24 time, if you want to ask your last question.

25 MR. KENNEDY: All done.

1 MS. HENN: Great. So I guess we will go off
2 the record.

3 THE VIDEOGRAPHER: We are going off the
4 record. The time is 5:34 p.m.

5 (Recess taken.)

6 THE VIDEOGRAPHER: We are back on the
7 record. The time is 5:54 p.m.

8 EXAMINATION

9 BY MS. HENN:

10 Q. Good evening, Mr. Walker.

11 A. Good evening.

12 Q. Mr. Walker, you testified earlier
13 today that you joined McKesson in 1987; is that
14 correct?

15 A. That is correct.

16 Q. Before joining McKesson, where did
17 you work?

18 A. Prior to -- immediately prior to
19 working for McKesson, I worked for a grocery
20 wholesale distributor, a trucking company. And then
21 prior to that, I spent ten years in law enforcement.

22 Q. What roles did you play in law
23 enforcement?

24 A. I was a city police officer in a city
25 in the East Bay of San Francisco.

1 Q. Back to your time at McKesson. Could
2 you describe for the jury the various positions you
3 held at McKesson beginning in 1987.

4 A. 1987 I joined the company with a
5 subsidiary company in the transportation group,
6 transportation and warehousing. And that company
7 transitioned to the McKesson Drug Company in roughly
8 1991. Was in a staff role for a short period of
9 time, a staff role in transportation.

10 Then I became the Distribution Center
11 Manager in Sacramento, promoted to the Vice President
12 of Distribution Operations for the Western Region.
13 It was a newly-created position.

14 And subsequently, in roughly 1996, I was
15 promoted to the Senior Vice President of Distribution
16 for McKesson Pharmaceutical.

17 Q. And when did you become Senior Vice
18 President of Distribution for McKesson
19 Pharmaceutical?

20 A. It was 1996. I don't remember
21 exactly when in '96.

22 Q. And that was also the position you
23 held when you retired from McKesson; is that correct?

24 A. Yes, it was.

25 Q. When did you retire?

1 A. June of 2015.

2 Q. You've mentioned today that your
3 former employer, McKesson, is a wholesale distributor
4 of pharmaceuticals. Can you describe how that
5 business operates at a high level?

6 A. At a high level, McKesson, as the
7 other major distributors operate, we purchase
8 pharmaceuticals and medicines from the manufacturers.
9 We virtually warehoused all of the various
10 medications of manufacturers in our warehouses.

11 And on a daily basis, we supplied those
12 pharmaceuticals to pharmacies. And the major groups
13 of pharmacies that we had were -- are independent
14 pharmacies, single owner; or generally our retail
15 national account customers, which were the large
16 chains, like Rite Aid, and CVS and Walmart; our
17 hospital group; and then the federal government.

18 Q. And briefly, what were your job
19 responsibilities as Senior Vice President of
20 distribution operations at McKesson?

21 A. I was the senior staff operations
22 person for McKesson. I had the overall
23 responsibility for the distribution network.

24 On my staff I had a support team made up of
25 a Transportation Group, an I.T. Support Group, our

1 Regulatory Affairs Group was in there, and I had a
2 group that was responsible for construction and
3 building of our distribution centers.

4 Q. You mentioned Regulatory Affairs.

5 What kind of regulatory affairs matters were you
6 responsible for as Senior Vice President of
7 operations -- distribution operations, I should say?

8 A. McKesson, and the wholesalers as an
9 industry, are highly regulated. We have
10 responsibilities for a number of regulatory
11 requirements. The FAA, the Department of
12 Transportation, DOT, OSHA. We had hazardous material
13 requirements. Certainly we had responsibility for
14 compliance with DEA regulations. And various state
15 and local regulations as well.

[REDACTED]





[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. And you described earlier to
10 Mr. Kennedy that you had a five-year period, I think
11 it was, when you ran McKesson's Six Sigma program; is
12 that correct?

13 A. That's correct. Roughly, in 2000 to
14 2005 I was not the Senior Vice President of
15 Operations, Distribution Operations, and did not have
16 responsibility for Regulatory during that time frame,
17 but was responsible for our Six Sigma process
18 improvement.

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]









A horizontal bar chart illustrating the percentage of children aged 0-17 years in each income quintile for 12 countries. The y-axis lists the countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Peru, Uruguay, Venezuela, United States, and Canada. The x-axis represents the percentage of children, ranging from 0% to 100%. Each country has five bars corresponding to the income quintiles, with the first bar representing the lowest quintile and the fifth bar representing the highest quintile.

Country	Q1 (%)	Q2 (%)	Q3 (%)	Q4 (%)	Q5 (%)
Argentina	10	15	20	25	30
Brazil	10	15	20	25	30
Chile	10	15	20	25	30
Colombia	10	15	20	25	30
Costa Rica	10	15	20	25	30
Ecuador	10	15	20	25	30
Mexico	10	15	20	25	30
Peru	10	15	20	25	30
Uruguay	10	15	20	25	30
Venezuela	10	15	20	25	30
United States	10	15	20	25	30
Canada	10	15	20	25	30

13 MS. HENN: I'd like to show you an exhibit.

14 Let's get this marked as 84.

15 THE REPORTER: 804.

16 MS. HENN: 804. Thank you.

(Exhibit No. 804 was marked.)

18 BY MS HENN.

19 Q. Mr. Walker, the court reporter handed
20 you an Exhibit No. -- that's been marked 804. The
21 Bates number is -571361 through -65.

22 MR. KENNEDY: Counsel, 804, is this a
23 defense exhibit?

24 MS. HENN: IT IS

25 MR. KENNEDY: Okay. Defense Exhibit 804

1 THE REPORTER: I just continued, if that's
2 okay, on the sequence.

3 MR. KENNEDY: Oh, okay.

4 BY MS. HENN:

5 Q. Mr. Walker, do you recognize
6 Exhibit 804?

7 A. Yes, I do.

8 Q. What is Exhibit 804?

[REDACTED]











20 Q. Mr. Kennedy had a lot of questions
21 for you earlier today about a 2008 Settlement
22 Agreement between McKesson and the DEA. Do you
23 recall those questions?

24 A. Yes.

5 Q. Did the 2008 Settlement Agreement
6 have provisions in it about what was to replace the
7 DU45 reporting?

8 A. Specifically in the Settlement
9 Agreement, it was agreed that there would be a
10 significant change in suspicious order reporting.
11 That at an agreed-upon time, we would cease providing
12 them a -- the DU45 suspicious order reporting, and we
13 would replace it with a format that was mutually
14 agreed upon between the two parties.

15 And probably the most significant change was
16 that we would no longer report suspicious orders to
17 field offices, as stated in the regulation because,
18 in fact, that we would be reporting directly to DEA
19 headquarters. And from that, we recognized that
20 there would be a mutual effort from the two I.T.
21 groups, being DEA and McKesson, to develop the
22 system's interface to execute the suspicious order
23 reporting.

24 MS. HENN: I'd like to mark as Exhibit 805,
25 Defense Exhibit 805, a copy of the Settlement and

1 Release Agreement from 2008.

2 (Exhibit No. 805 was marked.)

3 BY MS. HENN:

4 Q. Mr. Walker, do you recognize

5 Exhibit 805? The Bates number is -516360.

6 A. Yes, I do.

7 Q. Were you involved -- or let me just
8 ask you, what was your involvement in the process
9 that led to this 2008 Settlement Agreement with the
10 DEA?

11 MR. KENNEDY: Okay. Just to interrupt.

12 This has already been marked, do you understand? So
13 you have -- this exhibit will be marked twice?

14 MS. HENN: I'm not sure it's the same Bates
15 numbered version, but --

16 MR. KENNEDY: All right.

17 MS. HENN: -- that's fine.

18 Q. Did you want me to repeat the
19 question?

20 A. No. I think I remember your
21 question.

22 Q. Okay.

23 A. My -- my role in the overall
24 Settlement Agreement was to provide feedback to
25 counsel, who was interacting with DEA counsel, and to

1 primarily focus on operationalizing the commitments
2 that we were negotiating, making in the -- in the
3 agreement.

4 Q. And in the agreement you mentioned
5 there were provisions dealing with suspicious order
6 reporting. Could you point us to those provisions
7 that you were referring to?

8 A. Well, the first is -- is under "Terms
9 and Conditions" on page 3, 1(a), Obligations of
10 McKesson to -- Obligations of McKesson. And (a) --
11 do you want me to read this, Counsel, or --

12 Q. Yes, please.

13 A. (Reading) McKesson agrees to
14 maintain a compliance program designed
15 to detect and prevent diversion of
16 controlled substances as required
17 under the CSA and applicable DEA
18 regulations. This program shall
19 include procedures for -- to review
20 orders for controlled substances.
21 Orders that exceed established
22 thresholds and criteria will be
23 reviewed by a McKesson employee
24 trained to detect suspicious orders
25 for the purposes of determining

1 whether such orders should not be
2 filled and reported to the DEA or,
3 based on a detailed review, the order
4 is for a legitimate purpose and the
5 controlled substances are not likely
6 to be diverted into other than
7 legitimate medical, scientific, and
8 industrial channels. Orders
9 identified as suspicious will be
10 reported to the DEA as discussed in
11 subsection II (end of reading).

12 Do you want me to continue?

13 This compliance program shall apply --

14 Q. Actually, Mr. Walker, I would like to
15 stick on the subject of suspicious orders. So let's
16 continue to that cross-reference.

17 A. Okay. II.1(c). II.1(c):

18 (Reading) McKesson shall inform DEA of
19 suspicious orders as required by 21
20 C.F.R in a format mutually and
21 responsibly agreed upon by the
22 parties, except that contrary to DEA
23 regulations, McKesson shall inform DEA
24 headquarters rather than the local
25 field office of suspicious orders,

1 unless and until advised otherwise in
2 writing by DEA headquarters. DEA
3 agrees to notify all of the DEA Field
4 Offices within 30 days of the
5 effective date of this agreement that
6 McKesson will no longer be required to
7 provide suspicious order reports or
8 any other types of reports regarding
9 excessive purchases or controlled
10 substances to the DEA Field Offices,
11 and that this agreement shall
12 supersede any DEA regulatory
13 requirements to report suspicious
14 orders to DEA (end of reading).

[REDACTED]

2 You have described the Lifestyle Drug
3 Monitoring Program. Earlier today Mr. Kennedy asked
4 you a lot of questions about the next program that
5 McKesson developed. That was called what?

6 A. The Controlled Substance Monitoring
7 Program, or CSMP.

A horizontal bar chart with four categories. The first category has a very short bar. The second category has a slightly longer bar. The third category has a medium-length bar. The fourth category has a very long bar, extending almost to the end of the chart area.

The image consists of a sequence of horizontal grey bars of varying lengths, arranged vertically. The bars are set against a white background. Some bars are single segments, while others are composed of two or more segments joined together. The lengths of the bars decrease from top to bottom.





3 MS. HENN: Let's mark another exhibit,
4 No. -- Defense Exhibit 806.

5 (Exhibit No. 806 was marked.)

6 BY MS. HENN:

7 Q. Mr. Walker, you've been handed
8 Defense Exhibit 806, which is Bates
9 No. McKesson-WVA-167.

10 Do you recognize this document?

11 A. Yes, I do.

12 Q. What is this?

3 MS. HENN: Let's take a look at another
4 exhibit, which I will mark -- ask the court reporter
5 to mark as 807, Defense Exhibit 807.

6 (Exhibit No. 807 was marked.)

7 BY MS. HENN:

8 Q. Mr. Walker, you've been handed
9 Defense Exhibit 807, which is a Bates No. MCK-WVA-88.
10 Do you recognize this document?

11 A. Yes, I do.

12 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1 Exhibit 808, please.

2 (Exhibit No. 808 was marked.)

3 BY MS. HENN:

[REDACTED]







6 MS. HENN: Let's take a look at another
7 exhibit. This is internal No. 6. And I'm going to
8 have the court reporter mark this one as Defense
9 Exhibit 80?

10 THE REPORTER: 809.

11 (Exhibit No. 809 was marked.)

12 BY MS. HENN:

13 Q. Mr. Walker, you've been handed a
14 document marked Defense Exhibit 809, Bates
15 No. MCK-WVA-163.

16 Do you recognize Exhibit 809?

17 A. Yes, I do.

18 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. Who is Maureen O'Keefe?

10 A. I don't -- she's staff coordinator,
11 according to the memo from Kyle. She was on the
12 diversion staff.

13 MS. HENN: Okay. And let's mark another
14 exhibit. This will be -- I will ask that this be
15 marked Defense Exhibit 810, please.

16 (Exhibit No. 810 was marked.)

17 BY MS. HENN:

18 Q. You've been handed Defense
19 Exhibit 810 Bates No. MCK-WVA-187.

20 Do you recognize this document, Mr. Walker?

21 A. Yes, I do.

22 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

11 MS. HENN: I will show you one more example.

12 We will mark this exhibit as Defense Exhibit 811,
13 please.

14 (Exhibit No. 811 was marked.)

15 BY MS. HENN:

16 Q. Mr. Walker, you've been handed
17 Defense Exhibit 811. And I don't think we have a
18 Bates number, but I will try to find out what that
19 is. Oh, actually, I know what it is, but it's not
20 appearing on the document. The Bates number is
21 -534479.

22 Mr. Walker, do you recognize Exhibit 811?

23 A. Yes, I do.

24 Q. What is it?

A series of 15 horizontal bars, each consisting of a long gray rectangle with a small gray square at its left end. The bars are arranged vertically from top to bottom. The lengths of the bars vary, indicating different values or categories. The small gray square at the start of each bar likely serves as a marker or a starting point for a measurement.

20 MS. HENN: Okay. I'd like to mark this
21 exhibit as 812, Defense Exhibit 812, please. But
22 Counsel, a similar document was marked, but this is
23 different, a different version.

24 (Exhibit No. 812 was marked.)

25 //

1 BY MS. HENN:

2 Q. Mr. Walker, you've been handed
3 Defense Exhibit 812. And the Bates number, again, is
4 not appearing on the document you have, but it's
5 -542494. Or maybe it is on yours, not on mine.

6 A. I got it.

7 Q. What is Exhibit 812, if you recognize
8 it?





















A horizontal bar chart illustrating the distribution of 1500 samples across 15 different categories. The y-axis lists the categories, each preceded by a small gray square. The x-axis represents the count of samples, ranging from approximately 100 to 1500. The bars are gray, and their lengths correspond to the sample counts for each category.

Category	Sample Count
1	1200
2	1500
3	300
4	1500
5	100
6	100
7	1500
8	100
9	100
10	1500
11	1500
12	1500
13	1500
14	1500
15	1500
16	1500
17	1500
18	1500
19	1500
20	1500
21	1500
22	1500
23	1500
24	1500
25	1500
26	1500
27	1500
28	1500
29	1500
30	1500
31	1500
32	1500
33	1500
34	1500
35	1500
36	1500
37	1500
38	1500
39	1500
40	1500
41	1500
42	1500
43	1500
44	1500
45	1500
46	1500
47	1500
48	1500
49	1500
50	1500
51	1500
52	1500
53	1500
54	1500
55	1500
56	1500
57	1500
58	1500
59	1500
60	1500
61	1500
62	1500
63	1500
64	1500
65	1500
66	1500
67	1500
68	1500
69	1500
70	1500
71	1500
72	1500
73	1500
74	1500
75	1500
76	1500
77	1500
78	1500
79	1500
80	1500
81	1500
82	1500
83	1500
84	1500
85	1500
86	1500
87	1500
88	1500
89	1500
90	1500
91	1500
92	1500
93	1500
94	1500
95	1500
96	1500
97	1500
98	1500
99	1500
100	1500
101	1500
102	1500
103	1500
104	1500
105	1500
106	1500
107	1500
108	1500
109	1500
110	1500
111	1500
112	1500
113	1500
114	1500
115	1500
116	1500
117	1500
118	1500
119	1500
120	1500
121	1500
122	1500
123	1500
124	1500
125	1500
126	1500
127	1500
128	1500
129	1500
130	1500
131	1500
132	1500
133	1500
134	1500
135	1500
136	1500
137	1500
138	1500
139	1500
140	1500
141	1500
142	1500
143	1500
144	1500
145	1500
146	1500
147	1500
148	1500
149	1500
150	1500
151	1500
152	1500
153	1500
154	1500
155	1500
156	1500
157	1500
158	1500
159	1500
160	1500
161	1500
162	1500
163	1500
164	1500
165	1500
166	1500
167	1500
168	1500
169	1500
170	1500
171	1500
172	1500
173	1500
174	1500
175	1500
176	1500
177	1500
178	1500
179	1500
180	1500
181	1500
182	1500
183	1500
184	1500
185	1500
186	1500
187	1500
188	1500
189	1500
190	1500
191	1500
192	1500
193	1500
194	1500
195	1500
196	1500
197	1500
198	1500
199	1500
200	1500
201	1500
202	1500
203	1500
204	1500
205	1500
206	1500
207	1500
208	1500
209	1500
210	1500
211	1500
212	1500
213	1500
214	1500
215	1500
216	1500
217	1500
218	1500
219	1500
220	1500
221	1500
222	1500
223	1500
224	1500
225	1500
226	1500
227	1500
228	1500
229	1500
230	1500
231	1500
232	1500
233	1500
234	1500
235	1500
236	1500
237	1500
238	1500
239	1500
240	1500
241	1500
242	1500
243	1500
244	1500
245	1500
246	1500
247	1500
248	1500
249	1500
250	1500
251	1500
252	1500
253	1500
254	1500
255	1500
256	1500
257	1500
258	1500
259	1500
260	1500
261	1500
262	1500
263	1500
264	1500
265	1500
266	1500
267	1500
268	1500
269	1500
270	1500
271	1500
272	1500
273	1500
274	1500
275	1500
276	1500
277	1500
278	1500
279	1500
280	1500
281	1500
282	1500
283	1500
284	1500
285	1500
286	1500
287	1500
288	1500
289	1500
290	1500
291	1500
292	1500
293	1500
294	1500
295	1500
296	1500
297	1500
298	1500
299	1500
300	1500
301	1500
302	1500
303	1500
304	1500
305	1500
306	1500
307	1500
308	1500
309	1500
310	1500
311	1500
312	1500
313	1500
314	1500
315	1500
316	1500
317	1500
318	1500
319	1500
320	1500
321	1500
322	1500
323	1500
324	1500
325	1500
326	1500
327	1500
328	1500
329	1500
330	1500
331	1500
332	1500
333	1500
334	1500
335	1500
336	1500
337	1500
338	1500
339	1500
340	1500
341	1500
342	1500
343	1500
344	1500
345	1500
346	1500
347	1500
348	1500
349	1500
350	1500
351	1500
352	1500
353	1500
354	1500
355	1500
356	1500
357	1500
358	1500
359	1500
360	1500
361	1500
362	1500
363	1500
364	1500
365	1500
366	1500
367	1500
368	1500
369	1500
370	1500
371	1500
372	1500
373	1500
374	1500
375	1500
376	1500
377	1500
378	1500
379	1500
380	1500
381	1500
382	1500
383	1500
384	1500
385	1500
386	1500
387	1500
388	1500
389	1500
390	1500
391	1500
392	1500
393	1500
394	1500
395	1500
396	1500
397	1500
398	1500
399	1500
400	1500
401	1500
402	1500
403	1500
404	1500
405	1500
406	1500
407	1500
408	1500
409	1500
410	1500
411	1500
412	1500
413	1500
414	1500
415	1500
416	1500
417	1500
418	1500
419	1500
420	1500
421	1500
422	1500
423	1500
424	1500
425	1500
426	1500
427	1500
428	1500
429	1500
430	1500
431	1500
432	1500
433	1500
434	1500
435	1500
436	1500
437	1500
438	1500
439	1500
440	1500
441	1500
442	1500
443	1500
444	1500
445	1500
446	1500
447	1500
448	1500
449	1500
450	1500
451	1500
452	1500
453	1500
454	1500
455	1500
456	1500
457	1500
458	1500
459	1500
460	1500
461	1500
462	1500
463	1500
464	1500
465	1500
466	1500
467	1500
468	1500
469	1500
470	1500
471	1500
472	1500
473	1500
474	1500
475	1500
476	1500
477	1500
478	1500
479	1500
480	1500
481	1500
482	1500
483	1500
484	1500
485	1500
486	1500
487	1500
488	1500
489	1500
490	1500
491	1500
492	1500
493	1500
494	1500
495	1500
496	1500
497	1500
498	1500
499	1500
500	1500
501	1500
502	1500
503	1500
504	1500
505	1500
506	1500
507	1500
508	1500
509	1500
510	1500
511	1500
512	1500
513	1500
514	1500
515	1500
516	1500
517	1500
518	1500
519	1500
520	1500
521	1500
522	1500
523	1500
524	1500
525	1500
526	1500
527	1500
528	1500
529	1500
530	1500
531	1500
532	1500
533	1500
534	1500
535	1500
536	1500
537	1500
538	1500
539	1500
540	1500
541	1500
542	1500
543	1500
544	1500
545	1500
546	1500
547	1500
548	1500
549	1500
550	1500
551	1500
552	1500
553	1500
554	1500
555	1500
556	1500
557	1500
558	1500
559	1500
560	1500
561	1500
562	1500
563	1500
564	1500
565	1500
566	1500
567	1500
568	1500
569	1500
570	1500
571	1500
572	1500
573	1500
574	1500
575	1500
576	1500
577	1500
578	1500
579	1500
580	1500
581	1500
582	1500
583	1500
584	1500
585	1500
586	1500
587	1500
588	15

16 MS. HENN: Let's just mark quickly another
17 exhibit, defense Exhibit 812.

18 THE REPORTER: 813.

19 MS. HENN: 813, thank you.

20 (Exhibit No. 813 was marked.)

21 BY MS. HENN:

22 Q. Mr. Walker, I hand you Defense
23 Exhibit 813 Bates No MCK-WVA-230

24 Do you recognize that document?

25 A Yes. I do

1

o.

What is it?

—
—
—

[View Details](#) | [Edit](#) | [Delete](#)

[View Details](#) | [Edit](#) | [Delete](#)

[View Details](#) | [Edit](#) | [Delete](#)

—
—

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

—

A horizontal bar composed of three distinct grey rectangular segments. The first segment is a narrow vertical rectangle on the far left. To its right is a wider, horizontal grey rectangle. To the right of that is another narrower, horizontal grey rectangle.

Page 1 of 1

© 2013 Pearson Education, Inc.

[View Details](#) | [Edit](#) | [Delete](#)

A long, thin, light gray horizontal bar, likely a placeholder or a decorative element at the bottom of the page.

ANSWER The answer is (A). The first two digits of the number 1234567890 are 12.

[View Details](#) | [Edit](#) | [Delete](#)

A horizontal bar composed of three gray rectangles. The first rectangle is narrow and located on the far left. The second rectangle is wider and positioned to its right. The third rectangle is the widest and positioned to the right of the second. This visual element likely represents a menu or navigation bar.

For more information about the study, please contact Dr. Michael J. Hwang at (310) 794-3000 or via email at mhwang@ucla.edu.

1

1



Term	Percentage
GMOs	~85%
Organic	~88%
Natural	~85%
Artificial	~75%
Organic	~88%
Natural	~85%
Artificial	~75%
Organic	~95%
Natural	~92%
Artificial	~90%

12 MS. HENN: Thank you very much, Mr. Walker.

13 I have no further questions.

14 Do you mind if we take a break? It's been a
15 long time. Let's go off the record, please.

16 THE VIDEOGRAPHER: We are going off the
17 record. The time is 7:14 p.m.

18 (Recess taken.)

19 THE VIDEOGRAPHER: We are back on the
20 record. The time is 7:38 p.m.

21 FURTHER EXAMINATION

22 BY MR. KENNEDY:

23 Q. Mr. Walker, this is Eric Kennedy.

24 I'm allowed to ask you some questions in response to
25 the questions that your lawyer asked you a few

1 moments ago; all right?

2 A. I understand that.

3 Q. And I'm going to try to keep it brief
4 because I know it's late in the day.

5 One of the things that you were shown by

6 McKesson's lawyer was Defense Exhibit 804. And that

⁷ was a January 18, 2006, letter written by a gentleman

8 at McKesson to the DEA. It was written by Paul

9 Julian. Do you remember that? Do you remember

10 talking about that?

11 A. Yes.


□ □ □

© 2013 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

A horizontal bar composed of three gray rectangles of increasing width from left to right. The first rectangle is the narrowest, the second is medium-width, and the third is the widest, spanning most of the bar's length.

Three horizontal gray bars of increasing width from left to right.

For more information about the study, please contact Dr. Michael J. Hwang at (310) 794-3000 or via email at mhwang@ucla.edu.

© 2013 Pearson Education, Inc.

[View Details](#) | [Edit](#) | [Delete](#)

© 2013 Pearson Education, Inc.

24 BY MR. KENNEDY:

Q. All right. And you -- actually, I

1 think you read a footnote on page -1362 of the letter
2 written to the DEA. Do you remember reading that
3 footnote?

4 MS. HENN: Objection to form.

5 BY MR. KENNEDY:

6 Q. Sir, do you remember reading that
7 footnote?

8 A. Counselor, I remember describing the
9 content of the footnote. I don't remember that -- I
10 don't recall that I read it specifically. I just
11 want to be clear.

The figure is a horizontal bar chart with 1000 bars. The x-axis is labeled 'Index' and ranges from 1 to 1000. The y-axis is labeled 'Category' and ranges from 1 to 10. The bars are gray and represent the frequency of each sample belonging to a specific category. The distribution is highly skewed, with most samples belonging to categories 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, while category 0 has very few samples.

Category	Approximate Sample Range
0	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
1	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
2	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
3	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
4	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
5	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
6	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
7	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
8	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
9	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950
10	100-150, 200-250, 300-350, 400-450, 500-550, 600-650, 700-750, 800-850, 900-950

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 MR. KENNEDY: Could you give me 686,
9 Exhibit 686.

10 Q. And this is the Settlement Agreement
11 with respect to the Internet pharmacy dosages; right?

12 I'm going to pull it up so we can look at
13 it.

14 MS. HENN: Well, he may want it.

15 BY MR. KENNEDY:

16 Q. If you will go to the second page of
17 that Settlement Agreement.

18 A. I got it.

19 MS. HENN: Great.

20 BY MR. KENNEDY:

21 Q. And so the DEA, the conduct that they
22 were talking about was three million dosages to
23 Maryland; right? In Maryland, three million doses.
24 2.1 million into Florida. 2.6 million into Texas.
25 824,000 into Utah. Right?

1 I mean, that's what this DEA settlement was
2 all about for conduct in '04, '05, and '06; right?
3 Correct?

4 A. This settlement covered the
5 allegations that DEA made. So yes.

The image consists of a sequence of horizontal grey bars arranged vertically. Each horizontal bar is preceded by a small, separate vertical grey bar of the same shade. The length of the horizontal bars varies significantly, with some being very short and others extending almost to the top of the frame. The overall effect is a rhythmic pattern of长短不一的横线，每条横线前都有一个小小的垂直起始点。



1 BY MR. KENNEDY:

2 Q. Between 2000 and 2005, you said you
3 were out of Regulatory for that period of time, and
4 what was your job?

5 A. I was -- I can't remember my specific
6 title, but I was the Senior Vice President overseeing
7 Six Sigma.

8 Q. And what did that involve? Did that
9 involve regulation of controlled substances?

10 A. Not at all.

11 Q. Not at all.

12 How many meetings with the DEA did you go to
13 between 2000 and 2005?

14 A. None.

15 Q. How many DEA seminars did you go to
16 between 2000 and 2005?

17 A. None that I remember.

18 Q. How many regulatory meetings did you
19 go to at McKesson between 2000 and 2005 with respect
20 to controlled substances?

21 A. I don't recall going to any.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]





4 MS. HENN: Counsel, I'm going -- we're going
5 to need to go off the record so the court reporter
6 can get her car out of the garage.

7 THE VIDEOGRAPHER: We are going off the
8 record. The time is 7:50 p.m.

9 (Off the record.)

10 THE VIDEOGRAPHER: We are back on the
11 record. The time is 7:58 p.m.

12 BY MR. KENNEDY:

A horizontal bar chart illustrating the percentage of respondents who have heard of specific terms, categorized by age group. The y-axis lists ten terms, each preceded by a small gray square. The x-axis represents the percentage of respondents, ranging from 0% to 100% in increments of 10%. Each term has a corresponding horizontal bar indicating its popularity across the different age brackets.

Term	18-24	25-34	35-44	45-54	55-64	65-74	75-84	85+
AI	85%	88%	90%	92%	94%	96%	98%	99%
Cloud computing	82%	85%	88%	90%	92%	94%	96%	98%
Big data	78%	80%	82%	85%	88%	90%	92%	94%
Machine learning	75%	78%	80%	82%	85%	88%	90%	92%
Blockchain	70%	72%	75%	78%	80%	82%	85%	88%
Robotics	68%	70%	72%	75%	78%	80%	82%	85%
Quantum computing	65%	68%	70%	72%	75%	78%	80%	82%
Cloud storage	62%	65%	68%	70%	72%	75%	78%	80%
Cloud services	60%	62%	65%	68%	70%	72%	75%	78%
Cloud infrastructure	58%	60%	62%	65%	68%	70%	72%	75%

10 BY MR. KENNEDY:

11 Q. Let's look at how diligent you were
12 in executing, then. Let's look at Exhibit 730, if we
13 could.

14 MR. ASQUITH: It's a new one.

15 MS. HENN: Do you have a copy? That's the
16 only copy.

17 Oh, this is an exhibit you withdrew. There
18 you go.

19 (Exhibit No. 730 was marked.)

20 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

15 BY MR. KENNEDY:

16 Q. Exhibit 730 is an audit done by
17 McKesson in March of 2011. Is that what it says on
18 the cover page, March of 2011 Audit Report?

19 A. Yes.

20 Q. If you go to page -498069. Do you
21 see that? "Level 1 Forms," do you see that title?
22 Level 1 Forms.

23 A. Yes.

24 Q. Delran, what is that? Is that one of
25 your distribution centers?

1 A. Delran, New Jersey was one of our
2 distribution centers.

1 Q. Now, New Castle. This is another
2 distribution center; right?

3 A. Yes.

4 Q. Under that one it says:

Term	Percentage (%)
Climate change	95
Global warming	92
Green energy	88
Sustainable development	85
Environmental protection	82
Recycling	80
Organic food	78

14 Q. Washington Court House, is that
15 another distribution center?

16 A. Yes, it is.

17 Q. Does that say:

Term	Percentage
GMOs	~95%
Organic	~95%
Natural	~90%
Artificial	~75%
Organic	~85%
Natural	~80%
Artificial	~70%
Organic	~65%
Natural	~60%
Artificial	~55%

25 Q. Conroe, on the next page. That's

1 another distribution center; is it not?

2 A. Yes, it is.

3 Q. Does that state:

[redacted]









—
—

Figure 1. The effect of the number of clusters on the classification accuracy.

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

Figure 1. The effect of the number of clusters on the classification accuracy.

10

[View Details](#) | [Edit](#) | [Delete](#)

[View Details](#) | [Edit](#) | [Delete](#)

1

1

For more information about the study, please contact the study team at 1-800-258-4238 or visit www.cancer.gov.

For more information about the study, please contact the study team at 1-800-258-4929 or visit www.cancer.gov.

www.ijerpi.org

www.ijerpi.org

[View Details](#) | [Edit](#) | [Delete](#)

For more information about the study, please contact Dr. John Smith at (555) 123-4567 or via email at john.smith@researchinstitute.org.

Digitized by srujanika@gmail.com

Digitized by srujanika@gmail.com

© 2013 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).

© 2013 Pearson Education, Inc.

[View Details](#) [Edit](#) [Delete](#)

34 BY MR. KENNEDY.

25 0 Is Landover one of your distribution

1 centers, sir?

2 A. Landover was one of our distribution
3 centers. It closed in 2012, I believe.

4 Q. And this comes from the DEA, so you
5 should be aware of this.

[REDACTED]

23 BY MR. KENNEDY:

24 Q. Livonia, is that a distribution
25 center of McKesson?

1 A. Yes, it is.

2 Q. In Michigan?

3 A. Michigan.

[REDACTED]

19 BY MR. KENNEDY:

20 Q. Lakeland, Florida, that's a

21 distribution center; correct?

22 A. Yes.

[REDACTED]

7 BY MR. KENNEDY:

8 Q. Metheun, Massachusetts, is that
9 another distribution center?

10 A. Yes, it is.

[REDACTED]

25 Q. Sir, didn't McKesson get fined

1 \$150 million by the DEA because of their failures
2 with respect to the 2008 program, leading all the way
3 up from 2008 and '09, '10, '11, '12, '13, '14, '15,
4 '16, and '17? \$150 million.

5 MS. HENN: Objection to form.

6 BY MR. KENNEDY:

7 Q. Do you recall that, sir?

8 MS. HENN: Objection to form. Lacks
9 foundation. Mischaracterizes.

10 THE WITNESS: All that I'm aware of is
11 that -- and because it was public information, is
12 that McKesson paid \$150 million. I don't understand
13 any of the details of the settlement, of the
14 documentation, because all of it occurred after I
15 left the company.

16 BY MR. KENNEDY:

17 Q. When did you leave the company?

18 A. In June of 2015.

19 Q. And the DEA fine of \$150 million
20 involved conduct from '08 to '15, while you were the
21 head of Regulatory; do you understand that?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 THE WITNESS: Again, Counsel, I was not here
25 when they -- all of that was finalized and completed.

1 So I don't understand what was in the allegations
2 presented by the DEA.

3 MR. KENNEDY: Give me P.88, please. This is
4 Exhibit 814.

5 (Exhibit No. 814 was marked.)

6 BY MR. KENNEDY:

7 Q. If you will look at that very last
8 page. Do you see that this is dated 1-5-17, at least
9 the signatures, one of the signatures? 1-5-17, it's
10 on the back cover.

11 A. Yes.

12 Q. If you look at the front cover, the
13 front page, is this titled, "Administrative
14 Memorandum Agreement?"

15 A. Yes, it is.

16 Q. And does the first paragraph say:

17 (Reading) The Administrative
18 Memorandum Agreement is entered into
19 by and between the United States
20 Department of Justice, Drug
21 Enforcement Administration, and
22 McKesson Corporation (end of reading)?

23 Is that what it says?

24 A. Yes.

25 Q. And if you'll go to page 88.3 up at

1 the -- up at the top. And look at No. 2. Does No. 2
2 say, "Acceptance of Responsibility"?

3 A. Yes.

4 Q. That's acceptance of responsibility
5 by McKesson; isn't it, sir?

6 MS. HENN: Objection to form.

7 BY MR. KENNEDY:

8 Q. Is that what that means?

9 MS. HENN: Objection to form.

10 THE WITNESS: That's what it says, Counsel.
11 Quite honestly, I don't know under the legal terms of
12 a settlement agreement what that means. I don't have
13 the legal expertise.

14 BY MR. KENNEDY:

15 Q. Well, so what I'm -- can you explain
16 to me how you can come in here and tell us that
17 McKesson was diligent and aggressive in following and
18 implementing its 2008 agreement, and you haven't read
19 the settlement covering that same period of time with
20 respect to the implementation of that program? How
21 can you -- how can you not have read this?

22 MS. HENN: Objection to form.

23 THE WITNESS: Counsel, I wasn't with the
24 company when -- to my knowledge, when this document
25 was -- was generated.

1 BY MR. KENNEDY:

2 Q. How many hours have you spent with
3 McKesson's lawyer prior to today reviewing documents
4 and other materials in preparation for today's
5 testimony? How many hours, sir?

6 A. A number of them.

7 Q. How many, sir?

8 A. Five or six.

9 Q. And how many different days, sir?

10 A. How many different days?

11 Q. Yes.

12 A. Five or six.

13 Q. Five or six days?

14 A. Yes.

15 Q. And they never showed you this
16 document before you came in here to testify that
17 McKesson was aggressive and diligent in implementing
18 its policies? You were never shown this?

19 A. In reviewing this document, I think
20 it was shown. This document, I believe, we did not
21 cover in detail.

22 Q. Well, under "Acceptance and
23 Responsibility," go down about four or five lines
24 down in the middle where the sentence starts with,
25 "McKesson."

1 Does it state:

2 (Reading) McKesson acknowledges that,

3 at various times during the period

4 from January 1, 2009, up through and

5 including the effective date of this

6 agreement (the covered period of

7 time), it did not identify or report

8 to DEA certain orders placed by

9 certain pharmacies which should have

10 been detected by McKesson as

11 suspicious based upon the guidance

12 contained in the DEA letters about the

13 requirements set forth in 21 C.F.R

14 1301.74(b) and 21 U.S.C 842(a)(5)

15 (end of reading)?

16 Do you see where it states that McKesson
17 acknowledged those failures; sir? Is that what it
18 states?

19 MS. HENN: Objection to form.

20 THE WITNESS: That's what the document
21 states.

22 BY MR. KENNEDY:

23 Q. Look down to the next paragraph, if
24 you would. About five lines down it starts with
25 "McKesson." Do you see that?

1 A. Yes.

2 Q. Does it state, again:

3 (Reading) McKesson acknowledges that,
4 at various times during the covered
5 time period, it did not identify or
6 report to DEA certain orders placed by
7 certain pharmacies which should have
8 been detected by McKesson as
9 suspicious in a manner fully
10 consistent with requirements set forth
11 in the 2008 Memorandum of
12 Understanding (end of reading)?

13 Is that what it states?

14 A. That's -- yes, that's what it states.

15 Q. Covered conduct, No. 3, A. Does it
16 state:

17 (Reading) McKesson failed to maintain
18 effective controls against diversion
19 of particular controlled substances
20 into other than legitimate medical,
21 scientific, and industrial channels by
22 sales to certain of its customers in
23 violation of the Controlled Substance
24 Act and the Controlled Substance Act's
25 implementing regulations (end of

1 reading)?

2 Does it say that?

3 A. Yes.

4 Q. And then does it outline the
5 different distribution centers where these failures
6 occurred, sir?

7 MS. HENN: Objection to form.

8 Mischaracterizing the document.

9 BY MR. KENNEDY:

10 Q. Does it outline the distribution
11 centers where this conduct occurred?

12 MS. HENN: Same objection.

13 BY MR. KENNEDY:

14 Q. Does it, sir?

15 A. Just a minute.

16 What I -- what I read is that the
17 distribution centers listed there -- it said at
18 McKesson -- at the distribution centers, including
19 the following, with the list of distribution centers
20 that are down below.

21 Q. Right. Distribution center --

22 McKesson Distribution Center in Colorado, Illinois,
23 New Jersey, Wisconsin, Florida, Maryland, Nebraska,
24 Michigan, Massachusetts, and California; correct?

25 A. That's what's written in the

1 document.

7 Q. Let's look to the next page. If we
8 look at C, this was specific to what you've been
9 telling us. Does it state on C:

10 (Reading) McKesson failed to follow
11 the procedures and policies set forth
12 in the McKesson CSMP to detect and
13 disclose suspicious orders of
14 controlled substances (end of
15 reading)?

16 Is that what it states, sir?

17 A. Yes, that's what the document states.

18 Q. Does it next state:

19 (Reading) Among other things, McKesson
20 failed to conduct adequate due
21 diligence of its customers, failed to
22 keep complete and accurate records of
23 the CSMP files maintained for many of
24 its customers, and bypassed suspicious
25 order reporting procedures set forth

1 in McKesson's CSMP (end of reading)?

2 Did I read that right?

3 A. You read that correctly.

4 Q. And, sir, could we agree -- and I'm
5 only going to ask you one more time. Could we agree
6 that writing a policy, putting it on paper, meeting
7 with the FDA [sic] and saying these are our policies,
8 that doesn't do anybody any good unless you follow
9 your own policies?

10 MS. HENN: Objection to form.

11 BY MR. KENNEDY:

12 Q. Could we agree to that, sir?

13 A. I don't agree with that statement. I
14 strongly believe that we were executing and doing
15 everything in our capability that we could to manage
16 our Controlled Substance Monitoring Program.

17 Q. And the FDA [sic] disagreed when they
18 fined you \$150 million; correct?

19 MS. HENN: Objection to form.

20 THE WITNESS: Again, I'm not going to
21 speculate, because I wasn't involved in the process
22 of how that was negotiated and reached.

23 MR. KENNEDY: I have nothing further. Thank
24 you, sir.

25 MS. HENN: We have no further questions

1 either.

2 We have just two things to note. We would
3 request that the transcript be designated highly
4 confidential pending review and further designations.

5 And we request that the witness have the
6 opportunity to read and sign.

7 Thank you very much.

8 THE VIDEOGRAPHER: This concludes the video
9 deposition of Donald Walker, consisting of eight
10 media.

11 The time is 8:23 p.m. We are off the
12 record.

13 (The deposition was concluded at 8:23 p.m.)

14 --000--

15

16

17

18

19

20

21

22

23

24

25

1 Please be advised I have read the foregoing
2 deposition, and I state there are:

3 (Check one) _____ NO CORRECTIONS

4 _____ CORRECTIONS PER ATTACHED

5

6

7

8 DONALD WALKER

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 DEPONENT'S CHANGES OR CORRECTIONS

2 Note: If you are adding to your testimony, print the
3 exact words you want to add. If you are deleting from
4 your testimony, print the exact words you want to
5 delete. Specify with "Add" or "Delete" and sign this
6 form.

7 DEPOSITION OF: DONALD WALKER

8 CASE: IN RE NATIONAL PRESCRIPTION OPIATE LITIGATION

9 DATE OF DEPOSITION: JANUARY 10, 2019

10 PAGE LINE CHANGE/ADD/DELETE/REASON

11 _____

12 _____

13 _____

14 _____

15 _____

16 _____

17 _____

18 _____

19 _____

20 _____

21 _____

22 _____

23 _____

24 DEPONENT'S SIGNATURE _____

25 DATE _____

1 CERTIFICATE OF REPORTER

2 I, SANDRA BUNCH VANDER POL, a Certified
3 Shorthand Reporter, hereby certify that the witness in
4 the foregoing deposition was by me duly sworn to tell
5 the truth, the whole truth and nothing but the truth
6 in the within-entitled cause;

7 That said deposition was taken down in shorthand
8 by me, a disinterested person, at the time and place
9 therein stated, and that the testimony of the said
10 witness was thereafter reduced to typewriting, by
11 computer, under my direction and supervision;

12 That before completion of the deposition, review
13 of the transcript was requested. If requested, any
14 changes made by the deponent (and provided to the
15 reporter) during the period allowed are appended
16 hereto.

17 I further certify that I am not of counsel or
18 attorney for either or any of the parties to the said
19 deposition, nor in any way interested in the event of
20 this cause, and that I am not related to any of the
21 parties thereto.

22 DATED: JANUARY 14, 2019

23 _____

SANDRA BUNCH VANDER POL, CSR 3032

24

25